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Abstract 
 
Genetic Incorporation of Unnatural Amino Acids for the Study of Protein-Protein Interactions 
 
Proteins comprise the majority of the cell and are vital to all cellular functioning.  
Protein-protein interactions (PPIs) are the communication networks behind cellular processes, 
often functioning in machine-like complexes with exchangeable subunits or parts to convey 
different messages.  PPIs exhibit a wide range of structural features, surface areas, and affinities 
with some displaying dynamic interfaces allowing multiple binding partners to interact 
depending on cellular conditions.  This makes some PPIs more difficult to study than others.  
Understanding these PPIs and exploring larger PPI networks has been a challenge without 
considering the cellular context in which they belong.  Methods to study difficult PPIs in their 
native environments have thus been instrumental advancing the field.   
The predominant theme of this work is the demonstration of the utility of genetically 
incorporated photolabile unnatural amino acids for the study of the difficult PPIs between 
transcriptional activator-coactivator complexes.  Covalent chemical capture of protein binding 
partners in live cells is combined with mass spectrometry to discover novel PPIs and further 
expanded to include new ways to visualize direct PPIs on DNA.  Caveats to the covalent capture 
method are also explored with an illustration of capture efficiencies of two common photolabile 
groups across various PPI binding affinities and surface areas. 
The work presented here displays a thorough examination of the use and application of 
chemical capture for the study of PPIs in a cellular context.  The methods established within this 
work add to the foundation for the study of difficult PPIs and demonstrates the ability to 
understand new networks of low affinity, dynamic interactions.  The presentation of novel 
binding partners for the well-studied transcriptional activator, Gal4, expands traditional beliefs 
on transcriptional activator participation in binding dynamic complexes as well as highlights the 
potential of these PPIs for later therapeutic points of intervention.  In addition, the groundwork 
for guidelines on using covalent chemical capture in various PPIs was established which, when 
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completed, will enable not only easier use but also hopefully lead to the ability to tailor selection 
of a photocrosslinker based on the specific PPIs under study. 
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Chapter 1: Introduction – Defining Protein-Protein Interactions (PPIs): Challenges 
and Strategies in the Field1 
1A: Abstract 
Protein-protein interactions underlie every biological function in the cell, and as a 
result, dysregulation of PPIs accompanies many human diseases.  For example, 
approximately 30% of human PPIs have been linked to cancer.3  Due to their 
fundamental importance and role in disease, PPIs are a logical target for drug modulation; 
however, they are often challenging to study due to limited structural data, transient 
binding, and numerous binding partners, thus presenting many hurdles to a 
comprehensive understanding of the PPI network.6  One category that has been a 
considerable struggle to study are large, transient PPIs with this group frequently lacking 
small molecules even for tool purposes.8  Transcriptionally-related proteins are often 
within this large and transient interface category, leaving one of the most biologically 
important processes without methods to study their PPIs.11  Employing in vivo techniques 
to investigate these proteins has vastly expanded our ability to study their PPIs with the 
focus of this thesis being the utilization of genetically incorporated photocrosslinking 
amino acids to further the understanding of transcriptional activator PPIs. 
1B: Defining PPIs 
Proteins make up a large portion of a cell, comprising approximately 60% of its 
dry mass.12  The interactions between these proteins are integral to cellular functioning 
and control many cellular processes.  Signals transmitted through PPIs control everything 
from localization and activation of specific cellular constituents to the timing of events 
within the cell.  As a result, dysregulation of PPIs accompanies many human diseases.  
One example is the disruption of c-Myc in many human cancers.  C-Myc is a linchpin in 
many cellular processes ranging from proliferation to apoptosis, and disruption of its 
                                                
1 Portions of this chapter are taken from: Mapp, A. K.; Pricer, R.; Sturlis, S., Targeting transcription is no longer a quixotic quest. Nat 
Chem Biol 2015, 11 (12), 891-4.  My contributions to this work included Figure 1-1, Figure 1-2, Figure 1-4, Figure 1-5 and assisting 
in writing. 
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function leads to tumor regression, underscoring the importance normal functioning PPIs.  
Other examples include c-Myb, a transcription factor that is often required for the 
transformation of myeloid progenitor cells into a leukemic state;13 the tumor suppressor 
p53, is misregulated in more than half of all human malignancies;14 and the Ets family of 
transcription factors, which affect the status of growth receptors such as EGFR and Her2 
and contribute to metastasis.3  Given the fundamental importance of PPIs, they are a 
logical target of study for understanding disease, however, the broad landscape of PPIs 
has made it difficult to parse out clear interaction networks.   
Several features of PPIs make their study a challenging endeavor.  Proteins in 
many PPIs participate in a wide variety of interactions with multiple interacting partners 
that have varying cellular roles.15  Interactions may occur only under particular cellular 
conditions or regions of a cell.  In addition to compositional dynamics within PPI 
complexes, individual subunits may exhibit significant conformational plasticity as a 
means to interact specifically with a variety of binding partners.  Although challenging, 
studying complex PPI networks and understanding their purposes within a cell provides a 
foundation for understanding what malfunctioning interactions cause disease.  Regaining 
normal PPI functioning or blocking unwanted PPIs has been a long-term goal of drug 
development.  Although many years of research have gone into understanding PPIs, 
developing ways to better study and understand interaction networks still needs to be 
done. 
In order to examine the critical features of PPIs, several classification systems 
have been analyzed.  Several defining features for classifying PPIs include biological 
role, protein structure, interface surface area, and interaction binding affinity.  
Classification of PPIs by biological role has proven useful, as similar function within a 
cell often means a similar mode of action and structure.  In addition to functional 
classification, structural homology is a useful tool for proteins that have well-ordered 
structural features.  A molecular basis for the interaction can be established, since 
pinpointing specific requirements and contact points between the proteins is possible.  
For proteins that have less-defined structural features, in many cases it is possible to 
determine a range of amino acid residues that comprise the minimal interaction sequence 
and thus allows an estimated surface area of interaction.  An illustrative example of this is 
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the interaction between the yeast activator Gal4 and its repressor Gal80 for which limited 
structural data is Available.  Gal80 is a readily crystalized protein but Gal4 is largely 
unstructured and only a few residues have been well-defined in crystallography 
attempts.16, 17  In addition to useful properties gleaned from the amino acid content such 
as potential surface area and hydrophobicity of the interaction interface, more traditional 
biochemical methods can then be applied to deepen the understanding of the interface 
interactions.  For instance, mutational studies have been extensively used to assess a 
specific residue’s binding contributions to an interaction.18  Although understanding of 
specific molecular interactions between two proteins may be limited, this information 
aids in moving forward in accessing the size and potential for small molecule targeting of 
the interface.  Finally, PPIs may be classified by the binding affinity of an interaction.  
Binding affinity is a measure of how tightly two partners interact and often gives clues to 
the nature of an interaction.  For example, in processes that may only occur for a short 
period of time, such as gene expression, the “turning on” of the molecular switch requires 
Figure 1-1 Inhibitors Targeting Different Areas of PPI Chemical Space. 
Recent advances in protein-protein interaction inhibitor design and screening methodologies have led to the 
discovery of a number of new small-molecule inhibitors, although success in targeting high-affinity, small-surface-
area interactions has far outpaced broader or weaker interactions. SA, surface area. 
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binding affinity to be weak and transient, otherwise, the molecular switch would be very 
difficult to “shut off.”19   
Using surface area and binding affinity to plot the number of drugs discovered for 
PPIs, we can see a trend.  The largest body of successful work has focused on PPIs that 
have tighter interactions with a smaller surface area (Figure 1-1).8, 10  These PPIs are 
usually the most enzyme-like with defined binding pockets more amenable to small 
molecules.  One area that has particularly struggled are PPIs with large binding surfaces 
and transient affinities.15   Recent advances in biochemical methods, however, have 
allowed for the easier study of larger, more transient PPIs.  Although, the general 
advancement of laboratory instrument technology (cryo-electron microscopy and mass 
spectrometry for example) has allowed for the study of larger protein complexes, the 
Availability and application of biochemical probes has dramatically increased the 
convenience of doing in vivo studies.  This has allowed the field to advance toward 
conducting experiments involving PPIs within their native environments which decreases 
the chances of overlooking a weaker PPI and keeps larger interacting protein complexes 
assembled and in their functional forms. 
An additional complicating factor in many PPI studies is the dynamic interfaces 
that exist for proteins that are involved in multiple PPIs.  One example of this can be 
found by looking at the GACKIX (Gal11, Arc105, CBP/p300, kinase-inducible domain 
interacting) domain of the master coactivators and histone acetyltransferases CBP and 
p300.  GACKIX is highly plastic, and its two binding surfaces can accommodate more 
than 15 
distinct 
binding 
partners, in the 
context of 
binary or 
ternary 
complexes, 
that are 
involved in a 
Figure 1-2 Dynamic Protein Complexes. 
GACKIX has two binding sites to interact with more than 10 distinct transcriptional activators 
with each ternary complex having a signature conformation.1 
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variety of physiological processes and implicated in diseases from cancer to neuropathic 
pain (Figure 1-2).1  Low energy barriers between individual conformations mean that a 
participant can use the same group of amino acids to recognize a variety of binding 
partners, with each complex requiring a distinct conformation.  Much like the puzzle 
depiction of this process, synthetic regulation of complex assembly represents an 
opportunity to “freeze” the protein so only certain partners (or puzzle pieces) are able to 
bind furthering the selectivity of a molecule and give it context specificity. 
1C: Transcriptional Activators and Their PPIs 
Transcription-related proteins which are involved in the process of moving from 
information encoded within the DNA to messenger RNA (mRNA) for later translation 
into functional proteins combine aspects of the more difficult interactions to study 
mentioned previously such as large, low affinity, and dynamic PPI interfaces.  Although 
necessary for their biological function, to assemble the necessary proteins and protein 
complexes to eventually recruit RNA Polymerase II and begin the transcription 
process,20(Figure 1-3), the proteins in this process often contain dynamic binding 
interfaces allowing them to participate in many different interactions.21  One study found 
that of 401 transcription factors computationally analyzed, approximately 49% of the 
sequences indicated intrinsically disordered regions.6  In fact, a disordered to ordered 
transition is assumed to occur upon binding of proteins such that alterations in structure 
Figure 1-3 Transcription Initiation Process. 
Transcriptional activators participate bind DNA and begin recruiting coactivator complexes for the pre-initiation 
complex (middle).  This collection of complexes involves those such as Saga, Swi/Snf, Mediator, and RNA Pol II.  
Once RNA Pol II has been recruited, transcription can proceed.   
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may exist between different binding partners.22, 23  These broad and weak interactions 
lead to distinct networks of PPIs being used to assemble the transcriptional machinery 
and usually begin with one protein, a transcriptional activator.  To recruit proteins to a 
specific DNA sequence, a transcriptional activator will bind to DNA and begin recruiting 
protein complexes to modify and remodel the chromatin to make room for the 
recruitment of other proteins such as the general transcription factors and the large 
coactivator complex, Mediator24, 25.  The recruitment of these factors leads to the binding 
of RNA Polymerase II and allows the initiation of transcription (Figure 1-3).   
The proteins at the root of this process, transcriptional activators, wield great 
power within a cell by promoting or inhibiting the expression of genes.  This powerful 
role of activators places a bull’s eye on them for controlling and understanding 
transcriptional PPI regulation.  However, transcriptional activators have several features 
that make them difficult to study.  Traditional probe discovery or design methods are ill 
equipped to target these complexes because one or both binding partners are classified as 
intrinsically disordered proteins, and the complexes often form transiently in the cell, 
with affinities one to two orders of magnitude weaker than the category of small surface 
area and high affinity interactions previously discussed.8, 22  Further, the interaction 
surface is often considerably larger, with interaction energies shared over greater 
numbers of amino acids, defying hotspot analysis.  Using the prototypical transcriptional 
activator p53 as an example, we can see the wide range of affinity and surface areas a 
protein involved in many transcriptional PPIs can exhibit, (Figure 1-4).  The complexes 
formed between p53 and its regulatory partners such as MDM2 are typically high affinity 
with a relatively small surface area, and their interaction energy largely resides in a small 
number of residues (Figure 1-4, upper left image). These are structurally well-organized 
interfaces and are highly amenable to structural characterization. As with many 
activators, p53 typically functions as a multimer, and the oligomerization interface is 
another high affinity, well-organized interface, although it takes place over a 
considerably larger binding surface (Figure 1-4, upper right image). The final group of 
PPIs that activators such as p53 utilize are those with coactivator proteins, typically 
involved as part of the assembly of the transcriptional machinery in the early stages of 
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transcription (Figure 1-4, 
lower image). These 
interactions are most 
poorly characterized, 
likely because the binding 
partners are 
conformationally 
dynamic, inhibiting high-
resolution structural 
studies, and many are of 
only moderate affinity.  
 Although 
these features of 
transcriptional PPIs make 
them difficult to study, 
they are critical to the 
function of the activator 
and are responsible for 
their ability to control the 
level of gene expression.  
While a single interface is 
utilized for interacting 
with many proteins it also allows for exceptional specificity.  The larger interfaces that 
take on a dynamic structure, many varying with each binding partner or regulatory signal 
allows for the very specific targeting of a given interaction, theoretically without 
disturbing other interactions in which a given protein may participate in.22, 26  For 
example, screening techniques that directly address the conformational plasticity of 
coactivators have been effective for identifying small-molecule modulators that capture 
distinct conformers.  The site-directed fragment screening strategy of tethering first 
developed at Sunesis is one such strategy.  When applied to the conformationally 
dynamic GACKIX motif, (Figure 1-2) researchers identified chemical co-chaperones that 
Figure 1-4 Chemical Space of Protein-Protein Interactions. 
Protein-protein interactions can be effectively classified by the strength of the 
complex (Y-axis) and the surface area over which the interaction occurs (X-
axis). Using p53 as an example, transcriptional activator interaction networks 
span a broad range of strength and surface area. PBD ID codes for each 
structure are as follows: p53-Mdm2 repressor, PDB 1YCR; p53 dimer, PDB 
1PET; p53 with CBP 2L14. 
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stabilize a range of GACKIX conformations and dictate the formation of particular 
GACKIX– transcription factor assemblies either positively or negatively.27  In addition to 
conformational specificity, context specify is also a factor in transcriptional proteins. One 
example of this is the BAF-type chromatin remodeling complexes that play a key role in 
transcription initiation.  Most share a core enzymatic subunit (the ATPase Brg), but there 
are exchangeable subunits that vary according to tissue (Figure 1-5).2  Recently, evidence 
has emerged that transcription factors target both the enzymatic component and 
exchangeable 
modules in such 
complexes as part 
of the assembly of 
the transcriptional 
machinery.  Thus, 
one could imagine 
blocking a PPI 
that would affect 
the localization of 
a complex at 
particular gene promoters but would leave the core enzyme unaltered, providing 
functional capacity in other contexts.  The ability to prevent or initiate specific 
transcription events through controlling this process would be a huge gain for the medical 
field as the misregulation of transcription is critical to many human diseases (Figure 1-6). 
To begin deciphering the PPIs that are part of the network of transcriptional 
activators, this body of work focuses on amphipathic activators which are modular in 
makeup.  Amphipathic activators have a structured DNA-binding domain (DBD) tethered 
to an intrinsically disordered transcriptional activation domain (TAD) that usually only 
gains a concrete structure upon binding a transcriptional coactivator (Figure 1-3).21  As 
their name suggests, amphipathic activators are characterized by the predominance of 
amphipathic amino acid residues within the TAD that are important for coactivator 
binding.  A large body of classical transcriptional studies focused on amphipathic 
activators giving the foundation for subsequent methods to investigate transcriptional 
Figure 1-5 Dynamic Composition of Transcriptional Complexes Offers a Route 
to Specificity. 
The BAF chromatin remodeling complexes contain the same enzymatic core (BRG1) but 
have exchangeable subunits such as BAF45a and BAF45b that define tissue specificity.2 
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PPIs.  Most early studies in 
this area focused on yeast, an 
easy to manipulate model, 
since the transcriptional 
apparatus is conserved across 
species.   As it is responsible 
for producing all mRNA for 
gene translation, RNA Pol II 
and its associated factors is 
one of the most universally 
homologous protein 
complexes across species, 
and important for 
understanding misregulation 
in human disease28, 29.  Over 
the years, using yeast as a 
model, researchers have 
looked at many of the 
components needed by RNA 
Pol II for transcription as 
well as start to understand 
their assembly20, 28.  The 
amphipathic yeast activator, 
Gal4, has been historically 
used to study transcription30 
and is particularly useful due 
to its activation of gene 
expression in response to 
nutrient Availability in 
yeast.31-35  This allows for easy induction of this activator and its target genes.  The action 
of Gal4 has been well studied and an abundance of data exists pertaining to the activation 
Figure 1-6 Transcriptional Activators and Consequences of 
Misregulation. 
With many components needing to come together, there are many places for 
error during the transcription initiation process from lack of initiation to over 
expression to alteration of complex components.  Outlining the body, activators 
involved in specific diseases are shown indicating how many activators are 
involved in disease not accounting for other factors such as coactivators, and 
chromatin remodeling factors.7 
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domain including mutational studies, binding sites in the genome, interactions with 
repressor protein Gal80, and pathways activated by this gene17, 18, 31, 32, 34-48.  Using this 
wealth of information, the Gal4 transcriptional activator in yeast is an ideal system for 
pursuing methods to look at undiscovered binding partners and to gain insight into novel 
proteins/protein complexes activators may recruit to a promoter. 
Contrary to the seemingly well-rounded model activator Gal4 presents, there are 
still many questions surrounding activator recruitment during the transcriptional 
activation process.  One activator, discussed further in Chapter 2, VP16 is a viral 
activator from the Herpes simplex virus and has had years of swirling debate regarding 
the recruitment of TATA-binding protein (TBP) at the GAL1 promoter.  The traditional 
view of activator recruitment is the binding of SAGA, a histone acetyl transferase that is 
believed to aid in mediating interactions with the general transcriptional machinery, and 
Mediator, which attracts the nucleosome remodeling complex SWI/SNF, followed by the 
rest of the general transcription factors and RNA Pol II.  Based off this model, several 
groups have shown using ChIP and crosslinking methods in vivo that TBP may be 
recruited to the promoter through interactions with the SAGA complex.49-52.  In contrast 
with the accepted model, using purified protein, different groups have shown the ability 
to co-precipitate TBP from lysate using the activator VP16 as well as view binding with 
immobilization assays and fluorescence polarization.53-56.  As will be highlighted in 
Chapter 2, the methods that give us the ability to decipher what is recruited by 
transcriptional activators during transcription initiation allows us to edge our way closer 
to understanding the process and developing molecular tools to aid in its modulation.  
1D: Strategies for a New Age of Transcriptional Activator PPI Studies 
1DI: Current Methods Applied to PPIs 
With the described difficulties of investigating PPIs, a menagerie of methods has 
been created.  Some of the traditional biochemical methods used to study protein-protein 
interactions include co-immunoprecipitation and affinity purification followed by 
Western blotting.  These methods involve the selection of a protein through the 
attachment of epitope or affinity tags such as a Flag tag and poly-histidine tag or biotin, 
respectively57, 58.  The binding of an antibody or resin then allows the pull-down of the 
protein of interest for Western blot analysis (Figure 1-7).  While this method provides a 
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very clear display of interacting proteins, it often misses those that have weaker binding 
affinities that cannot withstand washing during a pull-down.  These methods are also not 
amenable to proteins that aggregate or easily become misfolded.  Moreover, this 
technique is performed in vitro using cell lysates and thus interactions that are only 
observed in the native context are not seen. 
The desire to keep proteins in their native environments while evaluating PPIs has 
led to the development of several in vivo techniques such as the yeast two-hybrid, Förster 
resonance energy transfer (FRET), and protein complementation methods.  These 
methods involve expression of the binding partners of interest within yeast or mammalian 
cells, allowing a native environment to be maintained, while looking for the interaction of 
interest (Figure 1-7).  The yeast two-hybrid involves the expression of the protein of 
interest attached to a DNA-binding domain, often of Gal4, while co-expressing the 
hypothesized binding partner fused to a transcriptional activation domain59.  Thus, if the 
proteins are interacting partners, a complete transcriptional activator is present and 
transcribes a reporter gene of choice.  In a similar fashion, protein complementation 
methods fuse half of a fluorescent protein such as GFP or a bioluminescent protein such 
as luciferase to the protein of interest with the other half fused to the hypothesized 
binding partner.  Once the two binding partners interact, a complete protein of fluorescent 
or bioluminescent nature is made and can be detected60, 61.  FRET applies the use of two 
fluorescent proteins or molecular probes such that, one fluorophore can be excited and 
will emit at the excitation level of the second fluorophore which will emit at a 
wavelength characteristic to that fluorophore62, 63.  As with pulldown methods, these in 
vivo techniques are not often amenable to protein structures or interactions sensitive to 
changes, as they involve the attachment of large tags or proteins.  It also requires the 
knowledge of both binding partners, so it limits a discovery motivated search coupled 
with the fact that using fluorescent readouts can often produce results that have a high 
background, making them difficult to apply to certain cellular conditions.    
In addition to general PPI methods that have been developed, further methods 
have been established for DNA-bound proteins.  Classical methods such as chromatin 
immunoprecipitation, ChIP, which employs the non-specific crosslinker formaldehyde to 
crosslink protein complexes to each other and DNA for immunoprecipitation and 
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verification at a given promoter (usually with an established activator) by PCR 
amplification of pulled down DNA pieces, have elucidated many transcriptional PPIs64, 
65.  This approach gives information about PPIs at the gene promoter under selected 
cellular conditions by “freezing” live cells to crosslink the PPIs in their native 
environment (Figure 1-7).  New techniques along this line of thought such as ChIP-Seq, 
also employ the principles of pulled-down DNA to map proteins to specific genomic 
locations66, 67.  One disadvantage of these methods is the lack of selectivity.  The 
formaldehyde crosslinking enables the pull-down of all proteins in a complex and doesn’t 
necessarily indicate a direct interaction if found.   Expanding on this method, a new 
method to improve the ability to observe direct binding partners at the promoter has been 
developed and discussed in detail in Chapter 2.    
The use of chemical crosslinkers such as amine-reactive N-hydroxysuccinimide 
esters, sulfhydryl-reactive maleimides, photocrosslinkers or formaldehyde (as mentioned 
above) have also been employed for the covalent attachment of binding partners within a 
cell68-70.  These methods have proven successful in identifying many PPIs and essentially 
suspend the protein interactions in their current state (Figure 1-7).  Although small and 
providing minimal structure perturbation, these crosslinkers do suffer from a lack of 
selectivity.  Most crosslinkers employed are non-specific or attack a specific amino acid 
type such that entire complexes are crosslinked and it can be hard to parse out direct PPIs 
versus indirect PPIs through the complex.26  As will be discussed in the next section, the 
recent application of crosslinkers to in vivo studies has greatly expanded their usefulness 
in looking at direct PPI binding partners in their native context. 
 A final and relatively new approach is the use of proteomics to identify novel 
PPIs.    This employs a mass spectrometer to analyze digested peptide fragments that 
have resulted from a pull-down of the protein of interest.  Quantitative measurements can 
also be made by using stable isotope labeling with amino acids in cell culture (SILAC) 
which applies a “heavy” or isotopically labeled amino acid to one sample to compare to a 
“light” or normal sample control.  The abundance ratio between light and heavy can then 
be used to quantify protein amounts between samples (Figure 1-7)71.  Similarly, 
crosslinked protein or reactive tags that are isotopically labeled or mass spec-cleAvable 
are also used for identification of PPIs70.  Though most studies done to map activator-
13 
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coactivator interfaces and activator interactions have been done using cell lysates or 
intact protein complexes, as pull-down efficiencies have increased with newer techniques 
and mass spectrometry technology has advanced, the ability to detect lower abundance 
proteins within the cell has improved as this has historically been a limiting factor to this 
strategy. 
1DII: Genetic Incorporation of Photolabile Unnatural Amino Acids 
In addition to the methods described above, another in vivo method of PPI 
identification applying crosslinking chemistry in cells has been developed.  This method 
inserts photocrosslinking amino acids in a site-specific fashion to allow for their use to 
covalently capture binding partners surrounding them.  Genetic incorporation of 
unnatural amino acids (UAAs) was first used by the Peter Schultz laboratory72, 73 and has 
since expanded to include over 100 different UAAs73.  This method relies on the fact that 
there are 3 stop codons present within the genetic code which are conserved throughout 
all of life.  The least used amber stop codon or TAG is nonsense suppressed by an 
orthogonal tRNA carrying the UAA of choice.  This tRNA also has a companion tRNA 
synthetase which loads the UAA onto the tRNA for incorporation (Figure 1-8.)74.  
Although this method often suffers from production loss due to truncation products 
(100% suppression of the amber codon is not possible) it has the advantage of producing 
protein with minimal tags or changes to the sequence.  Due to the large increase in 
Figure 1-8 Genetic Incorporation of Unnatural Amino Acids by Nonsense Suppression. 
Inserting a biorthogonal tRNA and tRNA synthetase pair into the expression system of choice with the complementary 
UAA allows for the site-specific incorporation of the UAA at the amber stop codon TAG without any interference to the 
normal translational machinery or tRNA pairs. 
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species capable of incorporating unnatural amino acids, often the protein can even be 
expressed in its native organism.   
Once produced, the protein can function in the cell as it naturally would and bind 
to its partners in the native cellular context.  This makes the method extremely useful as it 
enables in vivo characterization, is amenable to all protein types, and disruption of normal 
functioning is minimal.  In addition to providing a method to capture binding events in 
the native cellular context, photocrosslinkers also have a fast reaction rate (Figure 1-9).  
This permits the capture of more transient, short-lasting PPIs (Figure 1-9). 
1E: Overview of Thesis 
In the following chapters, it will be demonstrated how the use of genetically 
incorporated unnatural amino acids has expanded our ability to study difficult PPIs.  In 
Figure 1-9 Activation of Popular Photocrosslinking Amino Acids. 
Benzophenones (top) are a diradical reactive species with a 3.1Å reactivity radius and 120 µs reactive form until 
relaxation back to the inactivated ketone4, 5.  Azides (middle) lose N2 and form a nitrene which is reactive for 0.1 
ms before rearranging to the less reactive but more stable ketenimine that can only react with 
nucleophiles458585858485.  The aromatic diazirine (bottom) forms a highly reactive singlet carbene which has 
a lifetime of approximately 1 ns or a diazoisomer which ultimately converts to the carbene as well9, 10. 
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particular, examination of transcriptional activator-coactivator complexes in their native 
environment has been successfully demonstrated through the use of photolabile UAAs to 
covalently capture protein binding partners in live cells.  Chapters 2-3 contain a 
discussion of covalent capture methods combined with mass spectrometry to discover 
novel PPIs as well as show new ways to visualize direct PPIs on DNA.  Chapter 4 further 
explores a caveat to covalent capture, the lack of in vivo characterization of crosslinking 
moieties.  The window of capture for each moiety was determined across a various PPI 
binding affinities and surface areas.  The methods developed in this thesis provide a 
sound demonstration of the power of using covalent chemical capture for the study of 
PPIs in a cellular context. This work is significant to the field of biochemistry, as it adds 
to the framework indicating that difficult PPIs can be studied and into the future, 
understood. Retaining the native environment of these PPIs not only allows much easier 
study but also can indicate their importance to cellular functioning as many of these PPIs 
are part of critical cell processes that would allow researchers to understand diseases and 
potentially find better drug targets. In addition, I have discovered novel binding partners 
of our yeast model activator, Gal4, which broadens the perspective on transcriptional 
activator participation in dynamic complexes implicated in the transcription initiation 
process. 
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Chapter 2: TRIC - Capturing the Direct Cellular Targets of Promoter-Bound 
Transcriptional Activators2 
2A: Abstract 
Transcriptional activators coordinate the dynamic assembly of multi-protein coactivator 
complexes required for gene expression to occur. Here we combine the power of in vivo 
covalent chemical capture with p-benzoyl-L-phenylalanine (Bpa), a genetically 
incorporated photocrosslinking amino acid, and chromatin immunoprecipitation (ChIP) 
to capture the direct protein interactions of the transcriptional activator VP16 with the 
general transcription factor TBP at the GAL1 promoter in live yeast. 
2B: Background 
Transcriptional activators are essential in directing the assembly of the RNA 
polymerase transcriptional machine at individual promoters within the genome.  Though 
it is well understood that this occurs through the formation of protein-protein interactions 
(PPIs) between DNA-bound activators and individual components of the transcriptional 
machinery, resolving the network of activator PPIs that underpin this process has been 
technically challenging1.  For example, in vivo co-localization and chromatin 
immunoprecipitation (ChIP) studies have identified the complexes that are recruited by 
activators to the promoter, but distinguishing the individual subunits within these 
complexes that serve as the activator binding partner(s) in vivo has not been possible.  
Toward this goal, in vivo covalent chemical capture with genetically incorporated 
photocrosslinking amino acids has emerged as an important tool in the identification of 
PPIs in cells2-5.  Here we describe an expansion of this strategy that utilizes the rapid, 
reversible formaldehyde crosslinking of ChIP together with the site-specific, irreversible 
crosslinking of the non-natural amino acid p-benzoyl-L-phenylalanine (Bpa) to 
investigate the direct, in vivo PPIs of DNA-bound activators.  We demonstrate that this 
                                                
2 Portions of this chapter are taken from: Dugan, A.; Pricer, R.; Katz, M.; Mapp, A.K., TRIC: Capturing the direct cellular targets of 
promoter-bound transcriptional activators.  Protein Sci. 2016, 25, 8, 1371-1377.  My contributions to this work include initial 
optimization experiments contributing to the TRIC method, data in Figure 2-1D, Figure 2-2, and assisting in writing. 
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tandem reversible and irreversible crosslinking (TRIC) approach is able to capture the 
interaction of the viral activator VP16 and the general transcription factor TBP at the 
GAL1 promoter in live yeast. 
The identities and compositions of the multi-protein complexes that assemble at 
genes in order to initiate gene expression can vary significantly from promoter to 
promoter6-9.  Due to a lack of methods appropriate for determining the individual contacts 
made by activators at a promoter, these PPIs remain poorly defined.  As an example, the 
recruitment of TATA-binding protein (TBP) by the canonical transcriptional activator 
VP16 has been studied extensively, yet the mechanism by which TBP arrives at 
promoters is still contested, even in the case of well-studied promoter contexts such as 
GAL1.10-15  A significant body of in vitro data exists to support a direct interaction 
between VP16 and TBP16-19.  However, in vivo ChIP studies suggest that TBP 
recruitment to GAL1 is mediated via interactions with the SAGA complex, supporting a 
model in which the activator is not directly involved in TBP recruitment20-23.   
2C: Covalent Chemical Capture of TBP-VP16 Interaction 
To distinguish between the two mechanisms of TBP recruitment, in vivo covalent 
chemical capture was first used to determine if VP16 directly contacts TBP in living 
yeast.  In this approach, the photolabile unnatural amino acid Bpa is genetically 
incorporated into the transcriptional activation domain (TAD) of VP16 using an 
engineered nonsense suppression system24, 25.  Upon irradiation of live yeast with UV 
light, Bpa is activated and forms an irreversible covalent bond with any protein partners 
that are in direct contact with VP16 at the site of incorporation.  The covalently captured 
binding partners can then be isolated and analyzed to determine their identities.  As 
previously described, we used a chimeric activator in which the amino terminal half of 
the extended VP16 activation domain is fused to the LexA DNA binding motif2.  We 
chose to incorporate Bpa at position 444 in the VP16N (413-456) subdomain, as this 
residue has been shown to be involved in maintaining activator interactions and, 
consistent with this, our previous work showed a robust and repeatable multi-protein 
crosslinking profile at this position.  Furthermore, work from our group has demonstrated 
that incorporation at this site does not impair activator function2.  LexA+VP16 L444Bpa 
was expressed in yeast and the cells were irradiated with UV light to activate Bpa and 
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covalently capture any proteins directly contacting VP16.  Yeast were then lysed and the 
lysates immunoprecipitated with an antibody showed a robust and repeatable multi-
protein crosslinking profile at this position.  Furthermore, work from our group has 
demonstrated that incorporation at this site does not impair activator function2.  
LexA+VP16 L444Bpa was expressed in yeast and the cells were irradiated with UV light 
to activate Bpa and covalently capture any proteins directly contacting VP16.  Yeast were 
then lysed and the lysates immunoprecipitated with an antibody against TBP.  After 
washing away any non-covalently bound proteins, the immunoprecipitated TBP was run 
on SDS-PAGE and the resulting Western blot was probed with a Flag-HRP antibody to 
detect the presence of a covalently bound VP16-TBP species.  Indeed, a crosslinked band 
is observed at approximately 60 kDa that corresponds to the additive molecular weight of 
the LexA+VP16 construct and TBP (Figure 2-1A).  This data indicates that VP16 directly 
Figure 2-1 VP16 Directly Contacts TBP in Yeast. 
The VP16-TBP interaction was captured in vivo using covalent chemical capture in yeast expressing (a) LexA+VP16N 
L444Bpa and (b) LexA+VP16N WT and Myc-TBP L114Bpa.  Yeast were irradiated with UV light and the lysates 
immunoprecipitated with a TBP antibody.  The covalent VP16-TBP products were visualized on Western blot with an α-
Flag HRP antibody. (c,d) Tandem reversible and irreversible crosslinking captures the direct targets of DNA bound 
transcriptional activators.  Identical cultures of yeast expressing LexA+VP16N L444Bpa were either crosslinked with UV, 
formaldehyde, or treated with a combination of both procedures (formaldehyde followed by UV crosslinking).  The 
chromatin fractions of these cultures were washed to remove non-covalently bound protein and then the chromatin was 
sheared and solubilized using sonication.  Soluble chromatin was then immunoprecipitated with an α-TBP antibody and the 
formaldehyde crosslinks were reversed.  Western blots (c) were probed with an α-Flag antibody and immunoprecipitated 
DNA was amplified with GAL1-LacZ specific primers and visualized on an agarose gel stained with ethidium bromide (d). 
(e) Chromatin immunoprecipitation at the GAL1 promoter in yeast.  Bars are the mean of at least three biological replicates. 
Error bars indicate the standard error of the mean. 
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contacts TBP in live yeast.  Consistent with previous reports, introduction of a double 
point mutation in the VP16 activation domain (L439P and F442P) that abolishes activity 
also abrogates crosslinking to TBP, indicating that this interaction is specific (Figure 
2-1A)26, 27.   
To further substantiate this interaction, covalent chemical capture in which TBP is 
the captor was carried out.  Biochemical data suggest that residues along the concave face 
of TBP are involved in dynamic exchange with the other transcriptional proteins, 
including activators, which compete for binding at this site28-30.  We therefore co-
expressed LexA+VP16 WT alongside a Myc-TBP construct in which the leucine at 
position 114 was mutated to Bpa (L114Bpa) and carried out covalent chemical capture 
experiments.  We found that incorporation of Bpa at this position in TBP resulted in 
crosslinking TBP-VP16 adduct (Figure 2-1B).  Thus in support of previous biochemical 
data, our results indicate that this site on TBP is indeed a contact point for VP16 in vivo30.    
2D: TRIC-Tandem Reversible and Irreversible Crosslinking in Yeast 
While demonstrating a direct interaction between VP16 and TBP, the above 
experiments do not report on any one context.  In other words, the crosslinked species 
likely originate from a variety of different promoter-localized and non-DNA bound VP16 
species.  We next chose to design a straightforward method that would allow for the 
direct examination of the VP16-TBP interaction at the GAL1 promoter present in the 
yeast strain.  The first step of this strategy borrows principles from classic chromatin 
immunoprecipitation (ChIP) protocols in which formaldehyde is first administered to 
cells to rapidly stabilize dynamic protein-DNA interactions.  The fixed cells are then 
subjected to our covalent chemical capture workflow in order to activate Bpa and site-
specifically crosslink the direct targets of our Bpa-containing activators within the 
immobilized transcription complexes.  The advantage of this tandem crosslinking 
approach is rooted in the nature of the covalent bonds that are formed by each 
crosslinking moiety; more specifically, the formaldehyde crosslinks can be readily 
reversed in an appropriately nucleophilic buffer, whereas the Bpa crosslinks are 
irreversible under such treatment conditions.  Thus, after tandem crosslinking treatment, 
we could lyse the yeast, isolate the insoluble chromatin-containing pellet, and wash the 
pellet extensively to remove any non-DNA bound complexes.  Similar to ChIP, the DNA 
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could then be solubilized via sonication and immunoprecipitation carried out against the 
protein of interest, in this case TBP.  The formaldehyde crosslinks on the isolated 
complexes are then reversed, leaving only the irreversible photocrosslinked activator-
coactivator interactions intact and able to be visualized via Western blotting (Figure 2-2).   
When we executed our tandem reversible and irreversible crosslinking (TRIC) 
approach, we found that only under conditions where both formaldehyde and UV 
Figure 2-2 Tandem Reversible and Irreversible Crosslinking (TRIC) Allows for the Covalent Capture of 
Direct Targets of Transcriptional Activators at the Promoter. 
Yeast cells are treated with formaldehyde to stabilize protein-DNA and protein-protein interactions at the promoter. 
Treated cells are then gently irradiated with UV light to activate a genetically encoded photocrosslinking amino acid in the 
transcriptional activation domain (TAD) of the activator coordinating complex assembly. The cells are lysed and the 
chromatin isolated and sheared via sonication. Following immunoprecipitation of the immobilized complexes, the 
formaldehyde crosslinks are reversed and the irreversibly covalently linked PPIs are identified by Western blotting. 
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treatment were used were we able to observe a VP16-TBP crosslink in the DNA fraction, 
whereas UV alone was sufficient to capture this interaction in yeast lysate (Figure 2-1C).  
When this protocol was repeated to examine the DNA that co-purified during 
immunoprecipitation, we observed that the GAL1-LacZ gene could only be visualized 
under conditions in which formaldehyde was present.  This indicates that formaldehyde 
stabilization of promoter-bound proteins is required to observe the interactions of DNA-
bound activators (Figure 2-1D).  Finally, we executed a straightforward ChIP protocol to 
show that both LexA+VP16 and TBP co-localize to our reporter gene and confirm that 
we are indeed observing a direct protein-protein interaction at this specific location in the 
yeast genome (Figure 2-1E).  
We note that although the protocol is a hybrid of two powerful approaches, 
optimization efforts in several areas were required in order for this approach to work.  
The first point of optimization was the duration of formaldehyde crosslinking.  We were 
unable to observe a VP16-TBP interaction using previously reported one-minute rapid 
mixing protocols.31  We therefore tested several formaldehyde treatment times and found 
that five-minute treatment with formaldehyde was the shortest interval that could be used 
to achieve consistent results.  As has been noted elsewhere, formaldehyde crosslinking 
optimization will have to be examined on an individual protein basis in order to achieve 
sufficient crosslinking results.32, 33  Another key point of optimization for this study 
involved the extent of yeast lysis prior to sonication of the insoluble chromatin-
containing fraction.  Yeast have a tough cell wall that is notoriously difficult to break 
open.  We found that under conditions of incomplete lysis, any remaining cells that 
pelleted with the insoluble fraction would release their cellular contents upon sonication, 
resulting in contaminating bands in the UV treated lanes of the Western.  We thus 
screened a number of commercially Available chemical lysis reagents and mechanical 
lysis conditions to determine a method that would provide us with the most complete 
yeast lysis.  We evaluated the efficacy of lysis under each condition by measuring the 
total concentration of protein released in the lysate as well as by visually assessing the 
extent of lysis by monitoring cells under a microscope.  We found that only extended 
mechanical disruption with glass beads consistently achieved >95% cell lysis and yielded 
maximal protein release in the cell lysate. 
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2E: Conclusion 
In conclusion, we have described a new in vivo tandem crosslinking approach that 
is useful in capturing the PPIs of DNA bound activators, as demonstrated by the capture 
of VP16 and TBP at the GAL1 promoter.  The advantage of this strategy over previously 
described dual crosslinking applications (such as those using formaldehyde and 
disuccinimidyl suberate, for example) is that the use of a site-specific photocrosslinking 
amino acid allows one to distinguish the direct targets of a given protein within a DNA-
bound multiprotein complex.  This allows a level of resolution that, to the best of our 
knowledge, has not been achieved prior to this work.   
TBP is an essential transcription factor required for gene expression in yeast, yet, 
as is the case with other requisite transcriptional complexes, the mechanism by which it is 
recruited to promoters has remained elusive, even in the most well-studied promoter 
contexts.  Using TRIC, we were able to stabilize transcription factor-DNA contacts and 
then covalently capture proteins that were in direct contact with the Bpa-containing 
activator VP16 in live yeast.  This work suggests that VP16 directly contacts TBP in 
yeast to recruit the general transcription factor to the GAL1 promoter.  While our results 
thus suggest a direct mechanism of recruitment to GAL1, earlier observations that SAGA 
is required for TBP localization to GAL1 likely point to a role for SAGA in stabilizing 
TBP residency at this promoter.20-23  This work is an important first step toward resolving 
the PPI map of activators at a single promoter, work that will be useful in building a more 
complete picture of activator interactions as a whole.  Future work will be focused on 
combining TRIC with DNA microarray technologies to facilitate the identification of the 
direct interactions of a single activator at individual promoters across the genome. 
2F: Experimental 
All covalent chemical capture and TRIC experiments were carried out in yeast 
strain LS41 [JPY9::pZZ41, Mat his3∆200 leu2∆1 trp1∆63 ura3-52 lys2∆385 gal4 
URA::pZZ41].  Bpa was purchased from Chem-Impex International (Wood Dale, IL). All 
plasmids used in this study were constructed using standard molecular biology 
techniques.  Sanger sequencing verifying plasmid sequences was performed by the 
University of Michigan Core Facility (Ann Arbor, MI).  
Construction of plasmids  
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pLexA+VP16N WT  
A high copy plasmid expressing LexA(1-202)+VP16N (413-456)+5x FLAG tag 
under the control of the ADH1 promoter was created via ligation of the fusion gene into a 
pCLexA-5xFlag backbone containing BamHI and SalI sites.  Primers 5’- 
catgaattcATGGCCCCCCCGACCGATGTC-3’ and 5’- 
catGTCGACTTACTTGTCATCGTCGTCCTTGTAGTCTCCCGGCCCCGGGGAATC
CC-3’ were used to amplify VP16 (413-456) from a pCLexA-VP16-1xFlag template. The 
amplified PCR product was digested with SalI and BamHI and inserted into pCLexA 
digested with SalI and BamHI and treated with calf intestinal phosphate to create 
pLexA+VP16N WT-5X Flag.  
pLexAVP16N 444TAG  
To create each plasmid, site-directed mutagenesis was used to replace an existing 
amino acid codon with TAG codon within the VP16C or VP16N TAD.  In general, PCR 
primers were designed to have ~15 bases of homology on either side of the TAG 
mutation.  QuikChange protocol was used to incorporate the TAG mutants using 
manufacturer recommended conditions. 
pGADT7 Myc-TBP  
A high copy plasmid pGADT7 expressing an N-terminally Myc-tagged TBP was 
constructed by amplifying the DNA sequence encoding TBP from yeast genomic DNA 
using primers (5’- catCATATGATGGCCGATGAGGAACGTTTAAAGG-3’) and (5’- 
atgCTCGAGTCACATTTTTCTAAATTCACTTAGC -3’).  The purified PCR product 
was ligated into a Myc-pGADT7 vector digested with NdeI and XhoI using standard 
molecular biology techniques.  The Myc-pGADT7 cloning vector was created by 
inserting a c-Myc epitope tag in pGADT7 (Clontech) using site-directed mutagenesis 
with the following primers: (5’- 
AGCTATGGAACAAAAGTTGATTTCTGAAGAAGATTTGGGATCCAATGCATAT
GATCT -3’) and (5’- 
AGCTTGATCATATGCATTGGATCCCAAATCTTCTTCAGAAATCAACTTTTGTT
CCAT- 3’).  Leu114 in TBP was mutagenized to an amber stop codon using site-directed 
mutagenesis (Qiagen Quikchange Protocol).  
In vivo covalent chemical capture  
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In vivo covalent chemical capture experiments for pLexA+VP16N L444Bpa was 
carried out as previously described.25  For crosslinking studies with Myc-TBP L114Bpa, 
the procedure was identical except that cells were grown in SC media lacking histidine, 
leucine, and tryptophan.  For lysis, cells were resuspended in 600 µL Lysis buffer (50 
mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-
Deoxycholate and 2X Complete Mini, EDTA Free Protease Inhibitor (Roche) and lysed 
using glass beads by vortexing at 4°C.  Subsequently, the lysate was pelleted and the 
supernatant incubated with 2 µg of LexA antibody (sc-1725,  Santa Cruz 
Biotechnologies) for 2 hours at 4°C for immunoprecipitation.  The protein bound to the 
antibody was isolated by incubation for 1 hour with 50 µL of prewashed protein G 
magnetic beads slurry (Dynal Corporation, Invitrogen, Carlsbad, CA) and the beads were 
washed 6 times with 1 mL Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% 
NP-40, 0.1% Na-Deoxycholate and 1 mM EDTA) and stored dry at -80˚C until elution.   
The crosslinked sample was eluted from the beads by heating at 95˚C for 10 minutes in 
NuPAGE 4x LDS Sample buffer (Invitrogen, Carlsbad, CA) containing 250 mM DTT 
and probed using Western Blot analysis using anti-FLAG (M2) antibody (Sigma, St. 
Louis, MO). 
Tandem reversible and irreversible crosslinking 
To perform TRIC, 100 mL cultures of yeast were grown in SC media containing 
2% raffinose, 2% galactose, 1 mL of 100 mM Bpa dissolved in 1M NaOH, and 1 mL 1M 
HCl.  The cultures were incubated overnight at 30°C with agitation and grown to mid-log 
phase (OD660 ~1.0).  Cultures receiving UV treatment only were spun down by 
centrifuging at 3901 rcf at 4˚C for 5 minutes following which the cell pellets were 
washed with SC media lacking histidine and tryptophan.  These cell pellets were 
resuspended in 2mL SC media lacking histidine and tryptophan + 2% raffinose, 2% 
galactose and transferred to small cell culture dishes and subjected to UV irradiation at 
365 nm light (Eurosolar 15 W UV lamp) with cooling for 0.5 hour.  
For cultures receiving only formaldehyde treatment, 3 mL of 37% formaldehyde 
solution was added directly to the culture and allowed to remain in the incubator for 20 
minutes.  Repeat of this procedure with a 5-minute formaldehyde incubation yielded the 
same results as a 20-minute incubation.  Cultures were then quenched with 15 mL of 2M 
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Glycine.  Cells were then centrifuged and washed with 50 mL SC media lacking histidine 
and tryptophan.  Samples intended to additionally receive UV crosslinking were 
resuspended in 2 mL SC media (His-,Trp-) containing 2% raffinose and 2% galactose and 
transferred to a small cell culture dish and subjected to UV irradiation at 365 nm UV light 
(Eurosolar 15 W UV lamp) with cooling for 0.5 hour.  
For lysis, cells were resuspended in 600 µL Lysis buffer (50 mM HEPES-KOH 
pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X 
Complete Mini, EDTA Free Protease Inhibitor (Roche) and lysed using glass beads 
mechanical disruption at 4°C until >95% lysis was observed.  We found in these studies 
that complete cellular lysis is necessary to eliminate background signal caused by cell 
lysis during sonication.  Subsequent lysates were immunoprecipitated with 8 µL TBP 
antibody (Santa Cruz, sc-33736) and incubated for 2 hours at 4°C.  The remaining pellet 
was then washed 4x with “Harsh” ChIP buffer (50 mM HEPES-KOH pH 7.5, 1M NaCl, 
1 mM EDTA, 1% Triton X-100, 1% Na-Deoxycholate) followed by 2 washes with 
standard ChIP buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 0.1% Na-Deoxycholate and 2X Complete Mini, EDTA Free Protease 
Inhibitor (Roche)).  Pellets were resuspended in 600 µL standard ChIP buffer containing 
protease inhibitor and sonicated at a setting of 10% for 2 minutes with 30 second pulses 
on/off (double-step microtip, Fisher Scientific Dismembrator Model 500).  Samples were 
then centrifuged at 4°C for 20 minutes at 14,000 rpm (Eppendorf 5417C).  Soluble 
chromatin (supernatant) was immunoprecipitated with TBP antibody (Santa Cruz, sc-
33736) for 2 hours, 4°C.  The protein bound to the antibody was isolated by incubation 
for 1 hour with 50 µL of prewashed protein G magnetic beads (Dynal Corporation, 
Invitrogen, Carlsbad, CA).  After immunoprecipitation, the beads were washed 6 times 
with 1 mL Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.1% Na-
Deoxycholate and 1 mM EDTA) and stored dry at -80˚C until elution.  The crosslinked 
sample was eluted from the beads and formaldehyde crosslinks reversed by heating at 
95˚C for 20 minutes in SUTEB buffer containing 250 mM DTT and probed using 
Western Blot analysis using anti-FLAG (M2) antibody (Sigma, St. Louis, MO).  For 
studies examining the DNA immunoprecipitated during TRIC, the TRIC protocol was 
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followed with the exception of 50 µL of solubilized chromatin being saved prior to 
immunoprecipitation.  Additionally, lysates were discarded in these experiments. 
To examine the size of the sheared chromatin, 50 µL TE/SDS was added to the 
Input samples and incubated overnight at 65°C to reverse crosslinks.  2.5 µL proteinase K 
(20 mg/mL stock) was then added and incubated at 50°C for 3 hours to digest proteins, 
followed by a PCR cleanup.  0.5 µL RNAse A (1 mg/mL stock) was added and then 
incubated at 37°C for 30 minutes.  Samples were visualized on 1% agarose gel stained 
with Ethidium bromide.  Smears showed between 300-900 bps. 
For PCR on TRIC samples, 90 µL TE/SDS was added to 50 µL input and 
incubated overnight at 65°C followed by PCR Cleanup and elution in 58 µL EB buffer 
(Qiagen).  For immunoprecipitated samples, beads were washed 2x with lysis buffer, 1 
time with 500 mM NaCl lysis buffer, 1 time with wash buffer, and two times with TE 
buffer (10 mM Tris-HCl, 1 mM EDTA, 0.01% SDS (5 g in 500 mL ex).  50 µL elution 
buffer (50 mM Tris-HCl, 10 mM EDTA, 1% SDS) was then added to the beads and 
vortexed briefly before incubating at 65°C for 30 minutes, with vortexing every 5 
minutes to resuspend the beads.  Beads were centrifuged for 30 seconds at 3000 rpm and 
the eluent transferred to a new tube.  120 µL TE/SDS was added and the samples 
incubated overnight at 65°C.  Samples were purified using a PCR cleanup kit (Qiagen) 
and eluted in 58 µL EB buffer.  DNA was quantified and PCR reactions were set up with 
GAL1- LacZ specific primers (5’ 
CCTTCTCTTTGGAACTTTCAGTAATACGCTTAACTGC 3’ and 
5’GGGCGATCGGTGCGGGCCTCTTCGC 3’).  Products were visualized on a 1% 
agarose gel stained with ethidium bromide. 
Chromatin Immunoprecipitation at GAL1-LacZ 
For chromatin immunoprecipitation, cultures were grown and formaldehyde 
crosslinked as was done for TRIC experiments.  After mechanical glass bead shearing, 
the lysate and insoluble pellet were resuspended by gentle pipetting.  Samples were 
sonicated and centrifuged as described earlier.  Soluble chromatin was separated from the 
pellet and 10 µL was saved as an input sample.  The remaining soluble chromatin was 
split equally between three 1.75 mL tubes which were then immunoprecipitated with 
either 2 µg Snf1 antibody (sc-15621, Santa Cruz Biotechnologies), LexA antibody (sc-
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1725, Santa Cruz Biotechnologies), or control IgG (SC- 2027, Santa Cruz 
Biotechnologies).  Immunoprecipitations were allowed to proceed for 2 hours at 4˚C 
followed by incubation for 1 hour with ~40 µL of prewashed protein G magnetic 
Dynabeads slurry (Life Technologies).  Beads were washed in the same manner as TRIC 
DNA samples.  Immunoprecipitated complexes were eluted in 50 µL elution buffer (50 
mM Tris-HCl, 10 mM EDTA, 1% SDS) at 65˚C for 30 minutes.  The eluate was 
transferred to a new tube and 120 µL of TE-SDS (10 mM Tris-HCl, 1 mM EDTA, 0.1% 
SDS) buffer was added.  To the saved inputs, 90 µL TE-SDS was added.  Formaldehyde 
crosslinks were reversed overnight in a 65°C water bath.  Samples were purified using 
Qiagen PCR Clean Up protocol and eluted in 58 µL Buffer EB. qPCR on all samples and 
inputs was run using Promega GoTaq qPCR master mix (A6001, Promega) using primers 
specific for GAL1-LacZ (sequences above).  All qPCR runs were carried out on an 
Applied Biosystems StepOnePlus instrument.  At least three independent biological 
replicates were run for each condition, with each biological replicate run in triplicate for 
qPCR quantitation.  PCR amplification with the designed primers yielded a single band 
around 450 bps.  This band was gel purified and submitted for sequencing.  Results 
returned a sequence for the GAL1-LacZ gene, as expected. 
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Chapter 3: Discovery of Enzymatic Targets of Transcriptional Activators via In vivo 
Covalent Chemical Capture3 
3A: Abstract 
The network of activator protein-protein interactions (PPIs) that underpin transcription 
initiation is poorly defined, particularly in the cellular context. Through the coupling of in vivo 
covalent chemical capture and shotgun LC-MS/MS (MuDPIT) analysis, we discover that the 
prototypical activators Gal4 and VP16 target the Snf1 (AMPK) kinase complex via direct 
interactions with both the core enzymatic subunit Snf1 and the exchangeable subunit Gal83. 
Further, the Gal4-Snf1 interaction is localized to the GAL1 promoter and visualized through a 
tandem reversible formaldehyde and irreversible covalent chemical capture approach (TRIC). 
Together, these data support a critical role for activator PPIs in both the recruitment and 
positioning of important enzymatic complexes at a gene promoter and represents the discovery 
of new cellular binding targets of transcriptional activators. 
3B: Background 
Executive orders within a cell are implemented by multi-component complexes whose 
functional state and subcellular location are often influenced by association with exchangeable 
subunits.1-3  In the process of transcription initiation, for example, several lines of evidence 
indicate that the Snf1/AMPK kinase complex arrives at the promoters of galactose catabolism 
genes only when the exchangeable subunit Gal83 is present within the complex4.  Although the 
molecular mechanism by which enzymatic complexes such as Snf1/AMPK localize to promoters 
has been the subject of debate, biochemical and genetic data suggests that the most likely 
suspects performing the recruitment function are one or more transcriptional activators via 
protein-protein interactions (PPIs).5-9  Distinguishing which of the components of an enzymatic 
(or coactivator) complex is the binding target of a promoter-bound activator is, however, quite 
difficult using conventional strategies.  This is particularly true in cellular settings, where the 
                                                
3 Portions of this chapter are from published work: Dugan, A.; Majmudar, C.Y.; Pricer, R.; Niessen, S.; Lancia, J.K.; Fung, H.; Cravatt, B.F.; & 
Mapp, A. K.  Discovery of enzymatic targets of transcriptional activators via in vivo covalent chemical capture. .JACS Submitted.  My 
contributions to this work include data in Figure 3-3 and Figure 3-5 and assisting in writing and figure creation. 
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transient nature of the activator-PPI network and the structural plasticity of the individual 
binding partners proves especially challenging.10-12  For this reason, the PPI network of 
transcriptional activators that underpins transcriptional activation is limited to a handful of 
transcriptional machinery proteins.13 
The prototypical transcriptional activator Gal4 
stimulates the co-localization of a long list of enzymatic 
complexes at the promoters of yeast galactose 
catabolism genes.14  In the presence of glucose, Gal4 is 
tightly repressed by its masking protein Gal80; 
however, when galactose becomes the primary carbon 
source, repression of Gal4 is relieved, enabling 
recruitment of complexes involved in galactose sensing 
and catabolism.15  To define the protein-protein 
interaction network that Gal4 engages to recruit these 
functions to promoters, we sought an approach that 
would mitigate false positives caused by the often 
promiscuous in vitro binding profile of transcriptional 
activators.  Thus, we focused on the interrogation of 
activator PPIs in the native cellular environment. 
Here we describe the combination of in vivo 
covalent chemical capture with the photocrosslinking 
amino acid p-benzoyl-L-phenylalanine (Bpa) and label-
free shotgun liquid chromatography-mass spectrometry 
analysis using the multi-dimensional protein 
identification technology (MuDPIT) to identify novel 
binding targets of the yeast activator Gal4 in live 
Saccharomyces cerevisiae that accompany gene 
activation (Figure 3-1).  Both Gal4 and the viral 
activator VP16 associate directly with two components 
within the central metabolic regulator Snf1/AMPK: the 
kinase Snf1 and an exchangeable sub-unit Gal83.  
Figure 3-1 An In Vivo Covalent Chemical 
Capture and Mass-Spectrometric Based 
Approach for the Identification of the 
Cellular Targets of Transcriptional 
Activators. 
Live yeast ex-pressing p-benzoyl-L-phenylalanine 
(Bpa)-containing activators (blue and red) are 
irradiated with UV light to covalently capture the 
spectrum of protein binding partners that activators 
directly contact in cells.  Following cell lysis, 
affinity chromatography and immunoprecipitation 
are used to enrich for cross-linked complexes.  The 
purified products are then subjected to mass 
spectrometric-based analysis such as Mud-PIT, thus 
allowing for the concurrent verification of 
previously identified activator targets (green) and 
the discovery of novel binding partners (orange). 
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Additionally, the combined use of reversible formaldehyde-based crosslinking and covalent 
chemical capture pinpoints the location of the Gal4-Snf1 PPI directly within the Gal1 promoter 
region.  These data support a central role for amphipathic activators in the functional response of 
Snf1/AMPK to changes in cellular environment.  As protein-protein interaction networks emerge 
as viable therapeutic tar-gets, covalent chemical capture in vivo will be a powerful tool for the 
discovery of molecular interaction points, particularly in dynamic assemblies. 
3C: Combined Covalent Chemical Capture and MuDPIT Identifies Gal4-Gal80 
Interaction In Vivo. 
For in vivo covalent chemical capture, the strategy of unnatural amino acid incorporation 
using nonsense suppression was employed.16-18  Given the complexity of the activator PPI 
interaction network, it was critical to incorporate Bpa at a position in Gal4 that displayed a 
robust and repeatable crosslinking profile.  
For this reason, Bpa incorporation at 
position Phe849 in Gal4 was selected for the 
combined covalent chemical capture 
MuDPIT experiments.16  Initial optimization 
studies with this approach examined the 
sugar-dependent changes of the complex 
between Gal4 and Gal80 at a genomically 
integrated GAL1-LacZ reporter gene.19  
Importantly, earlier work by our group 
demonstrated that Bpa containing Gal4 
mutants retain responsiveness to changes in 
nutrient Availability (glucose, raffinose, and 
raffinose-galactose)16.  Thus, the Bpa-
containing Gal4 mutants in our yeast 
expression system behave in accordance 
with the findings of others who have studied activation and repression at the GAL1 promoter 
under various nutrient contexts.15, 20  Gal4 Phe849Bpa is functionally active in galactose but 
inhibited in glucose, indicating a change in the Gal4-Gal80 interaction that is reflected in the in 
vivo covalent chemical capture-MuDPIT data in which Gal80 was significantly enriched under 
Figure 3-2 In Vivo Covalent Chemical Capture and 
MuDPIT Validate the Masking Protein Gal80 as a Direct 
Target of Gal4 in Live Yeast. 
(a) Incorporation of the unnatural amino acid Bpa in at position 
849 in the Gal4 transcriptional activation domain yields a 
functional activator that retains its ability to sense changes in 
carbon source availability, as determined via β-galactosidase 
assays on an integrated pGal1-LacZ reporter gene.  In the presence 
of glucose, Gal4 is transcriptionally repressed but is activated in the 
presence of the inducing sugar, galactose, indicating that Gal4 
remains responsive to repression by its masking protein Gal80. b) 
In line with the activity data, in vivo covalent chemical capture 
followed by MuDPIT analysis of purified Gal4 covalent adducts 
shows significant enrichment of the Gal4-Gal80 interaction under 
repressive glucose conditions (N=3) biological replicates. 
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glucose growth conditions (Figure 3-2).  Together, these data indicate that the Gal4 mutant 
retains the responsiveness of its wild-type counterpart and additionally that Bpa crosslinking 
coupled with MuDPIT serves as a reliable platform upon which to examine activator PPIs in 
vivo. 
3D: Identification of Novel Targets of Gal4 via In Vivo Covalent Chemical Capture and 
MuDPIT 
Large scale (10L) transcriptionally active yeast cultures were subjected to the covalent 
chemical capture-MuDPIT workflow.  The resulting datasets for non UV-treated (N=2 biological 
replicates) and UV-treated (N=3 biological replicates) samples were compiled and the spectral 
counts detected for each protein under each condition were averaged.  Proteins demonstrating a 
maximal mean of less than two spectral counts were removed from further analysis.  The 
remaining 638 proteins were subjected to stringent filter cutoffs according to the following 
criteria (Figure 3-3a): (i) Proteins must display a minimum average of five spectral counts (ii) 
Proteins must show a fold enrichment (+UV/-UV) greater than or equal to five and (iii) a t-test 
between UV-treated and non-UV control data sets for a protein must generate a p-value of less 
than or equal to 0.0521.  A selection of protein targets meeting these criteria are displayed in 
(Figure 3-3a). 
These crosslinking-MS studies revealed several previously unidentified targets of Gal4, 
all of which are part of larger complexes (Figure 3-3a).  To validate a direct interaction between 
Gal4 and each of the proteins, Myc-tagged versions of each identified target were co-expressed 
alongside LexA+Gal4 F849Bpa and covalent chemical capture experiments were carried out.   
Following irradiation of live cells, yeast lysates were enriched with a LexA antibody and 
enriched proteins were analyzed via Western blot with a Myc-antibody to detect the presence of 
a covalently bound activator-target complex (Figure 3-3b).  Two chaperones, Mas5 and Sti1, 
directly interact with Gal4; consistent with this result, deletion of these chaperone proteins in 
yeast has been previously demonstrated to significantly delay or abrogate induction of GAL122.  
We additionally observe proteins involved in kinase complexes (Gal83)23, 24, RNA binding 
complexes (Rrp5)25, and those that are regulated by the TOR pathway (Nog1) directly interact, 
suggesting that previously identified crosstalk between the TOR and Snf1 nutrient sensing 
pathways extends to the level of transcription.26-29 
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Figure 3-3 Covalent Chemical Capture and MuDPIT Reveals Several Novel Targets of the Transcriptional 
Activator Gal4 In Vivo. 
a) Datasets from UV treated (n=3) and non-UV control (n=2) datasets were compiled and filtered to remove proteins with less than 
two average spectral counts detected.  Of the proteins remaining, 14 were unique to the non-UV treated samples, 61 proteins were 
unique to the UV-treated condition, and 563 proteins were detected under both conditions.  Stringent filtering criteria were applied to 
generate a list of proteins that were significantly enriched in the UV treated sample set.  Proteins that were less than 5 fold enriched 
(+UV/-UV) and with p-values greater than 0.05 were removed from further analysis.  A selection of previously unidentified direct 
targets of Gal4 Phe849Bpa are displayed as the number of spectral counts detected in UV treated and non-UV treated conditions.  
Novel targets detected via MuDPIT should be validated using covalent chemical capture Western blotting.  See Supporting 
Information for additional details and complete MS results.  b) Covalent chemical capture Western blot-ting validates the proteins 
identified from MuDPIT analysis are genuine targets of Gal4 within their respective complexes.  Proteins identified from MuDPIT 
analysis were co-expressed with Gal4 Phe849Bpa in yeast and then subjected to the covalent chemical capture workflow.  Yeast 
lysates were immunoprecipitated with a LexA antibody to enrich for covalent activator species and the subsequent Westerns were 
probed with a Myc-HRP antibody to detect the presence of covalently bound Myc-tagged proteins.  c) Gal4 directly contacts the 
catalytic subunit Snf1 and the exchangeable subunit Gal83 in live yeast.  In vivo covalent chemical capture was carried out in yeast 
expressing Gal4 Phe849Bpa.   Immunoprecipitation of yeast lysates with a Snf1 anti-body and Western detection with a Flag-HRP 
antibody indicated that Gal4 contacts two proteins within the Snf1 complex.  Myc-tagged versions of the Snf1 and Gal83 subunits 
were co-expressed alongside Gal4 Phe849Bpa in yeast.  The resulting yeast lysates were immunoprecipitated with a LexA antibody 
as indicated and the immunoprecipitated complexes were analyzed by Western blot with a Myc-HRP antibody to detect covalently 
bound Gal4 complexes. 
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3E: Gal4 Directly Contacts the Snf1 Kinase and Gal83 Exchangeable Subunit of the 
Snf1/AMPK Kinase Complex 
Of the targets identified in this study, one protein of particular note belongs to the Snf1 
kinase complex.  The Snf1 complex is a heterotrimeric complex containing a catalytic alpha 
subunit (Snf1), a regulatory gamma subunit (Snf4), and a third beta subunit that exchanges 
between Sip1, Sip2, and Gal83 to regulate subcellular localization of the complex.  Importantly, 
both Gal4 and the Snf1 complex regulate galactose-inducible genes such as GAL1.14, 30  The 
Snf1 complex plays a critical role in the response to environmental changes in carbon source.4, 24  
Several lines of evidence suggest that Snf1 phosphorylation of the Mig1 repressor contributes to 
the de-repression of carbon source-regulated genes.24, 31, 32  The Gal83-containing isoform has 
been shown to be the complex that predominantly localizes to the nucleus, and, consistent with 
this model, our MuDPIT data shows a five-fold increase in spectral counts over background, thus 
supporting a nuclear Gal4-Gal83 interaction when cells are grown in galactose.4  The Snf1 
subunit of the complex is also present in the Mud-PIT data set but it appeared robustly under 
both conditions.  A closer examination of the Snf1 sequence revealed the presence of a 
polyhistidine stretch on its amino terminus, and we thus postulated that it was likely enriched 
during the denaturing Ni-affinity column purification and additionally retained throughout the 
milder FLAG affinity purification, presumably via an interaction with Flag-tagged Gal4.  In 
support of Gal4 targeting multiple proteins within the Snf1 complex, enrichment of yeast lysates 
with a Snf1 antibody revealed two proteins that Gal4 directly contacts within the complex under 
irradiating conditions (Figure 3-3c).  We were able to confirm Snf1 and Gal83 as direct targets of 
Gal4 by co-expressing Gal4 Phe849Bpa with either Myc-Snf1 or Myc-Gal83 and following our 
established covalent chemical capture workflow (Figure 3-3c).  Furthermore, a functionally 
inactive mutant, Gal4 867-869Ala, was unable to crosslink to Snf1, demonstrating that this 
interaction is specific and is not mediated by the presence of Bpa (Figure 3-4). 
To further refine the Snf1 model, we performed chromatin immunoprecipitation (ChIP) 
to determine if Gal4 and Snf1 co-localize at the GAL1-LacZ gene used in our experiments.  
Consistent with earlier studies, both proteins showed significant enrichment, supporting a model 
where Gal4 and the Snf1 complex work collaboratively at GAL1 to drive reporter gene 
expression (Figure 3 5a).6  Additional ChIP experiments with the Gal4 triple alanine mutant 
show a substantial loss in Snf1 localization to GAL1, supporting the importance of Gal4 in 
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coordinating Snf1 localization to the promoter (Figure 3-7).  β-Galactosidase experiments with 
WT Gal4 in a Snf1 delete strain complemented with either WT Snf1 or a kinase dead T210A 
Snf1 mutant additionally support this model (Figure 3-7). 
3F: The Gal4-Snf1 PPI is Sustained at the Gal1 Promoter 
ChIP assays are suitable for determining the co-localization of proteins at the same 
promoter over a defined period of time, but they lack the resolution to determine if these proteins 
are in direct contact with one another when bound to DNA.33  In the absence of methods to 
accomplish this goal and determine if the Gal4-Snf1 interaction is sustained at GAL1, we 
developed a new strategy which we have coined TRIC (tandem reversible and irreversible 
crosslinking) that combines the irreversible crosslink arising from UV-activated Bpa and the 
reversible protein-protein and protein-DNA crosslinks formed upon formaldehyde (HCHO) 
treatment.  In this experiment, cells bearing Gal4 modified to have Bpa at position 849 were first 
treated with formaldehyde and then subjected to our standard UV-irradiation protocol.  The 
treated cells were then lysed, the chromatin fraction isolated and sheared, and then 
immunoprecipitation with α-Snf1 antibody was carried out.  Next, the formaldehyde crosslinks 
were reversed, thus leaving only the irreversible Bpa-crosslinks intact, and a Western blot of the 
Bpa crosslinked species with α-FLAG antibody conclusively demonstrated that Gal4 directly 
Figure 3-4 Activity and Expression of LexA+Gal4 F849Bpa Mutants. 
(a)  Bars represent the mean of at least three biological replicates.  Error bars are the standard error of the mean (SEM). p-
values were obtained by running an unpaired t-test between the two sample sets. (b) Expression and crosslinking of 
LexA+Gal4 F849Bpa mutants.  In vivo covalent chemical capture using LexA+Gal4 F849Bpa or its cognate 867-869 
triple alanine mutant was carried out. Yeast lysates were immunoprecipitated with a-LexA antibody and the blots were 
probed with a-Myc HRP antibody (top and middle panels) and then stripped and reprobed with a-Flag HRP antibody 
(bottom panel).  The top panel shows crosslinking between Gal4 F849Bpa and Snf1. The middle panel shows free Snf1-
6xMyc in yeast lysate input lanes. The bottom panel shows levels of Gal4 F849Bpa and its cognate mutant after 
immunoprecipitation with LexA antibody. Both mutants express in yeast, indicating that the loss of activity observed in (a) 
is not due to lack of mutant protein expression. 
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interacts with the Snf1 complex 
on the DNA (Figure 3-5b).  
Taken together, these data 
support a model of recruitment 
for the Snf1 complex in which 
Gal4 directly contacts the 
catalytic Snf1 subunit and forms 
additional contacts with the 
exchangeable regulatory subunit 
Gal83. 
3G: Snf1 and Gal83 are 
Shared Targets of Amphipathic 
Activators 
Given the high homology 
between yeast Snf1 and 
mammalian AMPK, the 
interactions of Snf1 and VP16, 
an amphipathic viral activator 
that functions in the HSV-1 
infection of mammalian cells, 
was examined.34  The VP16 
transcriptional activation domain 
is large (77 amino acids) and 
consists of two subdomains that 
can function independently. As 
has been done previously, we 
examined the binding behavior of each subdomain individually.35  In vivo covalent chemical 
capture with VP16N (413-456) bearing Bpa at position 444 resulted in an observable crosslink 
with Snf1 (Figure 3-5c) but no interaction with Gal83 was identified for this subdomain under 
any conditions examined.  In contrast, VP16C (446-490) with a Phe475Bpa mutation interacts 
with both of the subunits (Figure 3-5d).  These data suggest that the Snf1 and Gal83 subunits of 
Figure 3-5 In Vivo Photocrosslinking with Bpa Captures the Direct 
Targets of Amphipathic Activators within the Snf1 Kinase Complex. 
(a) Chromatin immunoprecipitation with Snf1 and LexA antibodies verify that Gal4 
and the Snf1 kinase complex co-localize to the Gal1-LacZ reporter gene used in 
these studies. (b) The Gal4-Snf1 interaction is maintained on DNA.  Tandem 
reversible and irreversible crosslinking (TRIC) was performed to investigate the 
interaction of DNA bound Gal4 with Snf1 at the Gal1 promoter.  (c,d) The Snf1 
complex is a common target of amphipathic activators. The amino- and carboxy-
terminal subdomains of the amphipathic activator VP16 were tested for crosslinking 
to the catalytic subunit of the Snf1 kinase complex as well as a Myc-Gal83 construct 
in yeast.  Covalent complexes were analyzed by Western blot with a Flag or Myc 
antibody to detect covalently bound Snf1-VP16 and Gal83-VP16, respectively. 
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Snf1/AMPK are a common target for these two activators specifically and perhaps for 
amphipathic activators as a class. 
3H: Conclusion 
Snf1/AMPK and Gal4 each play a central role in the ability of yeast to rapidly respond to 
changes in nutrient context.14, 36  Upon the switch to galactose, the Gal83-containing isoform of 
Figure 3-6 LexA+Gal4 and Snf1 Occupancy at GAL1-LacZ gene. 
All experiments were carried out in a yeast strain lacking Snf1 (DSnf1) and either WT Snf1-6xMyc or a kinase dead Snf1-6xMyc 
T210A mutant complemented back in. With the exception of the Gal4 867-869 triple alanine mutant, all ChIP studies were done 
with the Gal4 F849Bpa construct. Cultures were grown to mid-log phase in glucose and then induced with galactose prior to 
treatment with formaldehyde. Each bar on the graph represents the % input reported as the mean and standard error from at least 
three independent experiments.   (Left) ChIP analysis of Gal4 occupancy at the GAL1-LacZ gene as determined by 
immunoprecipitation with an antibody for LexA. (right) ChIP analysis of Snf1 occupancy at the GAL1-LacZ gene as determined by 
immunoprecipitation with an antibody for Snf1 protein. 
Snf1 Occupancy at GAL1 
LexA+Gal4 Occupancy at GAL1 
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Snf1/AMPK transits to the nucleus where it phosphorylates targets at galactose-catabolism 
genes, contributing to de-repression of nutrient response genes.4, 24  Galactose similarly signals a 
change in the Gal4-Gal80 complex, leading to rapid up-regulation of the GAL genes14.  The 
covalent chemical capture data with Gal4 reveals two direct PPIs that connect these two critical 
nutrient response pathways.  Our results show that the activator Gal4 directly contacts not only 
the kinase Snf1 within the Snf1/AMPK complex, but also the exchangeable subunit Gal83.  It is 
conceivable that by contacting two components of a single complex, Gal4 is not only able to 
cooperatively recruit the Snf1/AMPK complex and its associated kinase activities, but also orient 
the complex in its appropriate configuration, ultimately providing a rapid transcriptional 
response to process the external stimulus.  In retrospect, we observed the same phenomenon with 
the Swi/Snf chromatin modifying complex; in that case two regions of VP16 contacted the 
enzymatic subunit and a second scaffolding component.35  An open question is what role these 
two distinct types of interactions play.  Certainly, proper positioning at the promoter is critical 
and, in the case of the VP16-Swi/Snf interaction, EM studies support this role.37  An additional 
Figure 3-7 Activity and Expression of Snf1 Kinase Mutants. 
(a) Beta-galactosidase assays were carried out for LexA+Gal4 WT in the indicated yeast strains. Cultures were grown in glucose to 
mid-log phase and then induced with galactose prior to measuring activation potential.  Data labeled ‘WT’ were generated in a yeast 
strain (LS41) that expresses endogenous Snf1 kinase.  All other data was generated in a yeast strain that has had Snf1 kinase deleted 
(DSnf1) and either WT Snf1-6xMyc or a kinase dead Snf1-6xMyc T210A mutant co-expressed alongside the activator. (b) 
Expression of WT Snf1-6xMyc and Snf1-6xMyc T210A mutant.  An aliquot of whole cell lysate from cultures expressing either 
the WT or kinase-dead Snf1-6xMyc protein was separated on SDS-PAGE and analyzed via Western blot with a Myc-HRP 
antibody.  The free Snf1 protein runs at approximately 100 kDa, with both constructs expressing in the DSnf1 yeast strain.  
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possibility is that the PPIs alter the activity and/or substrate profile of the enzymatic subunit 
through allosteric effects. Studies investigating this latter possibility are currently underway. 
The use of in vivo covalent chemical capture followed by adduct analysis via shotgun 
LC-MS methods (e.g., MuDPIT) represents a significant step towards the development of a 
complete in vivo interaction map of transcriptional activators.  While a powerful approach, it 
should be noted that issues of relative abundance, stability, and ease of digestion may con-tribute 
to uneven coverage of proteins across the proteome.38  Indeed, many of the ‘typical’ targets of 
transcriptional activators are of lower abundance including, for example, Gal11/Med15.39, 40  In 
the case of Gal11/Med15, even in an in vitro crosslinking experiment in which an abundance of 
crosslinked products (Gal11/Med15-activator) were isolated and purified prior to MS analysis it 
was necessary to use two different digestion strategies and two different ionization techniques in 
order to achieve sufficient sequence coverage.41  Thus, continued advances in MS methods 
coupled with fine-tuning crosslinker reactivities will undoubtedly enhance the utility of tandem 
covalent chemical capture-MS approaches.42-45  Additionally, this study captured binding 
partners of Gal4 that rely upon the sequence surrounding position 849 for interaction.  As our 
previous work and that of others has shown, future experiments with Bpa placed at distinct 
positions will likely lead to additional binding partners.15-18, 35 
In this study, this strategy resulted in the identification of two subunits of the Snf1 kinase 
complex as novel, direct targets of the amphipathic activators Gal4 and VP16 in vivo.  The Snf1 
complex is highly conserved among eukaryotes and the mammalian counterpart of the yeast Snf1 
kinase complex, AMPK, plays a significant role in maintaining cellular homeostasis by 
functioning in some cases as a tumor suppressor and additionally as a regulator of energy 
response.36, 46  Given its important role in the cell, AMPK is a critical target in the treatment of 
diseases that exhibit abnormal metabolic profiles including certain cancers and diabetes.47, 48  
The establishment of a direct link between the Snf1/AMPK complex and transcriptional 
activators suggests a novel intervention point for extrinsic regulation of Snf1/AMPK promoter 
activity.  This will be the focus of future efforts. 
 
 
 
 
46 
 
3I: Experimental 
Yeast strains and plasmid construction 
Yeast strains used in this study were LS41 [JPY9::pZZ41, Matα  his3Δ200  leu2Δ1  
trp1Δ63  ura3-52 lys2Δ385  gal4 URA::pZZ41] and ∆Snf1 LS41 [JPY9::pZZ41, Matα  his3Δ200  
leu2Δ1  trp1Δ63  ura3-52 lys2Δ385  gal4 URA::pZZ41 SNF1::TRP1].  
All plasmids were generated using standard restriction enzyme digestion and ligation reactions 
and the sequences of all the isolated plasmids were verified by sequencing at the University of 
Michigan Core Facility (Ann Arbor, MI).  T4 DNA ligase and all restriction enzymes were all 
purchased from New England Biolabs.  Mutagenesis of Snf1 and Gal4 was carried out using a 
two-step site directed mutagenesis protocol (Quikchange, Qiagen).   
pLexAVP16N Leu444Bpa, pLexAVP16C Phe475Bpa, and pSNRtRNA-pBpaRS 
plasmids were constructed as previously described.16, 35  Briefly, the LexA fusion genes were 
cloned into vector pCLexA, which has a 2µ origin of replication and an ADH1 promoter that 
drives activator expression.  Importantly, in our previous work we demonstrate that maximal Bpa 
incorporation is about 20% compared to the wild-type protein expression.  Thus, while the vector 
used in these studies is high copy, the expression of Bpa-containing activators is likely much 
lower than that achieved with canonical protein expression.  pLexA+Gal4 Phe849Bpa-Flag-6HIS 
was created by modifying previously described pLexA+Gal4 Phe849Bpa to include a 6xHis tag 
3’ to the Gal4-Flag open reading frame.16  Insertion of the 6xHis tag was achieved by site-
directed mutagenesis with primers P11/P12 and Qiagen Quikchange two-step SDM protocol.  
For TRIC experiments, a 3x Flag tag was additionally inserted using site directed mutagenesis 
with primers P9 and P10 (Qiagen Quikchange).  To create p6xMyc-Snf1, primers P1 and P2 
were used to clone out the Snf1 gene from yeast genomic DNA.  The purified PCR product was 
then digested with XhoI and NdeI and ligated into XhoI and NdeI digested pGADT7-6xMyc 
backbone using standard molecular cloning techniques.  To create Gal83-6xMyc, primers P3 and 
P4 were used to clone out the Gal83 gene from yeast genomic DNA.  The purified Gal83 PCR 
product was then digested with HindIII and NdeI and ligated into a HindIII/NdeI digested 
pGADT7-6xMyc backbone using standard molecular cloning techniques.  Snf1-6xMyc T210A 
was made using the Qiagen Quikchange two-step mutagenesis protocol with primers P5 and P6.  
All sequences were verified by the University of Michigan DNA Sequencing Core.   
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∆Snf1 LS41 was constructed using a PCR-mediated gene deletion strategy with a cassette 
containing the full TRP1 open reading frame and ~40 bp complementarity to the 5’ and 3’ 
flanking regions of genomic Snf1.  The SNF1::Trp1 deletion cassette was transformed into LS41 
using a lithium acetate transformation protocol and transformants were selected on plates lacking 
uracil and tryptophan.49  Colonies were screened using polymerase chain reaction (PCR) with 
PCR products visualized on a 1% agarose gel stained with ethidium bromide.   
Primers P13 and P14 were used to clone out the Trp1 gene off pFA6a-TRP1-PGAL1-
HBTH (Addgene, plasmid # 26898).  The PCR product was verified on 1% agarose gel stained 
with ethidium bromide and the product was gel purified (QIAquik gel extraction kit and 
protocol, Qiagen).  The purified Snf1-Trp1 cassette was transformed into LS41 yeast using 
standard lithium acetate/PEG transformation methods and plated on plates containing 2% 
glucose and lacking uracil and tryptophan for selection.49  Transformants were screened via 
colony PCR using primer combinations P15/P16, which are specific for the Snf1 locus, and 
colonies showing a PCR product of ~750 bps were screened further using primer combinations 
P15/P18, P16/P17, P15/P20, and P16/P19 to verify that Snf1 was definitively replaced by the 
TRP1 gene at the Snf1 locus.  Further confirmation was obtained by submitting the P15/P16 gel 
purified PCR product for sequencing, which returned a TRP1 sequence. 
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Table 3-1 Primers Used in Study 
Primer ID Sequence (5’-3’) Description 
P1 GTACATCTCGAGATGAGCAGTAACAACAACACAAAC XhoI-Snf1 F 
P2 GCTACGCATATGATTGCTTTGACTGTTAACGGCTAATTC NdeI-Snf1 R 
P3 GACTTAAAGCTTATGGCTGGCGACAACCCTGA HindIII-Gal83 F 
P4 GCTACGCATATGATTACTGATCTGAGACTTTTG NdeI-Gal83 R 
P5 CATTACCTCGAGATGTCAGCATCAAAAGAAGAAATTGCTGCCC XhoI-Sgt2 F 
P6 GTAATGGGATCCCTATTGCTTGTTCTCATTGTCTGGTGTTTCATCTG BamHI-Sgt2 R 
P7 CATTACCTCGAGATGTCACAAGACGCTGCTATTGCAGAGC Xho1-Hxt6 F 
P8 GTAATGGGATCCTTTGGTGCTGAACATTCTCTTGTACAATGGC BamHI-Hxt6 R 
P9 CATTACCTCGAGATGGTTAAAGAAACTAAGTTTTACGATATTCTAGGTG XhoI-Mas5 F 
P10 GTAATGGGATCCTCATTGAGATGCACATTGAACACCTTCG BamHI-Mas5 R 
P11 CATTACCTCGAGATGTCATTGACAGCCGATGAATACAAACAACAAGG XhoI-Sti1 F 
P12 GTAATGGGATCCTTAGCGGCCAGTCCGGATGATACCAG BamHI-Sti1 R 
P13 CATTACCTCGAGATGCAACTTTCATGGAAGGATATCCCTACTGTCGCTCC XhoI-Nog1-F 
P14 GTAATGGGATCCTCAACGGAAATCTGTCTTACCGACACCACGCTTACCAC BamHI-Nog1-R 
P15 CATTACGGATCCATGGTAGCTTCCACCAAAAGAAAGAGAGATGAAGATTTTCC BamHI-Rrp5-F 
P16 GTAATGCCCGGGTTCGTCTGCTTTTTGAGATTCATGGCTAGCGAC XmaI-Rrp5 R 
P17 GACTGATGGTAATTTCTTAAAGGCTTCTTGTGGTTCTCCCAATTATGCG SDM Snf1 T210A F 
P18 CGCATAATTGGGAGAACCACAAGAAGCCTTTAAGAAATTACCATCAGTC SDM Snf1 T210A R 
P19 CAATGGATGATGTATATAACGCTGCTGCTGATGATGAAGATACCCC SDM Gal4 867-869 AAA F 
P20 GGGGTATCTTCATCATCAGCAGCAGCGTTATATACATCATCCATTG SDM Gal4 867-869 AAA R 
P21 
CAAACCCAAAAAAAGAGGATTACAAGGATCACGATGGTGATTACAAGGA 
TCACGATATTGACTATAAAGACGACGAC 
SDM 3xFlag insert F 
P22 
GTCGTCGTCTTTATAGTCAATATCGTGATCCTTGTAATCACCATCGTGAT 
CCTTGTAATCCTCTTTTTTTGGGTTTG 
SDM 3xFlag insert R 
CTATAAAGACGACGACGACAAACATCATCATCATCATCATTAAGGATCCGTCGACCTGCAG SDM 6HIS F 
CTGCAGGTCGACGGATCCTTAATGATGATGATGATGATGTTTGTCGTCGTCGTCTTTATAG SDM 6HIS R 
GTAACAAGTTTTGCTACACTCCCTTAATAAAGTCAACATGTCTGTTATTAATTTCACAGGTAGT
TCTGGTCC 
5' Snf1-TRP1 
cassette F 
CATAAAAAAAAGGGAACTTCCATATCATTCTTTTACGTTCCACCATTATTTCTTAGCATTTTTGA
CGAAATTTGC 
3' Snf1-TRP1 
cassette R 
 CTGCGCATTCGTGTCCAAACAGTCATTCAGG gSnf1 +210 seq F 
 CATAGAGCGTGAAATTTGCTTTTCATCCGAAG gSnf1 -193 seq R 
 GCCTACATCTTTACCTCAGATCCACAGAGC Snf1 int. F seq 
 GCCTATGGCAGTACTCGACGGCAC Snf1 int. R seq 
 CTGCATGGAGATGAGTCGTGGC Trp1 int. F seq 
 GCCACGACTCATCTCCATGCAG Trp1 int. R seq 
 CCTTCTCTTTGGAACTTTCAGTAATACGCTTAACTGC GAL1-LacZ F 
 GGGCGATCGGTGCGGGCCTCTTCGC GAL1-LacZ R 
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In vivo covalent chemical capture 
In vivo covalent chemical capture was carried out as previously described, but on larger 
scale (1-10 L).16  For all covalent chemical capture experiments, Bpa purchased from Chem 
Impex International (cat.# 05110) was used.  To perform in vivo cross-linking, an individual 
colony expressing pLexA+Gal4 F849TAG-Flag-6xHis was inoculated in 10 mL SC media 
containing 2% raffinose and lacking histidine, tryptophan, and uracil (H-W-U-) for selection.  
This culture was incubated overnight at 30 °C with agitation and used to inoculate 1L cultures of 
H-W-U- SC media containing either 2% glucose or 2% raffinose and 2% galactose.  To each 1 L 
culture, 10 mL of 100 mM Bpa dissolved in 1M NaOH and 10 mL 1M HCl were added.  
Cultures were incubated overnight at 30°C with agitation and grown to mid-log phase OD660 
(~0.8).  Yeast were harvested by centrifugation at 6000 rcf at 4˚C for 15minutes (Beckman 
Avanti J-201, JLA 8.1000).  Cell pellets were washed with SC media lacking histidine and 
tryptophan and resuspended in 2mL H-W-U- SC media with either 2% raffinose and 2% 
galactose or 2% glucose.  Yeast were transferred to cell culture dishes and subjected to UV 
irradiation at 365 nm light (Eurosolar 15 W UV lamp) with cooling for 0.5 hour.  Irradiated cells 
were then harvested by centrifugation and stored at -80˚C until lysis. 
To obtain each MS data set, 10 L yeast cultures were grown and irradiated as described 
previously but on larger scale.16  Briefly, yeast were grown in SC media containing 2% raffinose, 
2% galactose with 1 mM Bpa but lacking histidine, tryptophan, and uracil (H-W-U-) for 
selection and grown at 200 rpm, 30 ˚C with constant air bubbling using a bioreactor (New 
Brunswick, Bioflo 300) to mid-log phase OD660 (~0.8).  Yeast were harvested by centrifugation 
at 6000 rpm for 15 minutes and resuspended in SC media with 2% raffinose and galactose but 
lacking histidine, tryptophan, uracil (H-W-U-), Bpa and irradiated for 1 hour at 365 nm with 
cooling using a Euro Solar UV lamp.  Control samples, where no irradiation was to be performed 
were directly taken to the next step.  After irradiation, the yeast were centrifuged and washed 2X 
with 100 mM PBS and resuspended in ~ 40 mL MS Lysis Buffer (100 mM PBS pH 7.0, 150 mM 
NaCl, 10% glycerol, 0.5% NP-40 and 10 mM beta-mercaptoethanol) containing 2x protease 
inhibitor (complete mini EDTA free protease inhibitor tablets, Roche) and flash frozen with 
liquid Nitrogen and stored at -80˚C until lysis.   
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Cryolysis and Affinity Purification of Crosslinked Samples for MuDPIT Analysis 
Cryolysis was performed using a Retsch planetary ball mill PM 200.  All equipment was 
cooled in liquid nitrogen prior to use.  Frozen yeast cells were crushed in a chilled mortar and 
pestle with liquid nitrogen added.  Ground cells were added to the chilled lysis chambers and 
loaded into the ball mill.  PM-200 was run three times for two minutes/cycle at 500 rpm with 
liquid nitrogen cooling performed between each cycle.  Chambers were removed from machine 
after final spin and the frozen lysed yeast were recovered from the chambers and placed in a 50 
mL centrifuge tube on dry ice. 
Lysed yeast were allowed to thaw in a cold water bath and then centrifuged for 30 
minutes at 4˚C, 9299 rcf (Beckman Coulter Allegra X-22R, fixed rotor).  While cells were 
spinning, 300-500 mL Ni-agarose bead slurry was washed three times with 1 mL chilled PBS.  
Supernatant from lysed yeast was transferred to a clean 50 mL centrifuge tube and the Ni-
agarose beads (resuspended in 1 mL chilled PBS) were added to the supernatant.  Beads and 
supernatant were incubated for 1 hour on rotating carousel in 4˚C cold room.  After incubation, 
beads were spun down (low rpm) and the supernatant was poured off.  Ni-agarose beads were 
then resuspended in the residual supernatant and washed in 5 mL chilled Nickel Wash Buffer 
(100 mM PBS pH 7.0, 150 mM NaCl, 10% glycerol, 3M Guanidine-HCl, 30 mM imidazole, 
0.2% Tween-20, 10 mM Beta-mercaptoethanol) in a 15 mL centrifuge tube.  Washed beads were 
centrifuged at 2500 rpm for 2 minutes at 4˚C (Beckman Coulter Allegra X-22R, bucket rotor) 
and the supernatant decanted.  This procedure was repeated 4 more times for a total of five-5 mL 
washes.  The beads were then washed twice with 5 mL cold 100 mM PBS.  PBS was decanted 
and the beads were resuspended in 500 µL 100 mM PBS and transferred to a chilled 1.75 
microcentrifuge flip cap tube.  Residual beads on the 15 mL tube were washed with about 500 
µL 100 mM PBS and transferred to a microcentrifuge tube.  Beads were spun briefly at low rpm 
(Eppendorf 5417C microfuge).  
Beads were resuspended in 500 µL chilled Nickel Elution Buffer (100 mM PBS pH 7.0, 
500 mM Imidazole, 0.5% Tween-20) and mixed gently for 1 minute by inversion and then re-
centrifuged.  The supernatant (eluant) was pipetted off and collected in a separate, clean 1.75 mL 
microcentrifuge tube.  Another 500 µL chilled Nickel Elution Buffer was added to the beads and 
mixed by inversion for 10 minutes, 4˚C in a cold room.  During the second elution, a 10K 
microcentrifuge tube concentrator (Vivascience 10K MWCO) was washed with 100 mM PBS.  
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The first elution was centrifuged to remove any lingering Ni-agarose and the eluent was pipetted 
out and added to the concentrator.  Concentrator was spun at 15,000xg for 5 minutes at 4˚C.  
Elutions were repeated for a total of 3 elutions, each elution added to the concentrator after 
centrifugation to remove residual Ni-agarose.  500 µL of 100 mM chilled PBS was added to the 
protein and then run through the concentrator.  This was repeated for a total of 3 PBS buffer 
exchanges to get a final volume of 1000-1500 µL of protein. 
400 µL of Flag-agarose (Sigma, M2) was washed three times with 1 mL 100 mM PBS 
pH 7.0.  Concentrated sample was added to the Flag-agarose and incubated for 2 hours at 4˚C, 
with rotation.  Flag-agarose was then washed ten times with 1 mL/wash Flag Wash Buffer (100 
mM PBS pH 7.0, 150 mM NaCl, 0.5% NP-40), spinning between washes (5000 rpm, 30 second, 
Eppendorf 5417C).  Next, Flag-agarose was washed twice with 100 mM PBS to dilute out the 
NP-40.  Flag Elution Buffer (100 mM PBS pH 7.0, 350 mM NaCl, 0.1% NP-40) containing 10 
mg/mL Flag peptide was used for elution.  333 µL Flag elution buffer was added to washed 
Flag-agarose and incubated for 30 minutes, 4˚C, with rotation.   Beads were briefly centrifuged 
and the elution transferred to a new 1.75 mL Eppendorf tube.  Elution was quick frozen in liquid 
nitrogen and stored in -80˚C freezer.  Second elution was performed in the same fashion and the 
final 333 µL was added to beads for a third elution that was allowed to run overnight.  The next 
morning, the two frozen elutions were thawed and spun down to remove residual Flag-agarose.  
Elutions were transferred to new tubes and then centrifuged again to remove any chance of 
residual beads remaining.  These first two elutions, cleared of all beads, were then concentrated 
in a 10K concentrator at 15,000 xg until down to 100 µL.  The overnight elution was then added 
and centrifuged down to 100 µL.  500 µL of ammonium bicarbonate (50 mM) was then added to 
the concentrator for a total of 4 buffer exchange cycles with the protein.  Concentrated sample 
was then transferred to a clean microcentrifuge tube.  Sample was quick frozen in liquid 
nitrogen, packed in dry ice, and shipped for mass-spectrometry analysis.    
β-Galactosidase assays 
To evaluate the ability of each LexA+Gal4 F849Bpa-Flag-6HIS to activate transcription 
in the presence or absence of glucose, saturated cultures (SC media + 2% raffinose) of yeast 
expressing Gal4 Phe849Bpa were used to inoculate 5 mL SC media containing either 2% glucose 
or 2% raffinose & 2% galactose but lacking histidine and tryptophan for selection.  The cells 
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were grown to an OD660 of 0.8-1 and harvested.  The activity of each construct was monitored 
using β-galactosidase assays as previously described.16   
For activity of LexA+Gal4 WT in ∆Snf1strains, a single colony of each construct was 
inoculated in 5 mL yeast dropout media containing 2% glucose and grown overnight at 30°C.  
These cultures were then used to inoculate additional 5 mL cultures of dropout media containing 
2% glucose and 1 mM Bpa.  Cultures were grown to mid-log phase, harvested via centrifugation, 
washed with dropout media, and, with the exception of the glucose control culture, were then 
resuspended in media containing 2% raffinose, 2% galactose, and 1 mM Bpa.  Cultures were 
induced for 3 hours at 30°C before being harvested.  The activity of each construct was 
monitored using β-galactosidase assays as previously described.35 
MuDPIT analysis 
All MuDPIT analyses were performed at the Center for Physiological Proteomics in La 
Jolla, California.  For both the glucose-grown and galactose-grown cultures, three biological 
replicates were analyzed for UV-treated samples and two biological replicates were analyzed for 
non-UV control samples.  Spectral counting was used for identifying hits.  Crosslinked products 
were denatured by adding urea to a final concentration of 8 M, in 50 mM Tris (pH 8.0).  The 
protein was then reduced with 10 mM Tris(2-carboxyethyl) phosphine HCl (TCEP, Sigma) for 
30 minutes at room temperature.  The proteins were subsequently alkylated with fresh 12.5 mM 
iodoacetamide (IAA; Sigma) and the concentration of urea was reduced to 2 M by adding 50 
mM Tris (pH 8.0).  Next, crosslinked proteins were digested overnight with 1 mM CaCl2 and 2 
µg Trypsin at 37˚C.  Digested peptides were acidified to a final concentration of 5% formic acid 
and centrifuged at 17,000xg for 15 minutes.  Half of the digested mixture was pressure loaded 
onto a biphasic strong cation exchange/reverse phase capillary column and separated by 2D 
liquid chromatography and tandem MS using an 11 step gradient on an LTQ mass spectrometer.  
Full MS spectra were acquired with a mass range of 400-1,800 followed by 7 MS/MS scans.  All 
MS/MS spectra were collected using a normalized collision energy of 35% and an isolation 
window of 2 Da.  One microscan was applied for all experiments in the LTQ.  Spray voltage was 
set to 2.50 kV, and the flow rate through the column was 0.20 µL/minute.  The data was 
analyzed against the entire yeast genome using the SEQUEST algorithm and the analysis was 
performed using the DTASelect software package.  For both the glucose-grown and galactose-
grown cultures, three biological replicates were analyzed for UV-treated samples and two 
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biological replicates were analyzed for non-UV control samples.  Spectral counting was used for 
identifying hits.  Hits from each replicate were compiled and the mean spectral counts for each 
protein were calculated.  Proteins with less than two average spectral counts were removed from 
further analysis.  UV-treated and non-UV samples within a single carbon source condition were 
compared to determine enrichment values (Average +UV SC/average –UV SC).  Proteins were 
considered significant if the enrichment ratio (+UV/-UV) was greater than or equal to 5 and if a 
t-test comparing UV-treated and non-UV data for a protein generated a p-value of less than or 
equal to 0.05.  Hits with unknown function and proteins already identified as targets of Gal4 
were not displayed in.   
To avoid zero values in the denominator, all spectral count values were adjusted to 
contain an additional 0.1.  Spectral counts for each protein were averaged within the non-UV 
(N=2) and +UV (N=3) datasets.  Proteins with a spectral count average less than 2 in both the –
UV and +UV datasets were removed from further analysis.  Enrichment ratios were calculated 
for proteins with at least two average spectral counts in either condition (Average +UV 
SC/Average non-UV SC.) and t-tests were carried out in Excel to generate p-values for the 
enrichment ratios.  Proteins with an enrichment ratio of five or greater and a p-value of 0.05 or 
less were considered to be significant hits.  Those with an average of at least five spectral counts 
were considered high-scoring hits and those with an average between 2 and 5 spectral counts 
were considered moderate-scoring hits.  Proteins that were previously identified as Gal4 targets 
were excluded from the list (Gal80) as were proteins with no characterized function. 
Preparation and Western blotting of Snf1 and Gal83 crosslinked samples 
An individual colony expressing either pLexA+Gal4 Phe849Bpa-6xHis-Flag, 
pLexA+VP16 Leu444Bpa-Flag, or pLexA+VP16C Phe475Bpa-Flag was inoculated in 5 mL SC 
media containing 2% raffinose but lacking histidine, tryptophan, and uracil (H-W-U-) for 
selection.  This culture was incubated overnight at 30°C with agitation and then used to inoculate 
100 mL cultures of H-W-U- SC media containing 2% raffinose and 2% galactose.  To each 
culture, 1 mL of 100 mM Bpa dissolved in 1M NaOH and 1 mL 1M HCl were added.  Cultures 
were incubated overnight at 30°C with agitation and grown to mid-log phase OD660 (~0.8).  
Yeast were harvested by centrifugation at 3901 rcf at 4˚C for 5minutes (Beckman-Coulter 
Allegra X-22R).  Cell pellets were washed with H-W-U- SC media and resuspended in 2mL H-
W-U- SC media containing 2% raffinose and 2% galactose.  Yeast were transferred to cell 
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culture dishes and subjected to UV irradiation at 365 nm light (Eurosolar 15 W UV lamp) with 
cooling for 0.5 hour.  Irradiated cells were then harvested by centrifugation and stored at -20˚C 
until lysis.  For lysis, cell pellets were resuspended in 600 µL Lysis buffer (50 mM HEPES-KOH 
pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X 
Complete Mini, EDTA Free Protease Inhibitor (Roche)) and lysed using glass beads by 
vortexing at 4°C.  The lysate was pelleted and the supernatant incubated with 10 µL (2 ng) of 
Snf1 antibody (sc-15621, Santa Cruz Biotechnologies) for 2 hours at 4°C for 
immunoprecipitation.  The protein bound to the antibody was isolated by incubation for 1 hour 
with 40 µL of prewashed protein G magnetic Dynabeads (Life Technologies) at 4˚C.  After 
immunoprecipitation, the beads were washed 6 times with 1 mL Wash Buffer (10 mM Tris-HCl 
pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.1% Na-Deoxycholate and 1 mM EDTA) and stored dry at 
-20˚C until elution.  The crosslinked sample was eluted from the beads by heating at 95˚C for 10 
minutes in Laemmli 2x Buffer (BioRad) containing 250 mM DTT and run on a 4-20% Tris-
Glycine TGX gel (BioRad).  The separated proteins were then transferred to PVDF membrane 
and probed using Western Blot analysis with a 1:1000 dilution of anti-FLAG (M2) antibody 
(Sigma) in 5% milk PBST. 
Crosslinking to Gal83 was carried out in the same way, except that p6xMyc-Gal83 was 
co-expressed alongside each activator construct in yeast.  Cells were additionally grown in media 
lacking histidine, tryptophan, leucine and uracil for selection and lysates were 
immunoprecipitated with a LexA antibody (sc-1725, Santa Cruz Biotechnologies).  Resulting 
Western blots were probed with a 1:1000 dilution of Myc-HRP antibody (sc-40 HRP, Santa Cruz 
Biotechnologies) in 5% milk PBST.   
Chromatin Immunoprecipitation (ChIP) at GAL1-LacZ 
All ChIP experiments were conducted in ∆Snf1 LS41 strain with pGADT7-Snf1-6xMyc 
complemented back in.  An individual colony of pLexA+Gal4 Phe849Bpa-Flag-6HIS or its 
cognate triple alanine mutant was grown in 5 mL SC media containing 2% glucose but lacking 
histidine, tryptophan, leucine, lysine and uracil for selection.  The culture was incubated 
overnight at 30 °C with agitation.  This culture was used to inoculate 100 mL cultures of SC 
media containing 2% glucose, 1 mL 100 mM Bpa dissolved in 1M NaOH and 1 mL 1M HCl.  
The cultures were incubated overnight at 30 °C with agitation to an OD660 of ~0.8.  Cultures 
were harvested via centrifugation, washed with media, and added to induction media composed 
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of SC media lacking HWKLU and containing 2% raffinose, 2% galactose and 1 mM Bpa.  Cells 
were induced for 3 hours prior to formaldehyde treatment.  Non-formaldehyde treated cultures 
were harvested by centrifugation at 3901 rcf (Beckman Coulter Allegra X-22R, 4˚C) and washed 
with 25 mL media lacking his, trp, lys, leu, and ura.  Cell pellets were transferred to a 1.75 mL 
tube, re-centrifuged, and the pellet frozen and stored at -80˚C until lysis.  Formaldehyde treated 
samples were equipped with a stirbar on a stir plate.  To each culture, 2.9 mL 37% formaldehyde 
solution was then added and allowed to stir for 5 minutes at room temperature, at which point the 
reaction was quenched with excess 2 M glycine for 5 minutes with stirring.  The treated culture 
was harvested via centrifugation, washed with 50 mL media lacking his, trp, lys, leu and ura, 
transferred to 1.75 mL tube and the cell pellet frozen and stored at -80˚C until lysis. 
Cell pellets were thawed on ice and lysed as previously described.35  After mechanical shearing 
and whole cell lysate separation, the lysate and insoluble pellet were resuspended by pipetting 
and each sample was sonicated at a setting of 10% (double-step microtip, Fisher Scientific 
Dismembrator Model 500) for 2 minutes on ice with 30 second pulse on/off.  Samples were then 
centrifuged at 4˚C for 20 minutes at max speed.  Soluble chromatin was separated from the pellet 
and 10 µL removed as an input sample.  The remaining soluble chromatin was split equally 
between three 1.75 mL tubes.  Immunoprecipitation with either 2 µg Snf1 antibody (sc-15621, 
Santa Cruz Biotechnologies), LexA antibody (sc-1725, Santa Cruz Biotechnologies), or control 
IgG (sc-2027, Santa Cruz Biotechnologies) proceeded for 2 hours, 4˚C followed by incubation 
for 1 hour with ~40 µL of prewashed protein G magnetic Dynabeads slurry (Life Technologies).  
Beads were washed twice with 1X ChIP Lysis Buffer ((50 mM Hepes-KOH pH 7.5, 140 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X Complete Mini, EDTA 
Free Protease Inhibitor (Roche)), twice with 1X ChIP Lysis buffer containing 0.5M NaCl, twice 
with 1x ChIP Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 1% Na-
Deoxycholate and 1 mM EDTA), and twice with TE Buffer (10 mM Tris-HCl, 1 mM EDTA).  
Immunoprecipitated complexes were eluted in 50 µL elution buffer (50 mM Tris-HCl, 10 mM 
EDTA, 1% SDS) at 65˚C for 30 minutes.  The eluate was transferred to a new 1.75 mL tube to 
which 120 µL of TE-SDS (10 mM Tris-HCl, 1 mM EDTA, 0.1% SDS) buffer was added and 90 
µL TE-SDS was added to the 10 µL of input.  Formaldehyde crosslinks were reversed overnight 
in a 65 °C water bath.  Samples were purified using Qiagen PCR Clean protocol and eluted in 58 
µL Buffer EB.  qPCR on all samples and inputs was run using Promega GoTaq qPCR master 
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mix (A6001, Promega) using primers P21 and P22 on an Applied Biosystems StepOnePlus 
instrument.  At least three independent biological replicates were run for each condition, with 
each biological replicate run in triplicate for qPCR quantitation.  PCR amplification with primer 
P21 and P22 yielded a single band around 450 bps. This band was gel purified and submitted for 
sequencing.  Results returned a sequence for the GAL1-LacZ gene, as expected (below). 
Sequence of GAL1-LacZ PCR amplified product: 
5’TGCATAANCCACTTTAACTAATACTTTCAACATTTTCGGTTTGTATTACTTCTTATTC
AAATGTAATAAAAGTATCAACAAAAAATTGTTAATATACCTCTATACTTTAACGTCAA
GGAGAAAAAACTATAATGACTAAATCTCATTCAGAAGAAGTGATTGTACCTGAGTTC
AATTCTAGCGCAAAGGAATTACCAAGACCATTGGCCGAAAAGTGCGGAATTCCAAGC
TTGGCCAAGCCCGGATCCGGAGCTTGGCTGTTGCCCGTCTCACTGGTGAAAAGAAAA
ACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAA
TGCAGCTGGCACGACAGGTTTCCCGACTTAATCGCCTTGCAGCACATCCCCCTTTCGC
CAGCTGGCGTAATAGCGAAGAGGCCCGCACCG 3’ 
Input CT values for a single biological replicate were averaged and log2(1/60) was 
subtracted from this value to generate a normalized Input value.  The individual CT values 
generated for a set of technical triplicates were subtracted from the respective normalized input 
values to generate a ∆ CT value (negative number) for each measurement.  The ∆ CT value was 
then log transformed (100*2^(∆ CT)) to generate individual % input values.  The % input values 
generated across at least three biological replicates were averaged and the standard error of the 
mean calculated for graphical display.  p-values were calculated using an unpaired t-test. 
Tandem Reversible and Irreversible Crosslinking (TRIC) at GAL1-LacZ 
An individual colony of pLexA+Gal4 Phe849Bpa-6HIS-3xFLAG was grown in 5 mL SC 
media containing 2% raffinose but lacking histidine, tryptophan and uracil for selection.  The 
culture was incubated overnight at 30°C with agitation.  Following incubation, this culture was 
used to inoculate 100 mL cultures of SC media containing 2% raffinose and 2% galactose.  For 
Bpa incorporation, 1 mL 100 mM Bpa dissolved in 1M NaOH and 1 mL 1M HCl were added to 
the above cultures.  The cultures were incubated overnight at 30°C with agitation to an OD660 of 
~0.8.  When cultures reached the appropriate OD660, the cells were treated in the following 
manner: The cultures receiving only UV treatment were centrifuged at 3901 rcf, 4˚C (Beckman 
Coulter Allegra X-22R), washed with SC media lacking histidine, tryptophan and uracil, and 
recentrifuged.  Cell pellets were resuspended in 2mL SC media lacking histidine, tryptophan and 
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uracil and containing 2% raffinose, 2% galactose.  Cells were transferred to a small cell culture 
dish and subjected to UV irradiation at 365 nm light (Eurosolar 15 W UV lamp) with cooling for 
0.5 hour.  The cultures receiving formaldehyde treatment were equipped with a stirbar and 
placed on a stirplate in a fume hood.  2.9 mL of 37% formaldehyde was added directly to the 
culture and allowed to stir for 5 minutes before being quenched with 15 mL of 2 M Glycine for 5 
minutes.  Cells were then centrifuged and cell pellets were washed with 50 mL H-W-U- media 
and recentrifuged.  Samples intended to additionally receive UV crosslinking were then 
resuspended in 2 mL H-W-U- media containing 2% raffinose, 2% galactose and transferred to a 
small cell culture dish and subjected to UV irradiation at 365 nm UV light (Eurosolar 15 W UV 
lamp with cooling for 0.5hour. 
For lysis, cells were resuspended in 600 µL Lysis buffer (50 mM HEPES-KOH pH 7.5, 
140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X Complete Mini 
EDTA Free Protease Inhibitor (Roche) and lysed using glass beads and vortexing at 4°C.  We 
found in these studies that complete cellular lysis is necessary to eliminate background signal 
caused by cell lysis during sonication.  Subsequent lysates were removed and the remaining 
pellet was then washed twice with “Harsh” ChIP buffer (50 mM HEPES-KOH pH 7.5, 1M NaCl, 
1 mM EDTA, 1% Triton X-100, 1% Na-Deoxycholate) followed by 2 washes with regular ChIP 
buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-
Deoxycholate and 2X Complete Mini EDTA Free Protease Inhibitor (Roche)).  Pellets were 
resuspended in 600 µL ChIP lysis buffer containing protease inhibitor and sonicated at a setting 
of 10% (double-step microtip, Fisher Scientific Dismembrator Model 500) for 2 minutes on ice 
with 30 second pulses on/off.  Samples were then centrifuged at 4˚C for 20 minutes at max 
speed.  Soluble chromatin was then removed from the pellet and immunoprecipitated with Snf1 
antibody (sc-15621, Santa Cruz Biotechnologies) for 2 hours, 4˚C.  The protein bound to the 
antibody was isolated by incubation for 1 hour with ~50 µL of prewashed protein G magnetic 
Dynabeads (Life Technologies).  After immunoprecipitation, the beads were washed 6 times 
with 1 mL Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.1% Na-
Deoxycholate and 1 mM EDTA) and stored dry at -20˚C until elution.  The crosslinked sample 
was eluted from the beads and formaldehyde crosslinks reversed by heating at 95˚C for 20 
minutes in NuPAGE 4x LDS Sample buffer (Life Technologies) containing 250 mM DTT.  
Samples were run on a 4-20% Tris-Glycine TGX gel (Bio-Rad) and transferred to a PVDF 
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membrane.  Western Blot analysis was carried out using a 1:1000 dilution of anti-FLAG (M2) 
antibody (Sigma) in 5% PBST.   
 
References 3: 
 
1. Thompson, A. D., Dugan, A., Gestwicki, J. E., and Mapp, A. K. (2012) Fine-tuning 
multiprotein complexes using small molecules, ACS Chem Biol 7, 1311-1320. 
2. Paoletti, A., Parmely, T., Tomomori-Sato, C., Sato, S., Zhu, D., Conaway, R., Conaway, J., 
Florens, L., and Washburn, M. (2006) Quantitative proteomic analysis of distinct 
mammalian Mediator complexes using normalized spectral abundance factors, Proc Natl 
Acad Sci USA 103, 18928-18933. 
3. Sikorski, T. W., and Buratowski, S. (2009) The basal initiation machinery: beyond the general 
transcription factors, Curr Opin Cell Biol 21, 344-351. 
4. Vincent, O., Townley, R., Kuchin, S., and Carlson, M. (2001) Subcellular localization of the 
Snf1 kinase is regulated by specific beta subunits and a novel glucose signaling 
mechanism, Genes & Development 15, 1104-1114. 
5. Chen, X. F., Lehmann, L., Lin, J. J., Vashisht, A., Schmidt, R., Ferrari, R., Huang, C., McKee, 
R., Mosley, A., Plath, K., Kurdistani, S. K., Wohlschlegel, J., and Carey, M. (2012) 
Mediator and SAGA have distinct roles in Pol II preinitiation complex assembly and 
function, Cell Rep 2, 1061-1067. 
6. Lo, W.-S., Gamache, E. R., Henry, K. W., Yang, D., Pillus, L., and Berger, S. L. (2005) 
Histone H3 phosphorylation can promote TBP recruitment through distinct promoter-
specific mechanisms, EMBO J 24, 997-1008. 
7. Ptashne, M., and Gann, A. (1997) Transcriptional activation by recruitment, Nature 386, 569-
577. 
8. Vincent, O., and Carlson, M. (1999) Gal83 mediates the interaction of the Snf1 kinse complex 
with the transcriptional activator Sip4, EMBO J 18, 6672-6681. 
9. Sikorski, T. W., Joo, Y. J., Ficarro, S. B., Askenazi, M., Buratowski, S., and Marto, J. A. 
(2012) Proteomic analysis demonstrates activator- and chromatin-specific recruitment to 
promoters, Journal of Biological Chemistry 287, 35397-35408. 
10. Tsai, K.-L., Tomomori-Sato, C., Sato, S., Conaway, Ronald C., Conaway, Joan W., and 
Asturias, Francisco J. Subunit Architecture and Functional Modular Rearrangements of 
the Transcriptional Mediator Complex, Cell 157, 1430-1444. 
11. Wands, A. M., Wang, N., Lum, J. K., Hsieh, J., Fierke, C. A., and Mapp, A. K. (2010) 
Transient-state kinetic analysis of transcriptional activator-DNA complexes interacting 
with a key coactivator, Journal of Biological Chemistry 286, 16238-16245. 
12. Tanaka, Y., Bond, M. R., and Kohler, J. J. (2008) Photocrosslinkers illuminate interactions in 
living cells, Molecular BioSystems 4, 473-480. 
13. Mapp, A. K., and Ansari, A. Z. (2007) A TAD further: exogenous control of gene activation, 
ACS Chemical Biology 2, 62-75. 
14. Traven, A., Jelicic, B., and Sopta, M. (2006) Yeast Gal4: a transcriptional paradigm revisited, 
EMBO Rep 7, 496-499. 
15. Ansari, A. Z. R., R.J.; Ptashne, M. (1998) A transcriptional activating region with two 
contrasting modes of protein interaction, Proc. Natl. Acad. Sci. 95, 13543-13548. 
59 
 
16. Majmudar, C. Y., Lee, L. W., Lancia, J. K., Nwokoye, A., Wang, Q., Wands, A. M., Wang, 
L., and Mapp, A. K. (2009) Impact of nonnatural amino acid mutagenesis on the in vivo 
function and binding modes of a transcriptional activator, Journal of the American 
Chemical Society 131, 14240-14242. 
17. Chin, J. W., Cropp, T. A., Anderson, J. C., Mukherji, M., Zhang, Z., and Schultz, P. G. 
(2003) An expanded eukaryotic genetic code, Science 301, 964-967. 
18. Schmidt, M. J., and Summerer, D. (2014) Genetic Code Expansion as a Tool to Study 
Regulatory Processes of Transcription, Frontiers in Chemistry 2. 
19. Zaman, Z., Ansari, A. Z., Koh, S. S., Young, R., and Ptashne, M. (2001) Interaction of a 
transcriptional repressor with the RNA polymerase II holoenzyme plays a crucial role in 
repression, Proc Natl Acad Sci USA 98, 2550-2554. 
20. Johnston, M., Flick, J. S., and Pexton, T. (1994) Multiple mechanisms provide rapid and 
stringent glucose repression of GAL gene expression in Saccharomyces cerevisiae, Mol 
Cell Biol 14, 3834-3841. 
21. Martin, B. R., and Cravatt, B. F. (2009) Large-scale profiling of protein palmitoylation in 
mammalian cells, Nature Methods 6, 135-138. 
22. Floer, M., Bryant, G. O., and Ptashne, M. (2008) HSP90/70 chaperones are required for rapid 
nucleosome removal upon induction of the GAL genes of yeast, Proc Natl Acad Sci USA 
105, 2975-2980. 
23. Young, E. T., Zhang, C., Shokat, K. M., Parua, P. K., and Braun, K. A. (2012) The AMP-
activated protein kinase Snf1 regulates transcription factor binding, RNA polymerase II 
activity, and mRNA stability of glucose-repressed genes in Saccharomyces cerevisiae, J 
Biol Chem 287, 29021-29034. 
24. Papamichos-Chronakis, M., Gligoris, T., and Tzamarias, D. (2004) The Snf1 kinase controls 
glucose repression in yeast by modulating interactions between the Mig1 repressor and 
the Cyc8-Tup1 co-repressor, EMBO Reports 5, 368-372. 
25. Hierlmeier, T., Merl, J., Sauert, M., Perez-Fernandez, J., Schultz, P., Bruckmann, A., 
Hamperi, S., Ohmayer, U., Rachel, R., Jacob, A., Hergert, K., Deutzmann, R., 
Griesenbeck, J., Hurt, E., Milkereit, P., Bassler, J., and Tschochner, H. (2013) Rrp5, 
Noc1p and Noc2p form a protein module which is part of early large ribosomal subunit 
precursors in S. cerevisiae, Nucl Acids Res 41, 1191-1210. 
26. Hedbacker, K., and Carlson, M. (2006) Regulation of the Nucleocytoplasmic Distribution of 
Snf1-Gal83 Protein Kinase, Euk Cell 5, 1950-1956. 
27. Bertram, P. G., Choi, J. H., Carvalho, J., Chan, T. F., Ai, W., and Zheng, X. F. (2002) 
Convergence of TOR-nitrogen and Snf1-glucose signaling pathways onto Gln3, Mol Cell 
Biol 22, 1246-1252. 
28. Mitchell, S. F., Jain, S., She, M., and Parker, R. (2012) Global analysis of yeast mRNPs, Nat 
Struct Mol Biol 20, 127-133. 
29. Shashkova, S., Welkenhuysen, N., and Hohmann, S. (2015) Molecular communication: 
crosstalk between the Snf1 and other signaling pathways, FEMS Yeast Res 15, fov026. 
30. Flick, J. S., and Johnston, M. (1990) Two systems of glucose repression of the GAL1 
promoter in Saccharomyces cerevisiae, Molecular Cell Biology 10, 4757-4769. 
31. Treitel, M. A., Kuchin, S., and Carlson, M. (1998) Snf1 protein kinase regulates 
phosphorylation of the Mig1 repressor in Saccharomyces cerevisiae, Mol Cell Biol 18, 
6273-6280. 
60 
 
32. Ostling, J., and Ronne, H. (1998) Negative control of the Mig1p repressor by Snf1p-
dependent phosphorylation in the absence of glucose, Eur J Biochem 252, 162-168. 
33. Hall, D. B., and Struhl, K. (2002) The VP16 activation domain interacts with multiple 
transcriptional components as determined by protein-protein cross-linking in vivo, 
Journal of Biological Chemistry 277, 46043-46050. 
34. Woods, A., Munday, M. R., Scott, J., Yang, X., Calson, M., and Carling, D. (1994) Yeast 
Snf1 is functionally related to mammalian AMP-activating protein kinase and regulates 
acetyl-CoA carboxylase in vivo, J Biol Chem 269, 19509-19515. 
35. Krishnamurthy, M., Dugan, A., Nwokoye, A., Fung, Y. H., Lancia, J. K., Majmudar, C. Y., 
and Mapp, A. K. (2011) Caught in the act: covalent cross-linking captures activator-
coactivator interactions in vivo, ACS Chemical Biology 6, 1321-1326. 
36. Hardie, D. G. (2007) AMP-activated SNF1 protein kinases: conserved guardians of cellular 
energy, Nat Rev Mol Cell Biol 8, 774-785. 
37. Dechassa, M. L., Zhang, B., Horowitz-Scherer, R., Persinger, J., Woodcock, C. L., Peterson, 
C. L., and Bartholomew, B. (2008) Architecture of the SWI/SNF-nucleosome complex, 
Mol Cell Biol 28, 6010-6021. 
38. Falsone, S. F., Gesslbauer, B., Tirk, F., Piccinini, A. M., and Kungl, A. J. (2005) A 
proteomic snapshot of the human heat shock protein 90 interactome, FEBS Lett 579, 
6350-6354. 
39. Ghaemmaghami, S., Huh, W. K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., 
O'Shea, E. K., and Weissman, J. S. (2003) Global analysis of protein expression in yeast, 
Nature 425, 737-741. 
40. Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N., and Mann, M. (2014) Minimal, encapsulated 
proteomic-sample processing applied to copy-number estimation in eukaryotic cells, Nat 
Methods 11, 319-324. 
41. Majmudar, C. Y., Wang, B., Lum, J. K., Hakansson, K., and Mapp, A. K. (2009) A high-
resolution interaction map of three transcriptional activation domains with a key 
coactivator from photo-cross-linking and multiplexed mass spectrometry, Angew Chemie 
Int Ed 48, 7021-7024. 
42. Lancia, J. K., Nwokoye, A., Dugan, A., Joiner, C., Pricer, R., and Mapp, A. K. (2014) 
Sequence context and crosslinking mechanism affect the efficiency of in vivo capture of 
a protein-protein interaction, Biopolymers 101, 391-397. 
43. Hulce, J. J., Cognetta, A. B., Niphakis, M. J., Tully, S. E., and Cravatt, B. F. (2013) 
Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells, Nat Meth 
10, 259-264. 
44. Mann, M. (2006) Functional and quantitative proteomics using SILAC, Nat Rev Mol Cell 
Biol 7, 952-958. 
45. Preston, G. W., Radford, S. E., Ashcroft, A. E., and Wilson, A. J. (2014) Analysis of amyloid 
nanostructures using photo-cross-linking: In situ comparison of three widely used photo-
cross-linkers, ACS Chem Biol 9, 761-768. 
46. Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, 
C., Fuerth, B. J., Viollet, B., Mamer, O. A., Avizonis, D., DeBerardinis, R. J., Siegel, P. 
M., and Jones, R. G. (2013) AMPK is a negative regulator of the Warburg effect and 
suppresses tumor growth in vivo, Cell Metab 17, 113-124. 
47. Liang, J., and Mills, G. B. (2013) AMPK: A contextual oncogene or tumor suppressor?, 
Cancer Res 73, 2929-2935. 
61 
 
48. Viollet, B., Lantier, L., Devin-Leclerc, J., Hebrard, S., Amouyal, C., Mounier, R., Foretz, M., 
and Andreelli, F. (2009) Targeting the AMPK pathway for the treatment of type 2 
diabetes, Front Biosci 14, 3380-3400. 
49. Gietz, R. D., and Schiestl, R. H. (2007) High-efficiency yeast transformation using the 
LiAc/SS carrier DNA/PEG method, Nature Protocols 2, 31-34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
Chapter 4: Impact of Genetically Incorporated Photocrosslinker on PPI Capture 
Efficiency4 
4A: Abstract 
 The genetic incorporation of photocrosslinking amino acids has been applied to the study 
of difficult PPIs, but we recently found that this method did not capture a PPI for which there 
was abundant functional evidence.  The factors that influence the success of covalent chemical 
capture and the innate reactivity of the two UAAs utilized, p-benzoyl-L-phenylalanine (Bpa) and 
p-azido-L-phenylalanine (Azpa), plays a profound role in the capture of protein binding partners. 
Based upon these data, we propose the first guidelines for the successful use of in vivo 
photocrosslinking to capture novel PPIs and to characterize the interfaces has been developed. 
4B: Background 
Photocrosslinking to covalently chemically capture proteins interacting with one another 
has increased in popularity.  Photoreactive groups have been seen in everything from 
bifunctional ligand molecules to genetically incorporated unnatural amino acids.  Although 
photocrosslinking is not a new technique, its application to in vivo experiments is very recent.  
One consequence of this relatively new application is a shortage of data indicating crosslinker 
efficiencies and reactivity preferences within a cellular environment.  The enormous difference 
in the cellular environment and a controlled test tube reaction means that although a foundation 
is in place for understanding crosslinking moieties and their mechanisms, we still need to explore 
the reasons behind differences in the crosslinking efficiencies.   
Earlier work from our lab stimulated interest in exploring some of the reactivity 
considerations of genetically incorporated p-benzoyl-l-phenylalanine (Bpa) along the interface of 
a classical PPI.  Using the transcriptional activator Gal4 and its repressor protein Gal80 in 
Saccharomyces cerevisiae, Bpa was incorporated into 10 different positions within the 
transcriptional activation domain of Gal4 and photocrosslinking was carried out in living yeast 
                                                
4 Portions of this chapter are from published work: Lanacia, J.K.;  Nwokoye, A.; Dugan, A.; Joiner, C.; Pricer, R.; Mapp, A.K., Sequence context 
and crosslinking mechanism affect the efficiency of in vivo capture of a protein-protein interaction. Biopolymers 2014, 101 (4), 391-397.  Figure 
4-1 and Figure 4-2 are from this work and I contributed all data to these figures.  Work from section 4D was done in conjunction with Melanine 
Cheung-See-Kit. 
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under conditions in which Gal80 was expected 
to bind Gal4.  While complex formation via in 
vivo crosslinking was detected at most 
positions, several instances were noted where 
functional data and existing structural data for 
the Gal4–Gal80 complex supported a direct 
interaction, yet little to no crosslinking was 
observed.1-6  For example, Phe856 has been 
observed in structural studies to be buried 
within the Gal4-Gal80 binding interface.5, 6  
When Phe856 was replaced with Bpa, the 
resulting Gal4 mutant was repressed in the 
presence of Gal80, suggesting that the 
mutation did not negatively impact the Gal80 
binding interaction, yet no Gal4–Gal80 
covalent complex could be observed after 
crosslinking.  In the case of the Phe856Bpa 
Gal4 mutant, there was functional evidence 
excluding the lack of a binding interaction as 
an explanation.  Thus, other parameters were 
examined that would produce a negative result, focusing on the crosslinking mechanism of Bpa 
in addition to a second photocrosslinking UAA, p-azido-L-phenylalanine (Azpa). 
In addition to the exploration of this very specific case of an apparent crosslinking false 
negative, a larger surface area PPI between Gal80-Gal80 dimers was examined.  Looking at an 
interface differing in size and affinity gives an interesting comparison to the Gal4-Gal80 binding 
interface which is small and very high affinity.  We wanted to see if there were particular 
interface types that are more amenable to Bpa or Azpa to enable easier application of this method 
to less well-studied PPIs.   
 4C: Covalent Capture of Gal4-Gal80 Varies Between Bpa and Azpa 
 To delve further into the unexpected lack of a crosslinked adduct at the Gal4 interface 
with Gal80, we first began examining the potential mechanistic causes. Bpa forms a diradical 
Figure 4-1 The Effect of Methionine on LexA+Gal4 
F856Bpa Crosslinking to Gal80. 
(a) Scheme showing experiment results.  (b) Expression of 
LexA+Gal4 F856Bpa as detected by Western blot of cell lysates 
with α-Flag and crosslinking of LexA+Gal4 F856Bpa to Myc-
tagged Gal80 as shown by Western blot of cell lysates with α-
Myc antibody. (c) Expression of LexA+Gal4 F856Azpa as 
detected by Western blot of cell lysates with α-Flag antibody and 
crosslinking of LexA+Gal4 F856Azpa to Myc-Gal80 as shown 
by Western blot of cell lysates with α-Myc antibody.  
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upon UV irradiation at 350–365 nm and then 
undergoes a C-H insertion reaction with nearby 
backbones and amino acid side chains.7  Although 
Bpa is capable of inserting into most C-H bonds, 
experimentally, Bpa reacts preferentially with 
methionine (Met) where it will react at distances 
beyond the 3.1 Å  reactivity radius.8  Specifically, 
the apparent preference of Bpa for methionine 
suggests that Bpa efficiency can be altered 
dramatically when placed in close proximity to 
methionine’s thioether side chain.8-10  Further 
examination of position 856 in the Gal4 TAD 
reveals two methionines in close proximity to the 
Bpa side chain; thus, we hypothesized that these 
methionines at positions 855 and 861 are internally 
“quenching” Bpa, thereby preventing it from 
crosslinking to Gal80.  Consistent with this 
hypothesis, when Met855 and Met861 are mutated 
either individually or collectively to alanine, we see 
that the resulting mutants are functional and, importantly, that Bpa crosslinking to Gal80 is 
restored (Figure 4-1).  These data are consistent with a model in which an intramolecular 
crosslink was competing with the intermolecular reaction in the LexA1Gal4 Phe856Bpa mutant 
and led to a false negative in our original experiments.  
To test this hypothesis further, a second photoactivatable UAA, Azpa, was incorporated 
into Gal4 in S. cerevisiae using the nonsense suppression method.  The amino acid preference for 
Azpa crosslinking is less clear because it has a more complex crosslinking mechanism compared 
to Bpa.7  During excitation at 254 nm light it forms a nitrene and it is in this state that insertion 
into C-H or heteroatom-H bonds occurs.  If, however, insertion does not take place during the 
1024 second excitation lifetime (determined for simple nitrenes in a polystyrene matrix) it will 
rearrange to a more stable ketenimine which only reacts with nucleophiles.7, 11   Utilization of the 
same expression conditions for Bpa led to the incorporation of Azpa at position 856 and the 
Figure 4-2 Activation Potential by Liquid β-
Galactosidase Assays of Gal4 Mutants. 
In the yeast strain tested, β-galactose expression was 
controlled by a Gal1 promoter containing two LexA 
binding sites for LexA+Gal4 binding.  Each value is the 
average of at least three independent experiments with the 
indicated error (SDOM).  As displayed above, all 
constructs used were able to activate transcription. 
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resulting mutant was fully functional (Figure 4-2, Figure 4-1).  A direct comparison of Azpa and 
Bpa crosslinking at position 856 reveals that Azpa crosslinks readily with Gal80, whereas Bpa 
does not (Figure 4-1).  As expected, introduction of alanine at positions 855 and 861 yielded no 
changes in Azpa crosslinking, consistent with the reactivity profile of this amino acid.  These 
data indicate that the difference in reactive mechanisms of crosslinkers plays a critical role in the 
outcome of crosslinking experiments.  The results shown here illustrate that not only is 
optimization of UAA incorporation a key factor in successful application of the strategy, but 
careful consideration of the innate reactivity of the UAA utilized is also critical. 
4D: Covalent Capture Efficiency of Varied PPI Interfaces Comparing Bpa and Azpa 
Although these studies illustrated a difference in reactivity between Bpa and Azpa, a 
complete analysis of differences in binding partner capture ability between incorporated amino 
acids on different PPI interfaces has yet to be done.  To understand these preferences such that 
the proper crosslinker can be used with the interactions under study, a series of PPIs that span a 
range of affinities and surface area must be compared.  The Gal4-Gal80 interaction used to test 
the methionine preferences of Bpa has a native KD is 5 nM with a surface area of approximately 
1500 Å2(Figure 4-3).  
To look at a larger 
surface area interface, 
the Gal80-Gal80 
dimerization domain 
was chosen with a KD of 
1 nM and surface area of 
5000 Å2.  In both 
systems, a series of 
mutations can be made 
to access a range of 
lowered binding 
affinities. 
Mutations for the 
Gal4-Gal80 interface 
were selected based on 
Figure 4-3 Interactions with Potential Mutants to Highlight a Range of PPI 
Interfaces. 
The first model PPI is the high affinity/small surface area complex of Gal4 and its repressor 
protein Gal80.  Mutations introduced into Gal4 will be used to progressively weaken this 
complex to move this into the lower light blue quadrant.  The second model PPI, fitting into the 
strong and broad category of interactions, utilizes the Gal80-Gal80 dimer with Gal80 mutations 
listed to create weaker binding. 
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previous literature citing a dramatic decrease in Gal4 binding to 
Gal80.  These mutants were then run as a panel on a 
preliminary Western blot to see which mutants had the 
most effect on binding.  Contrary to literature, we were still 
able to capture Gal80 with the single mutations (Figure 
4-4).  Although surprising, when looking at the context of 
previous literature experiments it is easier to understand the 
potential differences.  To express and test the binding 
affinities, proteins are often truncated so the native 
environment with full-length protein will have a much 
higher binding affinity and thus be more difficult to 
attenuate.   A panel of double mutants will need to be made 
to attempt to attenuate binding of Gal80 such that a noticeable difference can be observed by 
Western Blot.   
Another observation made during the execution of these experiments, is that the 
traditional Western blotting method used with chemiluminescence is not quantifiable (Figure 4-
4).  Extensive optimization went into choosing antibodies for multiplex fluorescent Western 
blotting.   Although the yeast model is a simpler system, not many companies produce yeast 
antibodies making antibody selection a much more difficult process.  The first antibody pairs 
found to successfully detect both Gal4 and 
Gal80 protein were anti-Flag and Myc 
primary antibodies with rabbit and mouse 
Alexafluor conjugated secondaries.   
Although Alexafluor gave quantifiable 
detection, a significant background was 
observed, which may interfere with 
visualization and calculations (Figure 4-5).  
The pair of antibodies that produced the 
best signal with minimal background was 
Figure 4-4 Crosslinking of LexA+Gal4 
F849Bpa mutants with Gal80. 
In vivo covalent chemical capture using 
LexA+Gal4 F849Bpa and the panel of Gal4 
mutants was carried out. An α-LexA antibody 
was used for immunoprecipitation and the blot 
was probed with a c-Myc-HRP antibody.  The 
only mutant that appears to cause weaker 
binding may be F869A but this is not a 
quantitative blot so no firm conclusion can be 
made.  No loss of binding was observed as 
expected, however. 
Figure 4-5 Duplex Visualization of Gal4 Mutant Attenuation 
of Gal4-Gal80 Interaction. 
Single point mutants within the Gal4 TAD were examined for their 
effects on Myc-Gal80 binding compared to the wild-type LexA-Gal4 
849Bpa-Flag construct. These mutants were able to attenuate binding 
to Gal4 endogenous binding partners, but had little effect on the Gal4-
Gal80 binding event. 
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found to be secondaries conjugated to near-IR dyes with 680 
and 800 nm excitations (Figure 4-5). 
Using the optimized antibodies, we tested several 
Gal80 mutants proposed to decrease dimerization (Figure 
4-6).12, 13  We found that overall Apza had poorer capture of 
the Gal80 dimer then Bpa (Figure 4-7).  This is surprising, as 
the main defect of Azpa is thought to be crosslinking of 
accessible solvent but the site of incorporation F234 is 
proposed to be fully buried in the dimer interface using 
Protein interfaces, surfaces and assemblies' service PISA at 
the European Bioinformatics Institute.14 
4E: Conclusion 
Although the Gal4-Gal80 PPI that is 
the focus of this study is a well-
characterized complex, the present and 
future applications of in vivo covalent 
capture are in the discovery of novel PPIs.  
Thus, it is important to understand the 
meaning behind a negative result.  An 
absence of crosslinking adduct could arise 
from a variety of factors, including the lack of 
a binding interaction, low unnatural amino 
acid (UAA) incorporation yield and/or 
fidelity, poor positioning of the UAA, and the 
poor reactivity of the activated UAA with the 
amino acids in the binding partner.  To avoid 
false negatives, it is critical to carry out 
crosslinking with more than a single UAA 
mutant, since, as illustrated here and in a 
previous study, a small change in position can 
have a dramatic effect on crosslinking. 
Figure 4-5 Visualization of Gal4-Gal80 
with near-IR Antibodies. 
The near-IR secondary antibodies at 680 and 
800 nm showed the best specificity and 
signal. 
Figure 4-7 Gal80-Gal80 Crosslinking Comparing Bpa 
and Azpa. 
Mutations selected to attenuate Gal80 binding were compared 
between Bpa and Azpa crosslinkers. We can see bands for Bpa 
but extremely faint bands for Azpa. 
Figure 4-6 Visualization of Gal80-Gal80 Mutations 
Attenuating Binding. 
Gal80 containing Bpa was visualized to see which mutations 
attenuated dimer binding the most. 
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When selecting an amino acid for a particular experiment, the longer lifetime and lower 
reactivity toward solvent makes Bpa an attractive choice, particularly for PPIs that occur through 
shallow, exposed binding sites. However, the marked preference of Bpa for methionine raises 
some concern that crosslinking results could be influenced by the presence of methionine in the 
UAA-containing protein as shown here with Gal4 or by a lack of methionines in potential 
binding partners.15  Relevant binding partners could be missed in an unbiased study due to either 
of these factors.  
The panel of Gal80-Gal80 mutants tested presents a contrary view of Azpa which 
theoretically should excel in a buried site such as F234.  Looking closer at the Gal80 crystal 
structure, it is plausible that this mutation along with some of the others we selected for this 
study could drastically change the structure.  If this were the case, Azpa may be more solvent 
accessible than predicted resulting in non-specific crosslinking with solvent.  Further studies will 
need to be done to look at potential structural effects these mutations have on Gal80 as well as 
the creation and testing of double mutants within the Gal4 binding interface to enable a direct 
comparison between small and large PPIs over a spectrum of affinities.  Additional interfaces 
will also need to be examined to see if any trends are maintained over a wider variety of PPIs.  If 
trends for photocrosslinking amino acids use can be established, this will have widespread 
applications for laboratories interested in using this technology, as the selection of a crosslinking 
amino acid could thus be tailored to the PPI being studied. 
4F:Experimental 
All covalent chemical capture experiments were carried out in yeast strain LS41 
[JPY9::pZZ41, Mat his3∆200 leu2∆1 trp1∆63 ura3-52 lys2∆385 gal4 URA::pZZ41].  Bpa and 
Azpa was purchased from Chem-Impex International (Wood Dale, IL).  All plasmids used in this 
study were constructed using standard molecular biology techniques.  Sanger sequencing 
verifying plasmid sequences was performed by the University of Michigan Core Facility (Ann 
Arbor, MI). 
Plasmid Construction: 
All plasmids used were previously reported.  All mutations were made using site-directed 
mutagenesis (Qiagen Quikchange Protocol).  Insertion of the 6xHis tag was achieved by site-
directed mutagenesis and Qiagen Quikchange two-step SDM protocol.   
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In vivo Covalent Chemical Capture 
In vivo covalent chemical capture experiments was carried out as previously described.1  
To perform in vivo crosslinking, an individual colony expressing pLexA+Gal4 F849TAG-Flag 
and pGADT7-Myc-Gal80 was inoculated in 10 mL SC media containing 2% glucose and lacking 
histidine, tryptophan, leucine, and uracil (H-W-L-U-) for selection.  This culture was incubated 
overnight at 30 °C with agitation and used to inoculate 100 mL cultures of H-W-L-U- SC media 
containing 2% glucose.  To each 100 mL culture, 1 mL of 100 mM Bpa dissolved in 1M NaOH 
and 1 mL 1M HCl were added.  Cultures were incubated overnight at 30 °C with agitation and 
grown to mid-log phase OD660 (~0.8).  Yeast were harvested by centrifugation at 6000 rcf at 
4˚C for 15 minutes (Beckman Avanti J-201, JLA 8.1000).  Cell pellets were washed with SC 
media and resuspended in 2mL H-W-L-U- SC media with 2% glucose.  Yeast were transferred to 
cell culture dishes and subjected to UV irradiation at 365 nm light (Eurosolar 15 W UV lamp) 
with cooling for 0.5 hour.  Irradiated cells were then harvested by centrifugation and stored at -
80˚C until lysis. 
For lysis, cells were resuspended in 600 µL Lysis buffer (50 mM HEPES-KOH pH 7.5, 
140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X Complete Mini, 
EDTA Free Protease Inhibitor (Roche) and lysed using glass beads by bead beating at 2800 rpms 
for 10 minutes at 4°C.  Subsequently, the lysate was pelleted and the supernatant incubated with 
2 µg of LexA antibody (sc-1725,  Santa Cruz Biotechnologies) for 2 hours at 4°C for 
immunoprecipitation.  The protein bound to the antibody was isolated by incubation for 1 hour 
with 40 µL of prewashed protein G magnetic beads slurry (Dynal Corporation, Invitrogen, 
Carlsbad, CA).  The beads were washed 6 times with 1 mL Wash Buffer (10 mM Tris-HCl pH 
8.0, 250 mM LiCl, 0.5% NP-40, 0.1% Na-Deoxycholate and 1 mM EDTA) and stored dry at -80 
˚C until elution.  
Preparation and Western Blotting of Crosslinked Samples 
The crosslinked sample was eluted from the beads by heating at 95˚C for 10 minutes in 
NuPAGE 4x LDS Sample buffer (Invitrogen, Carlsbad, CA) containing 250 mM DTT.  Protein 
amounts were measure using the Pierce 660 Assay so equal concentrations of protein could be 
loaded per lane.  Samples were run on a 4-8% Tris Acetate gel and transferred to PDVF 
fluorescent membrane.  Blots were probed using a 1:500 dilution of mouse-anti-FLAG (M2) 
antibody (Sigma, St. Louis, MO) and rabbit-anti-Myc (Pierce) in 5% BSA PBST.  The secondary 
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detection antibodies used were a 1:10,000 dilution of donkey anti-mouse 680LT IRDye and 
donkey anti-rabbit 800CW IRDye (Lycore).  Blots were visualized using an Azure C600 
Imaging System. 
β-Galactosidase assays 
To evaluate the ability of each LexA+Gal4 F849Bpa-Flag mutants to activate 
transcription in the presence or absence of glucose, saturated cultures (SC media + 2% raffinose ) 
of yeast expressing Gal4 Phe849Bpa mutants were used to inoculate 5 mL SC media containing 
either 2% glucose or 2% raffinose & 2% galactose but lacking histidine and tryptophan for 
selection.  The cells were grown to an OD660 of 0.8-1 and harvested.  The activity of each 
construct was monitored using β-galactosidase assays as previously described.1   
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Chapter 5: Conclusion 
5A: Introduction 
Protein-protein interactions support all cellular functioning and execute everything from 
signaling pathways to ensuring the correct proteins localize to the proper locations within a cell.  
Because of their extremely critical nature, any dysregulation of PPIs can quickly drive a cell into 
a disease state.  The vast span of PPIs and their myriad of roles in disease make them logical 
points for drug intervention.  This has not been the reality for many PPIs, however.  Compared to 
traditional enzymes or enzyme-like PPI that have been successful drug targets, many PPIs have 
much larger surface areas with no clear binding pockets or hot-spots of inhibition.  This can 
often be compounded with the fact that many PPIs have dynamic structures allowing them to 
bind multiple binding partners sometimes with transient affinities.  Due to these complications 
more commonly used biochemical techniques to study proteins may miss important PPIs 
altogether or provide an incomplete picture of their binding network.  Therefore, methods that 
look at PPIs in their native environments with minimal perturbation to their structures/function 
are needed to form more complete pictures of PPI networks and their potential for therapeutic 
interaction. 
5B: In Vivo Covalent Chemical Capture Expands PPI Studies 
One such method employed throughout this thesis is the use of genetically incorporated 
photocrosslinking unnatural amino acids for the covalent chemical capture of PPIs.  This 
technique site-specifically incorporates a UAA, causing minimal perturbation to the protein and 
allowing it to still function as intended within the cell.  This method was used to specifically look 
at the PPIs of transcriptional activators, as their intrinsically disordered nature, multi-protein 
complex recruitment, and transient associations make them a difficult to investigate by 
traditional means.   
In Chapters 2-3 covalent chemical capture was combined with other techniques to 
illustrate not only the power of using genetically incorporated UAAs for PPI studies but also the 
ability to fuse with other techniques to answer specific questions.  In Chapter 2, the question 
being asked, how to we look at direct interactions of DNA-bound proteins, stemmed from a 
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long-time debate of general transcription factor TBP’s recruitment to a the GAL1 promoter.  We 
were able to resolve this question using TRIC, a method to reversibly formaldehyde crosslink 
followed by covalent chemical capture to isolate DNA-bound PPIs.  This led us to show direct 
binding of DNA-bound VP16 to TBP indicating the activator also plays a role in TBP 
recruitment.  Although TRIC was developed in yeast, its application could extend to other 
systems especially since the more difficult lysis of yeast provided substantial difficulties for 
method development initially.  It’s use with a mammalian system could be further optimized to 
include a dual isolation of DNA and protein.  This would be an exciting use of this methodology 
as it would provide a way to visualize direct DNA-bound interactions as well as split to a ChIP-
like experiment validating the promoter localization. 
In Chapter 3 we questioned the ability to isolate novel binding partners without a bias 
search by Western blot.  MuDPIT mass spectrometry with covalent chemical capture was 
utilized and yielded the novel Gal4 binding partners Snf1 and Gal83 of the Snf1/AMPK 
complex.  Furthermore, these discovered binding partners demonstrate the participation of 
transcriptional activators in complex recruitment beyond what was traditionally believed and 
broaden the perspective of transcriptional PPIs.  Although demonstrated with a yeast model, this 
study also points to the use of the Snf1/APMK complex as a potential place for therapeutic 
intervention and additional studies to elucidate the complete involvement of AMPK in 
transcription.  The mammalian version of this complex exists in many forms with varying 
subunits, potentially providing even further specificity for a drug target as our developed UAA 
and mass spectrometry technique could be employed to look at which subunits are part of 
transcriptionally related interactions.1, 2  This would allow the targeting of specific gene 
activation instead of interfering with the global action of this multipurpose complex.   
In Chapter 4, we began to think more analytically about covalent chemical capture and 
explored the potential for specific uses for individual UAAs.  Several guidelines emerged from 
these studies including the need for testing experiments with multiple UAAs as the 
benzophenone tested has a high methionine preference sometimes leading to false negatives and 
the azide used can have lowered reactivity in certain interfaces.  A quick check, if possible for 
methionines near the incorporation site to prevent intramolecular crosslinking as well as on the 
binding partner interface would be largely beneficial to ensure successful Bpa crosslinking.  The 
specific reasons for lowered azide reactivity need to be further studied as the instance shown in 
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chapter 4 is the first example we have encountered a complete lack of crosslinking.  Although 
additional work needs to be done to establish more firm guidelines, throughout this thesis I have 
demonstrated the power of covalent chemical capture as a technique for PPI studies, especially 
those that are more challenging to study by traditional means.  It begs for us to ask, what 
questions do we want to answer next? 
5C: Future Directions 
Applications of the genetic incorporation of UAAs can extend far beyond the discussed 
covalent chemical capture methods.  New UAAs that are capable of being incorporated into cells 
are constantly being added with new and exciting applications with over 100 different UAAs that 
have been successfully incorporated.  Incorporation has also expanded to easily include 
mammalian cells.  The work discussed in this thesis was done using a simplified yeast model, but 
switching to using mammalian cell line models would greatly increase the applicability of this 
work directly to human disease PPIs.  Yeast were chosen for their slightly simpler PPIs networks 
and relative ease of use but using a mammalian system will greatly increase the number and 
variations of PPI networks.  Understanding mammalian PPI networks will take considerable 
effort and time to decipher.   
Looking even further into the future, past understanding individual cellular PPI networks, 
I think a movement to looking at the biological system as a whole will be possible using UAA 
incorporation.  The ability to expand UAA incorporation to whole model organism such as 
Caenorhabditis elegans (worms) and Drosophila melanogaster (fruit flies) has already been 
demonstrated.3, 4  Ideal additions to this set of tools would be the ability to incorporate UAAs 
within mouse and zebra fish models as well.  The capability to probe PPIs over larger biological 
systems such as organs or even throughout the body would be a large leap in the field’s ability to 
relate to whole-organism biology. 
Multi-addition systems are becoming more practical to use as well.5-7  This has been 
accomplished through the use of the amber stop codon with an additional sense codon rarely 
used or the addition of a blank quadruplet codon.  In the future, one could envision this applying 
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capture, followed by an exposed UAA incorporating a 
bioorthogonal moiety such as a click group to allow extra 
chemical steps to be done like pull-downs or fluorescent 
tagging (Figure 5-1).   
UAAs have other interesting possibilities for the 
manipulation of post-translational modification signaling 
within a cell.  For example, photo-control over protein 
phosphorylation has been established with tyrosine (for 
use in receptors)8, and serine (often part of signaling 
cascades).9  Applications of this type of signaling and 
cellular control could be interesting especially through the 
observation of PPI changes mediated by the turning on of 
specific pathways.  Examining a pathway within the cell 
in this fashion may also provide information about 
overlooked proteins within a signaling cascade/pathway 
such as scaffolding proteins or other critical binding 
partners we do not normally study through traditional 
means. 
Looking forward, there are many exciting possibilities using the demonstrated power of 
covalent chemical capture and genetic incorporation of UAAs for the studying of PPIs in a 
cellular context.  This will expand our knowledge and understanding of PPIs in their native 
environments, allowing the further elucidation of the dynamic interworking’s of a cell.  With the 
vast number of PPIs that have already been linked to disease states, a more complete 
understanding of PPI networks will aid researchers in finding better therapeutic targets for drugs 
in the future. 
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Appendix 1: Work Accomplished in the Garneau-Tsodikova Lab 
1a: Biochemical and Structural Analysis of Aminoglycoside Acetyltransferase Eis from 
Anabaena variabilis5 
1ai: Abstract 
The Mycobacterium tuberculosis enhanced intracellular survival (Eis) protein is a 
clinically important aminoglycoside (AG) multi-acetylating enzyme.  Eis homologues are found 
in a variety of mycobacterial and non-mycobacterial species.  Variation of the residues lining the 
AG-binding pocket and positions of the loops bearing these residues in the Eis homologues 
dictates the substrate specificity and, thus, Eis homologues are Nature-made tools for elucidating 
principles of AG recognition by Eis.  Here, we demonstrate that the Eis from Anabaena 
variabilis (Eis_Ava), the first non-mycobacterial Eis homologue reported, is a multi-acetylating 
AG-acetyltransferase.  Eis_Ava, Eis from Mycobacterium tuberculosis (Eis_Mtb), and Eis from 
Mycobacterium smegmatis (Eis_Msm) have different structures of their AG-binding pockets.  
We perform comparative analysis of these differences and investigate how they dictate the 
substrate and cosubstrate recognition and acetylation of AGs by Eis. 
1aii: Introduction 
Upregulation of the enzyme Eis from Mycobacterium tuberculosis (Eis_Mtb) has been 
shown to be responsible for kanamycin A (KAN) resistance in a large fraction of KAN-resistant 
clinical isolates from tuberculosis patients around the globe.3, 4  We recently reported the unique 
and unprecedented ability of Eis_Mtb1 and of its homologue from Mycobacterium smegmatis 
(Eis_Msm)5 to multi-acetylate a variety of aminoglycosides (AGs).  Even though Eis_Mtb and 
Eis_Msm are structurally very similar,7 we identified differences in the substrate recognition by 
these two Eis homologues and in their inhibition.1  Di-acetylation of the rigid fused-ring AG 
apramycin (APR) was observed with Eis_Msm, but APR was found to not be a substrate of 
Eis_Mtb.  Moreover, the potency of common inhibitors of these two Eis proteins varied between 
                                                
5   Portions of this appendix are from published work: Pricer, R.E.; Houghton, J.L.; Green, L.D.; Mayhoub, A.S.; Garneau-Tsodikova, S., 
Biochemical and structural analysis of aminoglycoside-acetyltransferase Eis from Anabaena variabilis. Mol. Biosyst.. 2012, 8, 3305-3313.  I 
contributed to all aspects of this work and was kindly instructed by Dr. Green and Dr. Houghton in learning the techniques presented within. 
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the two homologues.  These data were consistent with structural differences between the AG-
binding cavities of the two enzymes. 
Due to the rising threat of mycobacterial infection from non-tuberculosis mycobacteria 
and the ever-growing emergence of resistance to AG antibiotics, it is important to extend the 
analysis of Eis homologues beyond Eis_Mtb and Eis_Msm to aid in the understanding of Eis 
substrate recognition principles across the bacterial kingdom. 
As a focus of this study, we chose a putative GCN5-related-N-acetyltransferase (GNAT) 
from the cyanobacterium Anabaena variabilis ATCC 29413, (termed Eis_Ava herein) 
structurally similar to Eis_Mtb.  A crystal structure of Eis_Ava was deposited into the Protein 
Data Bank (PDB) by the Joint Center for Structural Genomics (PDB code: 2OZG).  In this work, 
to gain insight into the structural requirements dictating substrate and cosubstrate profile as well 
as the inhibition of Eis proteins, we performed structural and biochemical comparative studies of 
Eis_Ava with Eis_Mtb and Eis_Msm.  Cyanobacteria do not cause any clinical infections that are 
treated with AGs.  However, the A. variabilis ATCC 29413 strain was isolated from a sewage 
oxidation pond,8 and the development of resistance to AGs through water contamination has 
been previously documented in various bacterial species.9  Thus, exposure to AGs through 
sewage waste provides a potential explanation as to why a putative AG-acetylating enzyme, 
Eis_Ava, has arisen in this cyanobacterial strain. 
1aiii: Results and Discussion 
In Silico Analysis of Eis Homologues Across 29 Bacterial Species 
To evaluate the evolutionary relationship among the 3 Eis homologues of interest 
(Eis_Ava, Eis_Mtb, and Eis_Msm), we first performed a phylogenetic tree analysis using 29 Eis 
homologue sequences from a variety of mycobacterial and non-mycobacterial species (Figure 
A1-1).  In general, the mycobacterial and non-mycobacterial Eis homologues can be divided into 
two distinct clades, with Eis_Ava and Eis_Mtb being two of the most evolutionary distinct 
proteins in this set.  Interestingly, the Eis homologue from Mycobacterium abscessus (Eis_Mab) 
is clustered with the Eis homologues from the non-mycobacterial clade instead of the expected 
mycobacterial group.  The genetic proximity of Eis_Ava to Eis_Mab further highlights the 
importance of studying non-mycobacterial enzymes such as Eis_Ava to understand the 
mycobacterial AG-acetylation resistance mechanisms, due to the current increase in drug-
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resistant Mab infections.10  In the future, the information learned about Eis_Ava could 
additionally be applied to problematic bacterial species closely related to Ava that also contain 
Eis, such as Enterococcus faecalis (Efa). 
Structural Comparison of Eis Homologues 
Eis_Ava, Eis_Mtb, and Eis_Msm all share a tripartite monomer structure containing N-
terminal and central GNAT regions and a similar homo-hexameric organization.1, 7  By 
performing structure-based sequence alignment of these three Eis homologues, we observed that 
Eis_Ava greatly differs in amino acid composition when compared to Eis_Mtb (18% sequence 
identity) and Eis_Msm (19% sequence identity; Figure A1-2).  In contrast, Eis_Mtb and 
Eis_Msm are more similar (53% identical).  In all 3 Eis proteins, the key catalytic residue 
involved in catalysis (Tyr125 in Eis_Ava) (Figure A1-2, yellow circles/squares) is strictly 
Figure A1-1 Phylogenetic Tree Analysis of 29 Eis Homologues. 
The numbers are proportional to the evolutionary distance between the branches of the tree. The Eis proteins discussed in this 
manuscript are in bold. The abbreviated names of the bacterial species correspond to the following: Anabaena  variabilis ATCC 
29413 (Ava), Bacillus anthracis str. Sterne (Ban), Enterococcus faecalis V583 (Efa), Mycobacterium abscessus ATCC 19977 
(Mab), Streptomyces venezuelae ATCC 10712 (Sve), Streptomyces albus J1074 (Sal), Streptomyces coelicolor A3(2) (Sco), Kocuria 
rhizophila DC2201 (Krh), Brevibacterium  mcbrellneri ATCC 49030 (Bmc), Tsukamurella paurometabola ATCC 8368 (Tpa), 
Gordonia bronchialis DSM 43247 (Gbr), Mycobacterium parascrofulaceum ATCC BAA-614 (Mpa), Mycobacterium 
intracellulare ATCC 13950 (Min), Mycobacterium avium subsp. avium ATCC 25291 (Mav), Mycobacterium phlei RIVM601174 
(Mph), Mycobacterium vanbaalenii PYR-1 (Mva), Mycobacterium gilvum Spyr1 (Mgi1), Mycobacterium gilvum PYR-GCK 
(Mgi2), Mycobacterium sp. JDM601 (Msp1), Mycobacterium smegmatis str. MC2 155 (Msm), Mycobacterium sp. JLS (Msp2), 
Mycobacterium sp. MCS (Msp3), Mycobacterium kansasii ATCC 12478 (Mka), Mycobacterium marinum M (Mma), 
Mycobacterium canettii CIPT 140010059 (Mca), Mycobacterium bovis BCG str. Pasteur 1173P2 (Mbo), Mycobacterium 
tuberculosis SUMu002 (Mtb1), Mycobacterium tuberculosis H37Rv (Mtb2), and Mycobacterium tuberculosis T17 (Mtb3). 
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conserved, and those involved in CoA binding (Figure A1-2, orange circles/squares) are highly 
conserved.  However, the amino acid residues predicted to bind AGs through site-directed 
mutagenesis studies of Eis_Mtb1 and structure analysis of Eis_Mtb and Eis_Msm5 are highly 
divergent between Eis_Ava and Eis_Mtb/Eis_Msm (Figure A1-2, red squares).  Taken together, 
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Figure A1-2 Structure-based Sequence Alignment of Eis_Ava, Eis_Msm, and Eis_Mtb. 
Eis_Ava is from A. variabilis ATCC 29413, Eis_Msm is from M. smegmatis str. MC2 155, and Eis_Mtb is from M. tuberculosis 
H37Rv with alignment generated using Secondary-structure Matching (SSM).6  Residues in bold red in blue boxes are conserved 
between the 3 Eis homologues. The circles above and the squares below the Eis_Ava and Eis_Mtb sequences, respectively, 
correspond to important residues in these sequences.  Based on structural and mutagenesis studies of Eis_Mtb, the residues proposed 
to be involved in catalysis, in CoA binding, and in the formation of the AG-binding pocket are marked by yellow, orange, and red 
circles/squares, respectively.1  The AG-binding pocket of Eis_Mtb is divided into two channels. Residues lining these two channels 
are marked by green and turquoise circles/squares.  The * and the + symbols indicate residues that structurally aligned when 
superimposing the crystal structures of Eis_Ava and Eis_Mtb. 
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these observations demonstrate the evolutionary divergence between the Eis proteins from 
mycobacterial and non-mycobacterial species observed in Figure A1-1. 
Even though Eis_Ava greatly differs in amino acid composition from both Eis_Mtb and 
Eis_Msm, its structure is generally very similar to those of Eis_Mtb and Eis_Msm (Figure A1-3A 
and B).  To explore the structural similarities and differences among the 3 studied Eis proteins 
and their relationship to function, we compared the structures of their substrate-binding cavities 
(Figure A1-3C-E) and observed striking differences.  We previously reported that the AG-
Figure A1-3. Structural Comparison of Eis Homologues from Ava, Msm, and Mtb with Molecular Models of Eis-
APR-AcCoA Complexes. 
A. Structural alignment of Eis_Ava (PDB: 2OZG) with Eis_Msm (PDB: 3SXN) (The alignment of one of the monomers of the 
hexameric structures is shown).  B. Structural alignment of Eis_Ava (PDB: 2OZG) with Eis_Mtb (PDB: 3R1K) (The alignment 
of one of the monomers of the hexameric structures is shown).  The active site of C. Eis_Ava, D. Eis_Msm, and E. Eis_Mtb with 
residues lining the two channels (green and blue) of the AG-binding pocket highlighted.  Surface representation of the Eis 
monomer active sites of F. Eis_Ava, G. Eis_Msm, and H. Eis_Mtb colored according to their electrostatic potential, positive in 
blue, negative in red, and hydrophobic in white.  I. A model of AcCoA and APR bound to Eis_Ava.  J. A model of AcCoA and 
APR bound to Eis_Msm.  K. Structure of APR. 
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binding site of Eis_Mtb is divided into two distinct narrow channels (highlighted in green and 
blue in Figure A1-3E), while the AG-binding pocket of Eis_Msm consists of one wide and open 
cavity (Figure A1-3D), as a result of the small amino acid side-chains of the residues lining one 
of the two Eis_Msm channels (blue channel of Eis_Msm: Ala289, Ala287, Gly266, and Gly401; 
corresponding residues in Eis_Mtb: Gln291, Trp289, Ile268, and Glu401).  As a result of the 
broadening of its AG-binding site relative to that in Eis_Mtb, Eis_Msm can accommodate the 
structurally rigid APR AG while Eis_Mtb cannot.5  Interestingly, the substrate-binding cavity of 
Eis_Ava is divided into two distinct channels, as in the case of Eis_Mtb, but it differs 
structurally.  As in Eis_Mtb, the blue channel of Eis_Ava composed of Asp283, Ser281, Lys261, 
and Phe394 (corresponding residues in Eis_Mtb: Gln291, Trp289, Ile268, and Glu401) (Figure 
A1-2, blue circles/squares and Figure A1-3C and E) is narrow.  However, the green channel of 
Eis_Ava is much larger than that of Eis_Mtb and could potentially accept APR as a substrate as 
does Eis_Msm.  Different positions of the loop between the α1 and α2- helices and the β13-sheet 
in Eis_Ava and Eis_Msm (Figure A1-3B) are also in part responsible for the broadening of the 
substrate-binding cavity of these two Eis homologues relative to that in Eis_Mtb helices and the 
β13-sheet in Eis_Ava and Eis_Msm (Figure A1-3B) are also in part responsible for the 
broadening of the substrate-binding cavity of these two Eis homologues relative to that in 
Eis_Mtb. 
Multi-acetylation, Substrate, and Cosubstrate Specificity Profiles of Eis_Ava 
We recently reported the substrate and multi-acetylation profiles of Eis_Mtb and 
Eis_Msm, demonstrating the unique ability of the Eis enzymes to multi-acetylate many AGs.1, 5  
To investigate a potential effect of the broadening of the substrate-binding pocket of Eis_Ava on 
its substrate specificity 
profile, we monitored 
the acetylation by 
Eis_Ava of 11 AGs: 
amikacin (AMK), APR, 
KAN, neamine (NEA), 
neomycin B (NEO), 
netilmicin (NET), 
paromomycin (PAR), 
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Figure A1-4 Structures of Aminoglycosides (AGs) Tested. 
The amine functionalities that could potentially be modified by Eis proteins are highlighted in 
bold red. 
83 
 
ribostamycin (RIB), sisomicin (SIS), 
spectinomycin (SPT), and streptomycin (STR) 
(Table A1: 1and Figure A1-4, Figure A1-6), 
by UV-Vis and mass spectrometry assays.  To 
ensure the validity of the comparisons made in 
this work, we cloned and overexpressed 
Eis_Ava in an identical fashion to Eis_Mtb 
and Eis_Msm, which we previously reported 
(Figure A1-5).  As predicted, based on the 
structural homology with other Eis proteins, 
Eis_Ava is a functional AG-acetyltransferase.  
As we previously observed with Eis_Mtb and 
Eis_Msm, we found SPT and STR to not be 
substrates of Eis_Ava.  By mass spectrometry, 
we observed that the number of acetylated positions on AMK, NEA, NEO, NET, and RIB by the 
3 Eis homologues studied was the same for the 3 enzymes.  With other AGs, such as KAN and 
SIS, we found the number of acetylations with Eis_Ava to be less than those observed with 
Eis_Mtb and Eis_Msm, which were equal for any given AG.  Of particular note is the tri-
acetylation of PAR by Eis_Ava and Eis_Msm, in contrast to only di-acetylation of PAR by 
Eis_Mtb.  This result suggests that the broader substrate-binding cavities of Eis_Ava (Figure A1-
3C and F) and Eis_Msm (Figure A1-3D and G) accommodate the large PAR molecule in more 
orientations than Eis_Mtb does.  In addition, we found APR to be mono-acetylated by Eis_Ava, 
which corroborated the previously proposed role of the expanded substrate-binding cavity in 
binding this rigid extended AG.  The presence of two channels (one 
narrow (blue) and one large (green) in Figure A1-3C) in the 
substrate-binding site of Eis_Ava versus a single AG-binding pocket 
in Eis_Msm that is larger than the green channel of Eis_Ava (Figure 
A1-3D) could explain the mono-acetylation and di-acetylation of 
APR observed with Eis_Ava and Eis_Msm, respectively. 
To explore how APR may be accommodated in the binding 
pocket of Eis_Ava for acetylation, we performed docking of APR to 
Table A1-1 Comparison of Number of Acetylations of 
Various AGs by Eis Homologues from A. variabilis, 
M. tuberculosis, and M. smegmatis. 
AG Eis_Ava Eis_Mtba Eis_Msmb 
AMK Tri Tri Tri 
APR Mono Xc Di 
KAN Mono Di Di 
NEA Tri Tri Tri 
NEO Tri Tri Tri 
NET Di Di Di 
PAR Tri Di Tri 
RIB Tri Tri Tri 
SIS Di Tri Tri 
SPT Xc Xc Xc 
STR Xc Xc Xc 
a These data were previously reported.1 b These data were previously 
reported.5 c X indicates no observed acetylation. 
 
Figure A1-5 Coomassie 
Blue-stained SDS-PAGE of 
Purified Eis_Ava. 
84 
 
Eis_Ava and 
Eis_Msm in complex 
with AcCoA (Figure 
A1-3I and J).  The 
shorter loop between 
the α1 and α2-helices 
of Eis_Ava that is 
responsible for the 
expansion of the 
green channel of this 
enzyme when 
compared to its 
counterpart in 
Eis_Msm (Figure A1-
3B, I and J) could 
account for the different conformations adopted by APR in the AG-binding site and the different 
number of acetylations of APR by these two Eis enzymes, mono- versus di-acetylation by 
Eis_Ava and Eis_Msm, respectively (Table A1-1).  Taken together, the structural analysis of the 
substrate-binding cavities of Eis homologues and their multi-acetylation profiles revealed that 
Eis_Ava behaves more similarly to Eis_Msm than to Eis_Mtb. 
In addition to studying the AG substrate promiscuity of Eis_Ava, we also investigated its 
cosubstrate profile.  We recently showed that Eis_Mtb is limited in its cosubstrates, efficiently 
accepting only AcCoA and n-propionyl-CoA and moderately so crotonyl-CoA and malonyl-CoA 
for transfer onto a few AGs.11  We determined that among the 6 acyl-CoA cosubstrates tested 
with Eis_Ava (AcCoA, butyryl-CoA, crotonyl-CoA, malonyl-CoA, myristoyl-CoA, and n-
propionyl-CoA), only the natural AcCoA cosubstrate and its close structural homologue n-
propionyl-CoA were accepted by the cyanobacterial Eis. 
Steady-state kinetic parameters for Eis_Ava 
To further understand the action of Eis_Ava and the subtleties differentiating the 3 
investigated Eis homologues, we performed steady-state kinetic measurements of AG acetylation 
by Eis_Ava and compared the Michaelis-Menten parameters, Km and kcat, to those of Eis_Mtb 
Figure A1-6 Mass Spectra of AGs Multi-acetylated by Eis_Ava. 
85 
 
and Eis_Msm 
(Table A1-2 
and Figure 
A1-7).  In this 
study, we 
determined all 
kinetic 
parameters 
(for Eis_Ava, 
Eis_Mtb, and 
Eis_Msm) for 
500 µM AcCoA, in a range of 0-2500 
µM AG, and 0.25 µM Eis.  In a previous 
report, we determined and compared the 
Km and kcat values for Eis_Mtb and 
Eis_Msm using 100 µM AcCoA, 0-2500 
µM AG, and 0.25 µM Eis.5  AcCoA was 
used at a higher concentration in this 
study to ensure that all enzyme was 
bound to AcCoA thereby allowing a 
direct interpretation of kinetics as a 
property of this holo-Eis.  For APR, a 
substrate of Eis_Ava and Eis_Msm, but 
not of Eis_Mtb, we found that Km and 
kcat values are very similar (337 ± 98 µM 
and 0.019 ± 0.002 s-1 for Eis_Ava and of 150 ± 43 µM and 0.019 ± 0.002 s-1 for Eis_Msm).  For 
KAN and NEO, the Km and kcat values for acetylation by Eis_Ava were also more similar to 
those of Eis_Msm than to those of Eis_Mtb.  Overall, the kinetic parameters of Eis_Ava appear to 
be most similar to those of Eis_Msm, which can be explained by the larger substrate-binding 
cavities of these two enzymes compared to the divided AG-binding site of Eis_Mtb. 
 
Figure A1-7 Michaelis-Menten Analysis of the Eis_Ava Catalyzed Acetylation. 
A. APR, B. KAN, C. NEA, D. NEO, and E. PAR. 
Table A1-2 Steady-State Kinetic Parameters for AG 
Concentration-Dependent Acetylation by Eis Homologues 
from A. variabilis, M. smegmatis, and M. tuberculosis. 
 Eis_Ava 
AG Km (µM) kcat (s-1) kcat/Km (M-1s-1) 
APR 337 ± 98 0.019 ± 0.002 57 ± 18 
KAN 1002 ± 43 0.205 ± 0.004 205 ± 9 
NEA 42 ± 9 0.352 ± 0.021 7413 ± 1938 
NEO 101 ± 16 0.106 ± 0.006 1052 ± 184 
PAR 237 ± 36 0.183 ± 0.013 773 ± 132 
    
 Eis_Msm 
AG Km (µM) kcat (s-1) kcat/Km (M-1s-1) 
APR 150 ± 43 0.019 ± 0.002 127 ± 39 
KAN 665 ± 42 0.360 ± 0.010 541 ± 37 
NEA 1302 ± 312 0.687 ± 0.083 528 ± 142 
NEO 110 ± 14 0.148 ± 0.006 1345 ± 180 
PAR 738 ± 158 0.235 ± 0.033 318 ± 82 
    
 Eis_Mtb 
AG Km (µM) kcat (s-1) kcat/Km (M-1s-1) 
APR ---a --- --- 
KAN 330 ± 40 0.526 ± 0.027 1594 ± 250 
NEA 1315 ± 492 0.699 ± 0.136 532 ± 224 
NEO 122 ±23 0.610 ± 0.029 5000 ± 972 
PAR 110 ± 21 0.136 ± 0.012 1236 ± 260 
a --- indicates that APR is not a substrate for Eis_Mtb. 
86 
 
Regio-Specificity of NEA Di-Acetylation by Eis_Ava. 
We previously demonstrated that 
Eis_Mtb1 and Eis_Msm5 sequentially tri-
acetylate NEA at the 2'-, 6'-, and 1-position.  
Seeking a deeper understanding of the 
differences and similarities between the 
mycobacterial and non-mycobacterial Eis 
proteins, we sought to compare the regio-
specificity and order of multi-acetylation of 
NEA by Eis_Ava to those by 
Eis_Mtb/Eis_Msm.  Interestingly, by thin-
layer chromatography (TLC) and NMR 
spectroscopy (1H, gCOSY, zTOCSY, and gHSQC), we could only observe di-acetylation of 
NEA by Eis_Ava (Figure A1-8, Figure A1-9, Figure A1-10, and Table A1-3).  Remarkably, we 
also established that the first position of the NEA scaffold acetylated was the 2'-position, as 
previously observed with Eis_Mtb and Eis_Msm, but that the second site modified was the 1-
position instead of the expected 6'-position.  It is important to note that, as established by mass 
spectrometry, a third position can be acetylated by Eis_Ava on the NEA scaffold.  The change in 
order of the position acetylated by Eis_Ava could potentially explain why for this enzyme we did 
not observe by UV-Vis and mass spectrometry assays a third acetylation, which could proceed at 
the much slower rate.  These data suggest that the order and number of acetylations may vary for 
each AG based on the Eis homologue utilized.  Further studies aimed at establishing the number 
and positions of acetylation on multiple AGs by a variety of Eis homologues are currently 
underway in our laboratory. 
Inhibition of Eis_Ava 
We recently reported the discovery and characterization of Eis_Mtb inhibitors,2 which 
also inhibited Eis_Msm (Figure A1:11).5  As Eis homologues are found in a variety of bacterial 
strains (Figure A1-1), including emerging resistant species such as Mab, the importance of 
finding Eis inhibitors that efficiently work across various species is increasing with the number 
of resistant bacterial species that harbour Eis homologues continuously rising.  To perform 
preliminary exploration of the potential of the identified Eis_Mtb inhibitors against Eis 
Figure A1-8 Formation of 1,2'-di-acetyl-NEA by Eis_Ava 
Monitored by a TLC Assay. 
Lanes 1-6: a time course showing the mono- and di-acetyl-NEA 
products of the Eis_Ava reaction. Lanes 7-12: Controls for mono- 
and di-acetylation of NEA by AAC(2')-Ic, AAC(3)-IV, and 
AAC(6') used individually or sequentially. 
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homologues from various bacterial species, we tested 5 Eis_Mtb inhibitors against Eis_Ava and 
Eis_Msm.  For chlorhexidine (1), the IC50 value of 20 ± 7 µM observed for Eis_Ava was was 
107-fold higher than that for Eis_Mtb (188 ± 30 nM) and 11-fold higher than that against 
Eis_Msm (1.85 ± 0.39 µM). For compounds 2 and 3, the IC50 values were comparable for both 
mycobacterial strains. Interestingly, for compound 4, the IC50 value of 455 ± 92 nM observed for 
Eis_Msm was 4.4-fold lower than that for Eis_Mtb (2.01 ± 0.12 µM). The poor inhibition of 
Eis_Ava by all 5 inhibitors (IC50 values of 20 ± 7 µM for compound 1 and >200 µM for 
compounds 2-5) tested could be attributed to the electrostatics of its substrate-binding cavity, 
which is more hydrophobic (Figure A1-3F) than in Eis_Mtb (Figure A1-3H) and in Eis_Msm 
(Figure A1-3G).  For example, the hydrophobic Met32 and Pro185 residues of the substrate-
binding pocket in Eis_Ava replace the structurally homologous negatively-charged Asp28 and 
 
Figure A1-9 NMR of NEA. 
Left: 1H NMR of NEA in 1.2:8.8/D2O:H2O at pH 7.5 (500 MHz).  The full spectrum is shown in 
panel A and the expansions in panels B-D.  Right Top: gCOSY of NEA in 1.2:8.8/D2O:H2O at 
pH 7.5 (500 MHz).  Right Middle: zTOCSY of NEA in 1.2:8.8/D2O:H2O at pH 7.5 
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Asp195 in Eis_Msm.  Therefore, to assess the utility of discovered Eis_Mtb inhibitors on new 
potential Eis homologues, a thorough analysis of the substrate-binding pocket residues is needed.  
 
Figure A1-10 NMR of 1,2'-di-acetyl-NEA. 
Left: 1H NMR of 1,2'-di-acetyl-NEA in 1.2:8.8/D2O:H2O at pH 7.5 (500 MHz).  The full spectrum is 
shown in panel A and the expansions in panels B-D.  Right Top: gCOSY of 1,2'-di-acetyl-NEA in 
1.2:8.8/D2O:H2O at pH 7.5 (500 MHz).  Right Middle: zTOCSY of 1,2'-di-acetyl-NEA in 1.2:8.8/D2O:H2O 
at pH 7.5 (500 MHz).  Right Bottom: gHSQC of 1,2'-di-acetyl-NEA in 1.2:8.8/D2O:H2O at pH 7.5 (500 
MHz). 
Table A1-3 Proton Chemical Shifts determined for NEA and 1,2'-di-acetyl-NEA.a 
Ring H position NEA 1,2'-di-acetyl-NEA  Dppm 
II 1 2.91-2.88b (m) [2.89]d 3.70-3.84 (m) [3.77]  0.88 
 2ax 1.33 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.0 Hz)c 1.72 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 13.0 Hz)  0.39 
 2eq 2.08 (ddd (app. dt), J2eq,2ax = 12.0 Hz, J2eq,1 = J2eq,3 = 4.0 Hz) 2.25 (ddd (app. dt), J2eq,2ax = 13.0 Hz, J2eq,1 = J2eq,3 = 4.1 Hz)  0.17 
 3 2.96b (ddd, J3,2eq = 4.0 Hz, J3,2ax = 12.0 Hz, J3,4 = 9.5 Hz)  3.33-3.41 (m) [3.38]  0.42 
 4 3.35e (dd, (app. q) J4',3' = J4',5' = 9.5) 3.91-3.79 (m) [3.82]  0.45 
 5 3.59-3.55 (m) [3.57] 3.66-3.58 (m) [3.62]  0.05 
 6 3.29-3.23e (m) [3.26] 3.51-3.37 (m) [3.42]  0.16 
I 1' 5.42 (d, J1',2' = 4.0 Hz) 5.76 (d, J1',2' = 3.8 Hz)  0.34 
 2' 2.87 (dd, J2',1' = 4.0 Hz, J2',3' = 10.5 Hz) 4.01-3.93 (m) [3.98]  1.11 
 3' 3.63 (dd (app. t), J3',4' = 9.5 Hz, J3',2' = 10.5 Hz)  3.92-3.85 (m) [3.89]  0.26 
 4' 3.35 (dd, (app. q) J4',3' = J4',5' = 9.5) 3.51-3.37 (m) [3.44]  0.09 
 5' 3.91 (ddd, J5',4' = 9.5 Hz, J5',6'a = 7.5 Hz, J5',6'b = 3.0 Hz) 4.01-3.93 (m) [3.96]  0.05 
 6'a 3.04 (dd, J6'a,6'b = 14.0 Hz, J6'a,5' = 7.5 Hz) 3.22 (dd, J6'a,6'b = 13.0 Hz, J6'a,5' = 7.5 Hz)  0.18 
 6'b 3.29-3.23 (m) [3.25] 3.51-3.37 (m) [3.49]  0.24 
Acetyl NH-2' ´ 8.30 (d, JNH,2' = 8.0 Hz)   
 NH-1 ´ 8.24-8.14 (m) [8.20]   
 CH3C=O on 2' ´ 2.05 (s)   
 CH3C=O on 1 ´ 1.97 (s)   
 aThe chemical shift were established based on 1H, zTOCSY, gCOSY, and gHSQC NMR (500 MHz). bCould be analogous position of the 2-deoxystreptamine (DOS) ring. cMultiplicity and 
J are given in (). dThe numbers in [] were determined from gCOSY and/or zTOCSY. eCould be analogous position of the DOS ring. ´Indicates that the acetyl moiety is not present in the 
molecule. 
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Reduced Activity of Eis Homologues Towards 
6’-glycinyl-KAN. 
The development of AGs capable of 
avoiding acetylation by Eis enzymes could present 
an alternative strategy to the discovery of Eis 
inhibitors to combat the Eis resistance problem.  
We recently reported a simple chemical approach 
for the production of biologically active 6’-N-
acylated AG derivatives.12  To explore the 
potential of these acylated AGs to evade Eis 
multi-acetylation, we tested 6’-glycinyl-
KAN against Eis_Ava, Eis_Msm, and 
Eis_Mtb (Figure A1-12). We observed that 
in contrast to KAN that efficiently gets 
multi-acetylated by all Eis homologues 
tested (blue, red, and green circles in Figure 
A1-12), 6’-glycinyl-KAN is not a substrate for these 
enzymes (blue, red, and green triangles in Figure A1-12). 
These data demonstrate the potential of developing novel 
AG derivatives towards combating AG acetyltransferase 
enzymes.  
1aiv: Conclusion 
In this work, we refined our understanding of the 
details of the substrate recognition for multi-acetylation of 
AGs by Eis homologues from mycobacterial and non-
mycobacterial Eis homologues.  We also explored the 
applicability of Eis_Mtb inhibitors to the inactivation of Eis 
homologues from other bacterial species.  From these studies we concluded that (i) the substrate-
binding cavities of Eis homologues vary greatly even though the overall structures of the 
enzymes are highly comparable, (ii) Eis_Ava behaves more similarly to Eis_Msm than to 
Eis_Mtb, (iii) the order of acetylation for a given AG can vary for different Eis homologues, and 
Table A1-4 Inhibition of Eis Homologues from A. 
variabilis, M. smegmatis, and M. tuberculosis by 
Compounds 1-5 for NEO Acetylation. 
 IC50 [µM] 
Compound Eis_Ava Eis_Msm Eis_Mtba 
1 20 ± 7 1.85 ± 0.39 0.188 ± 0.030 
2 >200 0.925 ± 0.201 1.09 ± 0.14 
3 >200 1.69 ± 0.32 1.24 ± 0.16 
4 >200 0.455 ± 0.092 2.01 ± 0.12 
5 >200 >200 2.29 ± 0.52 
a These data were previously reported.2 
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Figure A1-12 UV-Visible Spectrum 
Showing the Activity of Eis 
Homologues Against KAN and 6'-
glycinyl-KAN. 
All Eis homologues (Eis_Ava - blue, 
Eis_Msm - red, and Eis_Mtb -green) are 
active against KAN (circles) and almost 
inactive against 6'-glycinyl-KAN (triangles).  
As a result, the red triangles are completely 
hidden behind the blue triangles. 
Figure A1-11 Structures of Inhibitors Tested 
Against Eis_Ava, Eis_Msm, and Eis_Mtb. 
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(iv) inhibitors of Eis_Mtb could be applied with varying degree of efficiency against bacterial 
strains containing Eis homologues.  Further studies are underway in our laboratory aimed at 
establishing the positions acetylated by Eis homologues on a number of AG scaffolds.  Structure 
activity relationship studies towards the development of Eis inhibitors with high potency and 
broad application are also ongoing. 
1av: Experimental 
Bacterial Strains, Plasmids, Materials, and Instrumentation 
Chemically competent Escherichia coli TOP10 and BL21 (DE3) strains were purchased 
from Invitrogen (Carlsbad, CA).  A. variabilis ATCC 29413 genomic DNA was purchased from 
the American Type Culture Collection (ATCC).  The pET28a plasmid used in this study was 
purchased from Novagen (Gibbstown, NJ).  Primers used for PCR were purchased from 
Integrated DNA Technologies (Coralville, IA).  All reagents and enzymes used for cloning, 
including restriction enzymes, Phusion DNA polymerase, and T4 DNA ligase, were purchased 
from New England Biolabs (Ipswich, MA).  DNA sequencing was performed at the University 
of Michigan DNA Sequencing Core.  Dithionitrobenzoic acid (DTNB), AcCoA, acyl-CoAs 
(butyryl-CoA, crotonyl-CoA, malonyl-CoA, myristoyl-CoA, and n-propionyl-CoA), and 
aminoglycosides (AGs) (AMK, APR, KAN, NEO, RIB, SIS, SPT, and STR; Figure A1-4) were 
purchased from Sigma-Aldrich (Milwaukee, WI) and used without further purification.  The 
remaining AGs (NEA, NET, and PAR; Figure A1-4) were purchased from AK Scientific 
(Mountain View, CA). Eis_Mtb and Eis_Msm were purified as previously described using the 
pEis_Mtb-pET28a1 and pEis_Msm-pET28a5 constructs, respectively.  All UV-Vis 
spectrophotometric assays were performed in 96-well plates (Fisher Scientific; Pittsburg, PA) 
using a multimode SpectraMax M5 plate reader.  A Shimadzu LCMS-2019EV equipped with a 
SPD-20AV UV-Vis detector and a LC-20AD liquid chromatograph was used for all liquid 
chromatography mass spectrometry (LCMS) measurements.  The PDB structures 3R1K 
(Eis_Mtb), 3SXN (Eis_Msm), and 2OZG (Eis_Ava) were analyzed using Coot13 and PyMOL 
(The PyMOL Molecular Graphics System, Version 1.4.1, Schrödinger, LLC). 
Phylogenetic Tree Creation for Eis Homologues 
The amino acid sequences of 29 Eis homologues were retrieved from NCBI through the 
Geneious Pro 4.8.5 program.  The phylogenetic tree (Figure A1-1) was built by neighbor-joining 
using the Geneious Pro 4.8.5 program with the following parameters: Jukes-Cantor genetic 
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distance and the cost matrix Blosum45.  The NCBI accession numbers for the Eis homologues 
were YP_325469 (Ava), YP_029001 (Ban), NP_814755 (Efa), YP_001705255 (Mab), 
CCA55694 (Sve), ZP_06590713 (Sal), NP_628362 (Sco), YP_001855041 (Krh), ZP_06804610 
(Bmc), YP_003645809 (Tpa), YP_003272441 (Gbr), ZP_06852004 (Mpa), ZP_05228133 (Min), 
ZP_05216001 (Mav), ZP_09975446 (Mph), YP_956800 (Mva), YP_004079667 (Mgi1), 
YP_001132138 (Mgi2), YP_004522750 (Msp1), YP_887817 (Msm), YP_001071002 (Msp2), 
YP_639864 (Msp3), ZP_04749484 (Mka), YP_001852011 (Mma), YP_004745879 (Mca), 
YP_978521 (Mbo), ZP_07418795 (Mtb1), CAB03742 (Mtb2), and ZP_06450792 (Mtb3). 
Preparation of pEis_Ava-pET28a Overexpression Construct 
PCR for the amplification of the homologous eis gene from A. variabilis was performed 
using Phusion DNA polymerase according to instructions provided by NEB.  A. variabilis ATCC 
29413 (Ava) genomic DNA was used as the template for PCR with forward primer 5’-
GTGCTTCATATGGTAGAACCAATGAC-3’ and reverse primer 5’-
CTATGCCTCGAGTTAAAAGAAATCAATC-3’.  The amplified PCR product, eis_Ava, was 
inserted into a linearized pET28a vector between NdeI and XhoI restriction sites.  The plasmid 
containing eis_Ava was transformed into chemically competent E. coli TOP10 cell and used to 
confirm the sequence of the Eis_Ava gene (gene locus Ava_4977) (University of Michigan DNA 
Sequencing Core). 
Overproduction and Purification of Eis_Ava Protein 
The Eis_Ava protein, containing a N-terminal His6-tag, was overexpressed and purified 
using the pEis_Ava-pET28a overexpression construct as previously reported for its homologue in 
Mycobacterium tuberculosis (Eis_Mtb).1  The Eis_Ava protein was dialyzed in Tris-HCl buffer 
(50 mM, pH 7.5 adjusted at rt), flash frozen in the dialysis buffer containing 10% glycerol, and 
stored at -80 °C.  The protein yield after purification was 1.5 mg per L of culture (Figure A1-5).  
UV-Vis Spectrophotometric Assay Determination of AG Selectivity Profile of Eis_Ava 
The Eis_Ava acetyltransferase activity was monitored by using the Ellman’s method in 
which the CoA thiol, freed by the Eis_Ava catalyzed reaction, is reacted with DTNB to produce 
an increase in absorbance that can be monitored at 412 nm (ε412 = 13,600 M-1cm-1).14  
Reactions (200 µL) containing AG (0.1 mM, 1 eq), acyl-CoA (0.5 mM, 5 eq), DTNB (2 mM), 
and Tris-HCl (50 mM, pH 7.5 adjusted at rt) were initiated by the addition of Eis_Ava (0.5 µM) 
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at 25 °C. The reactions were monitored by taking readings every 30 seconds for 1 hour in 96-
well plate format. 
Determination by Mass Spectrometry of the Number of AG Amine Functionalities 
Acetylated by Eis_Ava 
To determine the number of acetylations performed by Eis_Ava on each AG substrate, we 
used LCMS.  Reactions (30 µL) containing AG (0.67 mM, 1 eq), AcCoA (6.7 mM, 10 eq), Tris-
HCl (50 mM, pH 8.0 adjusted at rt), and Eis_Ava (10 µM) were run overnight at rt.  To prepare 
samples for the LCMS, ice-cold MeOH (30 µL) was added to the reaction mixture, followed by 
incubation for 20 minutes at -20 °C to precipitate the protein.  Centrifugation (13,000 rpm, rt, 10 
minutes) was then used to pellet the protein and the supernatant was used for LCMS injection 
after its dilution in H2O (10 µL of supernatant into 20 µL of H2O).  The whole sample (30 µL) 
was injected onto the LCMS, used in positive mode with H2O (0.1% formic acid).  Mass spectra 
showing the number acetylations on AMK, APR, KAN, NEA, NEO, NET, PAR, RIB, and SIS 
are presented in Figure A1-6. These data are also summarized in Table A1-1. 
Molecular Modeling of APR with Eis_Ava and Eis_Msm 
The APR structure was built using the Sybyl-X software and minimized to 0.01 kcal/mol 
by the Powell method, using Gasteiger-Hückel charges and the Tripos force field.  The 
coordinates of the Eis_Ava and Eis_Msm (PDB codes: 2OZG and 3SXN, respectively) were 
downloaded from the Protein Data Bank website.  Except for CoA, the H2O molecules and all 
other substructures were removed from the two proteins.  In the structure of Eis_Ava (PDB code: 
2OZG), the selenium atoms were replaced manually by sulfur.  An acetyl group was added to 
CoA in both Eis_Ava and Eis_Msm.  The surrounding protein residues were then kept frozen and 
the AcCoA was subjected to energy minimization using the Steepest descent method.  Hydrogen 
atoms were added and the energy of the Eis_Ava-AcCoA and Eis_Msm-AcCoA complexes were 
minimized using the Amber force fields with Amber charges.  The energy-optimized APR was 
docked into the AG-binding site in both Eis_Ava-AcCoA and Eis_Msm-AcCoA minimized 
complexes using GOLD.15  The parameters were set as the default values for GOLD.  The 
maximum distance between hydrogen bond donors and acceptors for hydrogen bonding was set 
to 3.5 Å.  After docking, the first-ranked conformation of APR in both cases was merged into the 
corresponding APR-free Eis_Ava-AcCoA and Eis_Msm-AcCoA complexes.  The new Eis_Ava-
APR-AcCoA and Eis_Msm-APR-AcCoA complexes were subsequently subjected to energy 
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minimization using the Amber force fields with Amber charges.  During the energy 
minimization, the structure of APR and residues within an 8-Å radius were allowed to move.  
The remaining residues were kept frozen in order to save calculation time.  The energy 
minimization, in both cases, was performed using the Powell method with a 0.05 kcal/mol 
energy gradient convergence criterion and a distance dependent dielectric function.  The 
Eis_Ava-APR-AcCoA and Eis_Msm-APR-AcCoA complexes are depicted in Figure A1-3I and 
J. 
Characterization of Eis_Ava Steady-State Kinetic Parameters 
For several AGs tested in this study (APR, KAN, NEA, NEO, and PAR) the kinetic 
parameters (Km and kcat) were determined for acetylation by Eis_Ava in reactions (200 µL) with 
a fixed AcCoA (0.5 mM) concentration.  For NEA, NEO, and PAR the AG concentration range 
used was 0, 20, 50, 100, 250, and 500 µM.  Due to their higher Km values, APR and KAN were 
tested in a higher concentration range of 0, 50, 250, 500, 1000, and 2000 µM.  The reaction 
mixture containing DTNB (2 mM), Tris-HCl (50 mM, pH 7.5 adjusted at rt), and Eis_Ava (0.25 
µM) was initiated by the addition of AG.  Reactions were monitored by taking readings every 20 
seconds for 20 minutes at 25 °C.  For determination of the Km and kcat parameters, a non-linear 
regression fit to the Michaelis-Menten dependence was carried out by using Sigma Plot 11.0 
software (Systat Software Inc.; San Jose, CA) (Figure A1-7and Table A1-2).  The same 
procedure was used to determine the kinetic parameters (Km and kcat) reported in Table A1-2 for 
Eis_Mtb and Eis_Msm. 
Monitoring of NEA Acetylation by TLC 
The eluent system utilized for all TLCs of NEA reactions was 92.5:7.5/MeOH:NH4OH.  
The TLCs showing various mono-, and di-acetylated NEA along with their respective Rf values 
are depicted in Figure A1-8.  The mono-acetylated standards 2'-, 3-, and 6'-acetyl-NEA were 
obtained by using AAC(2')-Ic, AAC(3)-IV, and AAC(6')-Ie/APH(2")-Ia, respectively.  These 
enzymes were overexpressed and purified as previously reported.1, 16  The acetylation reactions 
(30 µL) by these enzymes were run at rt in MES buffer (50 mM, pH 6.0 adjusted at rt) (AAC(3)-
IV and AAC(6')) or in potassium phosphate buffer (100 mM, pH 7.0 adjusted at rt) (AAC(2')-Ic) 
with NEA (5 mM, 1 eq), AcCoA (25 mM, 5 eq) and AAC enzyme (10 µM).  After overnight 
incubation at rt, the protein was precipitated by addition of MeOH (30 µL; 20 minutes, -20 °C).  
The protein was pelleted by centrifugation (13,000 rpm, rt, 10 minutes).  An aliquot (5 µL) of the 
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supernatant was diluted with MeOH (5 µL) before loading onto SiO2 TLC plates.  The di-
acetylation control reactions (30 µL) were carried out in a similar fashion with the addition of the 
second AAC enzyme (10 µM) and an additional portion of AcCoA (25 mM, 5 eq) after a 24 hour 
incubation period. 
 The reactions with Eis_Ava (30 µL) were run in Tris-HCl (50 mM, pH 7.5 adjusted at 
rt) with AcCoA (25 mM, 5 eq), NEA (5 mM, 1 eq), and Eis_Ava (10 µM).  At different time 
points: 0 (before Eis_Ava addition), 5, 10, 30, 120 minutes, and overnight, aliquots (5 µL) were 
removed and processed as described above before loading onto SiO2 TLC plates. 
Determination by NMR of NEA Amines Acetylated by Eis_Ava 
To determine which two positions of NEA are acetylated by Eis_Ava, a reaction was 
designed for characterization in solution by NMR without the need for purification.  A reaction 
(200 µL) containing NEA (10 mM, 1 eq), AcCoA (50 mM, 5 eq), and Eis (10 µM) in Tris-HCl 
(50 mM, pH 7.5 adjusted at rt) containing 12% D2O was prepared and allowed to proceed to 
completion as monitored by TLC.  After 24 h, 1H, gCOSY, zTOCSY, and gHSQC NMR 
experiments were performed on the reaction solution, applying PURGE solvent suppression to 
establish the positions of acetylation.  LCMS was used to confirm the structure identification.  
Proton connectivity was assigned using zTOCSY, gCOSY, and gHSQC spectra.  Representative 
spectra for 1,2'-di-acetyl-NEA are provided in Figure A1-10. 
 To establish unambiguously the two acetylated positions on the NEA scaffold, the 
NMR spectra of 1,2'-di-acetyl-NEA were compared to those of a standard of pure NEA [(10 mM 
in Tris-HCl (50 mM, pH 7.5 adjusted at rt) containing 12% D2O], which was prepared identically 
to the reaction mixture, but omitted AcCoA and Eis_Ava (Table A1-3).  Representative spectra 
for the standard reaction solution of NEA in the absence of AcCoA and Eis_Ava are provided in 
Figure A1-9. 
Inhibition of Eis_Ava 
IC50 values were measured by the UV-Vis assay described above. The reactions (200 µL 
total) were initiated in several steps. The inhibitors 1-5 (Figure A1-11) were dissolved in Tris-
HCl (50 mM, pH 8.0 adjusted at rt with 10% DMSO) (100 µL) with a fivefold serial dilution 
with the highest concentration of inhibitor being 250 µM. A second mixture (50 µL) containing 
Eis_Ava or Eis_Msm (2 µM), NEO (400 µM), and Tris-HCl (50 mM, pH 8.0 adjusted at rt) was 
added to the inhibitor solutions and incubated for 10 minutes at rt. Reactions were initiated by 
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the addition of a third mixture (50 µL) containing AcCoA (8 mM), DTNB (8 mM), and Tris-HCl 
(50 mM, pH 8.0 adjusted at rt).  The final concentrations of compound 1 ranged from 250 µM to 
650 pM. The final concentrations of compounds 2-5 ranged from 200 µM to 102 pM.  The assay 
was run in triplicate and the data was normalized to DMSO control reactions.  A Hill plot 
analysis performed by using Kaleidagraph 4.1 software yielded the IC50 values. 
UV-Vis Spectrophotometric Assay Determination of Eis_Ava, Eis_Msm, and Eis_Mtb 
Activity Against KAN and 6'-glycinyl-KAN 
The activity of Eis homologues against KAN and 6'-glycinyl-KAN was tested as 
described for the determination of the AG selectivity profile of Eis_Ava described above. 
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  1b: Unexpected N-acetylation of Capreomycin by Mycobacterial Eis Enzymes6 
1bi: Abstract 
The enhanced intracellular survival (Eis) protein from Mycobacterium tuberculosis 
(Eis_Mtb), a regio-versatile N-acetyltransferase active towards many aminoglycosides (AGs), 
confers resistance to kanamycin A in some cases of extensively drug-resistant tuberculosis 
(XDR-TB).  We assessed the activity of Eis_Mtb and of its homologue from Mycobacterium 
smegmatis (Eis_Msm) against a panel of anti-tuberculosis (TB) drugs and lysine-containing 
compounds.  Both enzymes acetylated capreomycin but not other non-AG non-lysine-containing 
drugs tested.  Using Msm, we also demonstrated for the first time to our knowledge that 
acetylation of capreomycin results in deactivation of the drug.  Eis is a unique acetyltransferase 
capable of inactivating the anti-TB drug capreomycin, AGs and other lysine-containing 
compounds. 
1bii: Introduction 
Causing 1.4 million deaths globally in 2010, tuberculosis (TB) is the second leading 
pathogen-related cause of death, surpassed only by HIV/AIDS.  Although worldwide incidences 
of TB are beginning to modestly decline, occurrences of drug-resistant TB are increasing rapidly.  
Drug resistance to TB occurs when infected patients are treated with an improper regimen of 
antibiotics or when the patients fail to comply with the proper multi-drug regimen, which occurs 
most frequently in areas with sub-standard TB control programmes.  Bacteria that are resistant to 
at least isoniazid and rifampicin, the two most powerful first-line treatments for TB, are 
designated as multidrug-resistant TB (MDR-TB).  Strains of Mycobacterium tuberculosis (Mtb) 
are classified as extensively drug-resistant (XDR) if they are shown to be resistant to rifampicin 
and isoniazid, to one of the fluoroquinolones and to at least one of the second-line anti-TB drugs 
such as kanamycin A, amikacin or capreomycin.  The cure rates for MDR- and XDR-TB are 
~50% and ~30%, respectively. 
In one-third of kanamycin A-resistant Mtb clinical isolates from a large and diverse set, 
the resistance to kanamycin A was shown to be a result of up-regulation of the enhanced 
intracellular survival (eis) gene due to mutations in its promoter.1, 2  The Eis protein is a unique 
                                                
6 Portions of this appendix are from published work: Houghton, J.L.; Green, K.D.; Pricer, R.E.; Mayhoub, A.S.; Garneau-Tsodikova, S. 
Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes.  J. Antimicrob. Chemother. 2013, 68, 800-805 and have been edited to 
reflect my contributions which included purifying protein used in the study and setting up enzymatic reactions for the testing of various drugs. 
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aminoglycoside (AG) acetyltransferase (AAC)2  that inactivates AGs by unusual regio-versatile  
acetylation  of  AGs at multiple amine positions.3  Specifically, kanamycin A and amikacin, 
which are both multi-acetylated by Eis,3-6 are two important second-line anti-TB drugs. The 
structural and functional characterization of Eis from Mtb (Eis_Mtb) has been the focus of 
several recent studies.2, 3, 5, 7-12  Eis homologues can be found in mycobacteria as well as in 
several non-mycobacterial prokaryotes.  We have shown that Eis homologues from 
Mycobacterium smegmatis (Eis_Msm) and Anabaena variabilis (Eis_Ava) also act as a regio-
versatile AG acetyltransferase (AAC) and that they can be inhibited by Eis_Mtb inhibitors.4, 6  
Additionally, it was recently reported that Eis_Msm and Eis_Mtb are also capable of acetylating 
lysine residues of dual-protein phosphatase 16/mitogen-activated protein kinase phosphatase-7 
(DUSP16/MPK-7).5 
The broad specificity of Eis towards a large number of AGs, its acetylation function 
towards some proteins and previous reports of acetylation by other AACs of drugs other than 
AGs, including the second-line anti-TB drug ciprofloxacin,13 prompted us to ask whether Eis is 
capable of conferring resistance to other non-AG anti-TB drugs. As Eis was shown to acetylate 
protein lysine residues,5 in this study, we sought to explore the potential of Eis to acetylate 
capreomycin, a cyclic peptide antibiotic with a β-lysine side chain (commercially Available as a 
mixture of capreomycin IA and capreomycin IB; particularly effective against Mtb and used as a 
second-line anti-TB drug.  We demonstrated that Eis_Mtb and Eis_Msm are both capable of 
acetylating capreomycin IA and capreomycin IB.  The position of acetylation on capreomycin 
was confirmed as the ɛ-amine of the β-lysine 
side chain using Eis_Mtb.   
1biii: Results and Discussion 
Exploration of Non-AG Anti-TB Drugs as 
Potential Substrates of Eis7 
In addition to capreomycin, we chose 
other first- and second-line non-AG anti-TB 
drugs as candidate Eis acetylation substrates, as 
follows.  Previous studies have shown that 
                                                
7 My contributions to this work included testing CAP for acetylation with Eis_Mtb and Eis_Msm using the Ellman 
method described and aiding in making Figure A1: 14. 
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Figure A1-13 Structures of non-AG anti-TB drugs 
tested against Eis proteins. 
CAP = capreomycin; IN  = isoniazid; PZA = 
pyrazinamide; CIP = ciprofloxacin.  The amine 
functionalities of CAP, CIP, and INH that could 
potentially be acetylated by Eis are highlighted in 
bold red.  The amide functionality of PZA in blue is 
unlikely to be acetylated due to a lack of 
nucleophilicity 
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isoniazid (Figure A1-13) becomes acetylated by arylamine N-acetyltransferase 2 on the 
hydrazide functional group, demonstrating its potential for deactivation via acetylation.14  
Pyrazinamide (Figure A1-13) was chosen for its structural similarity to isoniazid, allowing 
comparison of isoniazid with a similar drug that is not likely to be acetylated.  Ciprofloxacin was 
selected because its acetylation by another resistance-conferring AAC was previously reported.13 
We first tested acetylation of capreomycin, ciprofloxacin, isoniazid and pyrazinamide by 
Eis proteins from Mtb and Msm by using a UV-Vis spectrophotometric assay.  We found that 
Eis_Mtb and Eis_Msm did not acetylate ciprofloxacin, isoniazid and pyrazinamide to any 
observable levels.  For pyrazinamide, this result is not surprising, given the lack of nucleophilic 
amines likely to undergo acetylation.  In contrast, we observed efficient acetylation of 
capreomycin by both Eis_Mtb and Eis_Msm (Figure A1-14A and C).  Even though Eis can 
acetylate AGs at multiple positions, we confirmed, by TLC (Figure A1-14B) and LCMS (Figure 
A1-14D), that both capreomycin IA and capreomycin IB were converted to mono-acetylated 
products.  Steady-state kinetic experiments (Figure A1-14E) yielded the following values of 
Michaelis–Menten parameters for capreomycin acetylation by Eis_Mtb: Km = 654 ± 45 µM and 
kcat = 1.25 ± 0.03 s−1.  Both Km and kcat values are slightly greater than the respective values for 
AG acetylation by Eis_Mtb or Eis_Msm.3-5  The catalytic efficiency (kcat/Km) of 1911 ± 139 M−1 
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Figure A1-14 6′-N-Acetylation of Capreomycin (CAP) by Eis. 
(a) Scheme showing the conversion of CAP IA and CAP IB into 6′-N-acetyl-CAP IA (Ac-CAP IA) and 6′-N-acetyl-CAP IB (Ac-
CAP IB), respectively, by Eis_Mtb.  (b) TLC showing the Ac-CAP IA and Ac-CAP IB products (left-hand lane) generated by 
Eis_Mtb using CAP (mixture of CAP IA and CAP IB) (right-hand lane) with 2.5 eq of AcCoA.  (c) Spectrophotometric assay plot 
monitoring the conversion of CAP into Ac-CAP by Eis_Mtb (black circles) and Eis_Msm (grey circles).  (d) Mass spectrum of Ac-
CAP (a mixture of Ac-CAP IA and Ac-CAP IB).  (e) Michaelis–Menten analysis of the Eis_Mtb-catalyzed N-acetylation of CAP. 
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s−1 is equivalent to or better than that for many of the AGs previously tested,3, 4 suggesting that a 
somewhat lower affinity of Eis for capreomycin than for AGs is over-compensated by the more 
efficient acetyl transfer onto capreomycin or a quicker product release. 
1biv: Conclusion 
We have assessed the potential of Eis proteins from Mtb and Msm to acetylate various 
first- and second-line non-AG anti-TB drugs, finding that capreomycin is the only non-AG anti-
drug tested to date that can be modified by either protein.  These observations expand upon our 
understanding of Eis proteins as acetyltransferases, specifically in terms of their ability to modify 
a broad range of small molecules as well as proteins; all known acetylations occur at a primary 
amine. It was also shown that acetylation of capreomycin inactivates the drug against Msm and 
supports the potential role of acetylation in resistance to capreomycin.  
1bv: Experimental 
The acetylation of the non-AG anti-TB drugs isoniazid, pyrazinamide, ciprofloxacin and 
capreomycin was explored using the previously described Ellman method,4, 7 monitoring the 
reaction of coenzyme A (CoA) released by the Eis enzymes with Ellman's reagent (DTNB).  
Briefly, Eis (from Mtb or Msm, 0.5 µM) was added to a mixture containing Tris (50 mM, pH 8.0, 
adjusted at room temperature), AcCoA (500 µM), anti-TB drug or lysine-containing compound 
(100 µM) and DTNB (2 mM) to initiate reactions (200 µL total volume). The reaction progress at 
25°C was monitored at 412 nm (ɛ412 = 14 150 M−1 cm−1) by taking measurements every 30 
seconds for 1 hour (Figure 1c and Figure 2a and b). 
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1c: Comparative Study of Eis-like Enzymes from Pathogenic and Nonpathogenic 
Bacteria.8 
1ci: Abstract 
Antibiotic resistance is a growing problem worldwide.  Of particular importance is the 
resistance of Mycobacterium tuberculosis (Mtb) to currently Available antibiotics used in the 
treatment of infected patients.  Up-regulation of an aminoglycoside (AG) acetyltransferase, the 
enhanced intracellular survival (Eis) protein of Mtb (Eis_Mtb), is responsible for resistance to the 
second-line injectable drug kanamycin A in a number of Mtb clinical isolates.  This 
acetyltransferase is known to modify AGs, not at a single position, as usual for this type of 
enzyme, but at multiple amine sites.  We identified, using in silico techniques, 22 homologues 
from a wide variety of bacteria, that we then cloned, 
purified, and biochemically studied.  From the selected Eis 
homologues, 7 showed the ability to modify AGs to various 
degrees and displayed both similarities and differences 
when compared to Eis_Mtb.  In addition, an inhibitor 
proved to be active against all homologues tested.  Our 
findings show that this family of acetyltransferase enzymes 
exists in both mycobacteria and non-mycobacteria and in 
both pathogenic and nonpathogenic species.  The bacterial 
strains described herein should be monitored for rising 
resistance rates to AGs. 
1cii: Introduction 
Resistance to aminoglycosides (AGs, Figure A1-15) 
has been a growing problem with numerous species of 
bacteria, driving the development of novel antibiotics and 
research into the causes of resistance.  Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species, all together known as the “ESKAPE” 
                                                
8 Portions of this appendix come from Green, K.D.; Pricer, R.E.; Stewart, M.N.; Garneau-Tsodikova, S.  Comparative Study of Eis-like Enzymes 
from Pathogenic and Nonpathogenic Bacteria.  ACS Infect. Dis. 2015, 1 (6), 272-283.  I contributed to the cloning, purification, and 
testing/analysis of various enzymes presented in this work.   
Figure A1-15 Chemical Structures of 
Drugs Used in this Study. 
(A) all AGs found to be modified by Eis 
homologues, (B) the polypeptide 
capreomycin (sold as a mixture of CAP 
IA and CAP IB), and (C) an Eis_Mtb 
inhibitor, chlorhexidine. 
103 
 
pathogens, have been particularly difficult to treat.8  The most common mode of resistance to 
AGs is their inactivation by AG-modifying enzymes (AMEs), such as the AG acetyltransferases 
(AACs), AG phosphotransferases (APHs), and AG nucleotidyltransferases (ANTs). AACs, 
comprising the majority of these AMEs, are known for their monoacetylating specificities 
toward the 2′-, 3-, or 6′-positions of a variety of AGs.  More recently, a unique AAC, the 
enhanced intracellular survival (Eis) protein of Mycobacterium tuberculosis (Mtb), was found 
capable of multiacetylating AGs.2  It was originally shown that it is the up-regulation of the eis 
gene that is responsible for resistance to kanamycin A (KAN) in a large number of clinical 
isolates,11 and since then, numerous additional papers on mutation in the eis promoter have been 
published.12-14 
We have shown that multiacetylation by Eis completely inactivates AGs.15, 16  We have 
also performed studies monitoring the effect that different modifications have on a second 
modification and its catalyzing enzyme.16  We found that Eis from Mtb (Eis_Mtb) is capable of 
multiacetylating AGs,2 and we observed a similar multiacetylating behavior when studying Eis 
from Mycobacterium smegmatis (Eis_Msm1),9 Eis from Anabaena variabilis (Eis_Ava),1 and the 
Eis homologue from Bacillus anthracis (Eis_Ban).5  AACs are known to be cosubstrate 
promiscuous,15 although we have shown that Eis_Mtb has a much more limited cosubstrate 
tolerance.4  In addition, we have studied the metabolically possible competition between acetyl-
CoA (AcCoA) and n-propionyl-CoA (ProCoA) and the effects it has on multiacetylation of AGs. 
Although the cellular role of Eis is still unclear, there have been several proposed 
functions and substrates for this enzyme.  Eis_Mtb has been found in the sera of infected 
patients, suggesting it may play a role in the persistence of bacterial infection.17  The eis protein 
product that is secreted from the organism has been proposed to modulate the host inflammatory 
response.18  Additionally, T-cells treated with Eis_Mtb have an inhibited ERK1/2, JAK pathway, 
which subsequently produces TNF-α and IL-4, thus disrupting the cross-regulation of T-cells.19  
This effect of aiding the survival of the Mtb bacteria in macrophages is thought to be associated 
with Eis_Mtb’s extreme stability under harsh conditions.20  Suh and co-workers have shown that 
this modulation of the host immune system may happen through the acetylation of 
DUSP16/MKP-7 by Eis_Mtb3 and have performed docking studies that corroborate this 
hypothesis.21 
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In an effort to better understand Eis’s role 
in bacteria and attempt to understand the 
evolution that occurred with this gene in Mtb to 
modify AGs along with its other substrates, we 
looked to other bacterial species containing Eis 
homologues.  Through a rigorous in silico search, 
we found Eis homologues in a variety of 
mycobacteria and non-mycobacteria (Figure 2).  
Herein, we examine several properties of these 
enzymes and compare them to Eis_Mtb.  We 
present in silico results for bacterial species 
containing Eis homologues.  We cloned and 
purified 18 new Eis homologues.  We tested these 
proteins against a small group of antibacterial 
compounds checking for any acetylation activity.  
For each AG-active enzyme, we determined the 
kinetic parameters for a representative of each 
structural class of AG, kanamycin (KAN) for 4,6-
disubstituted deoxystreptamine (DOS) and PAR 
for 4,5-disubstituted DOS.  For combinations 
producing a positive UV–vis test, we determined 
the degrees of acetylation and n-propionylation.  
We also explored the cosubstrate tolerance of AG-
active enzymes and examined the competition of 
AcCoA and ProCoA binding in the GNAT 
domain.  In an effort to identify broad or specific 
inhibitors of these enzymes, a compound known 
to inhibit Eis_Mtb6 was tested against the AG-
active homologues. 
 
 
Figure A1-16 Phylogenetic Tree Analysis of the 22 
Eis Homologues Studied Based on Sequence. 
The numbers are proportional to the distance of the 
evolutionary branches of the tree.  The abbreviated names of 
the tree correspond to the following species and gene: 
Anabaena variabilis ATCC 29413 (Ava); Bacillus anthracis 
34F2 Sterne strain (Ban); Gordonia bronchialis ATCC 
25592 (Gbr); Kocuria rhizophila ATCC 9341 (Krh); 
Mycobacterium abscessus ATCC 19977 genes MAB4124 
(Mab1) and MAB4532c (Mab2); Mycobacterium avium 
subsp. avium ATCC 25291 genes MaviaA2_07418 (Mav1), 
MaviaA2_15865 (Mav2), and MaviaA2_00691 (Mav3); 
Mycobacterium hassiacum DSM 44199 (Mha); 
Mycobacterium intracellulare ATCC 13950 genes 
MintA_24600 (Min1), MintA_21739 (Min2), and 
OCU_01560 (Min3); Mycobacterium kansassii ATCC 
12478 genes Mkan A1_16037 (Mka1) and Mkan A1_05800 
(Mka2); Mycobacterium parascrofulaceum ATCC BAA-
614 genes ZP_06852004 (Mpa1), ZP_06848356 (Mpa2), 
and ZP_06849426 (Mpa3); Mycobacterium smegmatis 
MC2 155 genes MSMEG_3513 (Msm1) and 
MSMEG_4540 (Msm2); Mycobacterium tuberculosis 
H37Rv (Mtb); Tsukamurella paurometabola ATCC 8368 
(Tpa).  Active enzymes are indicated with an asterisk.  The 
percent identity of each homologue compared to that of 
Eis_Mtb is presented in the Table A1-5. 
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1ciii: Results and Discussion 
In Silico Analysis of Potential Eis Homologues 
A 
BLAST 
search 
against 
Eis_Mtb 
revealed a 
myriad of 
Eis 
homologues.  
Eis proteins 
were found 
in the 
genome of 
several 
mycobacteria including Mycobacterium avium subsp. avium ATCC 25291 (Mav), 
Mycobacterium kansasii ATCC 12478 (Mka), Mycobacterium abscessus ATCC 19977 (Mab), 
Mycobacterium hassiacum DSM 44199 (Mha), Mycobacterium intracellulare ATCC 13950 
(Min), and Mycobacterium parascrofulaceum ATCC BAA-614 (Mpa).  Because Eis was 
originally found in Mtb22 and later in Msm,9 it is not surprising Eis homologues were found in 
other mycobacteria.  Curiously, some species were found to have two (Mab and Mka) or three 
(Mav, Min, and Mpa) Eis homologues, and upon further examination of the genomic sequence, a 
second Eis-like protein was found in Msm.  Many of the listed mycobacteria are involved in 
atypical mycobacterial infections,23 and Mab has been noted, particularly, as being “a new 
antibiotic nightmare”;24 however, this is likely due to mutations in the rRNA,25 yet drug 
combinations are being investigated for this pathogenic species.26  Mav–Min complex, Mka, and 
M. fortuitum extracts have been analyzed for AMEs, and an unspecified AAC was found to act 
on KAN, tobramycin (TOB), and neomycin B (NEO) in Mka and M. fortuitum.27  Outside the 
mycobacterial genus, three other species were found to harbor Eis homologues in their respective 
Table A1-5 NCBI Nucleotide and Protein Sequence Numbers, Alternate Gene Names, and Identity 
to Eis_Mtb for Eis Homologues. 
Protein NCBI nucleotide sequence # NCBI protein sequence # Alternate gene identifier % Identity to Eis_Mtb 
Eis_Avaa NC_007413.1 YP_325469  18 Eis_Bana NC_005945.1 YP_029001  18 
Eis_Gbra NC_013441.1 YP_003272441  41 
Eis_Krha NC_010617.1 YP_001855041 KRH_11880 34 
Eis_Mab1
b
NC_010397.1 YP_001704851 MAB4124 33 
Eis_Mab2
a
NC_010397.1 YP_001705255 MAB4532c 29 
Eis_Mav1b NZ_ACFI01000055.1 ZP_05216001* MaviaA2_07418 35 
Eis_Mav2b NZ_ACFI01000149.1 ZP_05217647 MaviaA2_15865 33 
Eis_Mav3b NZ_ACFI01000006.1 ZP_05214704* MaviaA2_00691 32 
Eis_Mhab AMRA01000079.1 EKF23162  33 
Eis_Min1b NZ_ABIN01000322.1 ZP_05228133* MintA_24600 36 
Eis_Min2b NZ_ABIN01000280.1 ZP_05227568* MintA_21739 32 
Eis_Min3b NC_016946.1 YP_005335697* OCU_01560 32 
Eis_Mka1b NZ_ACBV01000045.1 ZP_04749484* Mkan A1_16037 74 
Eis_Mka2b NZ_ACBV1000010.1 ZP_04747464* Mkan A1_05800 32 
Eis_Mpa1
b
NZ_GG770554.1 ZP_06852004*  34 
Eis_Mpa2
b
NZ_GG770564.1 ZP_06848356*  34 
Eis_Mpa3
b
NZ_GG770553.1 ZP_06849426*  34 
Eis_Msm
1a
NC_008596.1 YP_887817 MSMEG_3513 53 
Eis_Msm2
b
NC_008596.1 YP_888812 MSMEG_4540 34 
Eis_Mtba AF144099.1 AAF03768.1  100 
Eis_Tpaa NC_014158.1 YP_003645809  40 
   a  Indicates Eis homologues found to be active in acetylating AGs in this work. 
   b Indicates Eis homologues found to be inactive in acetylating AGs in this work. 
  * These proteins (all of which we found to be inactive) were recently marked as obsolete in NCBI 
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genomes: Gordonia bronchialis ATCC 25592 (Gbr), Kocuria rhizophila ATCC 9341 (Krh), and 
Tsukamurella paurometabola ATCC 8368 (Tpa).  As the name suggests, Gbr is a bacterium that 
often affects the lungs; the sample used here was originally isolated from the sputum of a patient 
with cavitary pulmonary disease. Tpa was originally isolated from the microflora of a bedbug,28 
and Krh is a soil microorganism,29 but is now appearing more often in the clinic.30, 31  A 
phylogenetic tree (Figure A1-16) of these proteins was constructed, revealing that these enzymes 
break into two major groups and three outliers (Eis_Ava, Eis_Ban, and Eis_Mab2).  One of the 
groups consists of strictly proteins from mycobacteria that align well (35% exact amino acid 
Figure A1-17 Alignment of All Eis Homologue Protein Sequences Found to be Active in Acetylating AGs. 
Alignment of Eis_Mtb and its closest homologue in amino acid sequence tested, Eis_Mka1.  Turquoise boxes indicate areas of 
difference for the Mka1 homologue, which are hypothesized to be important in protein–protein interactions of the Eis monomers.  
For both alignments, the catalytic tyrosine (Y) residue is indicated with a purple circle, AG-binding site residues are indicated with 
orange circles, and AcCoA-binding site residues are indicated with green circles.  All of the residues marked with colored circles 
were originally identified by site-directed mutagenesis of the Eis_Mtb enzyme.2 White letters with blue background indicate amino 
acids completely conserved throughout the sequences, whereas red residues indicate amino acids highly conserved throughout the 
sequences. 
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match) with each other and include Eis_Mab1, Eis_Mav3, Eis_Mha, Eis_Min2, Eis_Min3, 
Eis_Mka2, Eis_Msm2, and Eis_Mpa3.  The second group contains all of the remaining Eis 
homologues that align poorly (7% exact amino acid match).  Taking a closer look at their amino 
acid sequences, we found most homologues to have the AcCoA binding residues and the 
catalytic residues in the appropriate position.  However, the residues proposed to bind the AG are 
found to a lesser extent in the homologous enzymes.   
AG Activity of Eis Enzymes 
All Eis homologues were tested against a small library of antibiotic compounds including 
amikacin (AMK), chloramphenicol (CAM), capreomycin (CAP), ciprofloxacin, hygromycin 
(HYG), KAN, neamine (NEA), NEO, netilmicin (NET), norfloxacin, paromomycin (PAR), 
ribostamycin (RIB), sisomicin (SIS), spectinomycin (SPT), and streptomycin (STR) to establish 
the substrate profile of these enzymes (Table A1-6).  CAM was included in our study because 
there are known CAM-modifying enzymes;32 CAP was included because of the recent discovery 
that Eis_Mtb can modify this cyclic peptide;33 and the fluoroquinolones were included as an 
AAC mutant was found to acetylate these drugs.34  Enzymes purified from Mav, Mka, Min, and 
Mpa, along with one enzyme from Mab (Eis_Mab1) and the new Msm enzyme (Eis_Msm2), 
were all found to be AG inactive.  These enzymes also all proved to be less soluble than the AG 
active homologues, with Eis_Mka2 being completely insoluble and remaining in the pelleted cell 
debris under the conditions used to purify Eis_Mtb.  Eis_Mha had excellent expression and 
solubility, but was also AG inactive under conditions identical to those used in acetylating assays 
with Eis_Mtb.  Eis_Gbr, Eis_Krh, Eis_Mab2, and Eis_Tpa all showed various degrees of activity 
with the AGs tested (AMK, HYG, KAN, NEA, NEO, NET, PAR, RIB, and SIS) with the 
exception of Eis_Mab2, which proved to be inactive when tested with AMK.  Although the 
explanation of inactivity of Eis_Mab2 toward AMK would be highly speculative without a 
crystal structure, the 14 Eis homologues showing complete AG inactivity can be analyzed on the 
basis of their amino acid sequence. Eis_Mab1, Eis_Mav3, Eis_Mha, Eis_Min2, Eis_Min3, 
Eis_Mka2, Eis_Msm2, and Eis_Mpa3 all find themselves in one main branch of the phylogenetic 
tree (Figure A1-16).  It is highly possible that they have some other unknown biological purpose 
that differs from that of Eis_Mtb.  One residue that is found to differ from Eis_Mtb in all of these 
AG-inactive Eis homologues is F24 (Eis_Mtb numbering used throughout).  In the majority of 
these homologues, an arginine residue is found in place of F24.  This arginine would repel AGs 
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under 
physiological 
conditions.  The 
remaining 
inactive 
enzymes are in 
the second 
branch of the 
phylogenetic 
tree and include 
the AG-active 
homologues 
Eis_Mtb, 
Eis_Msm1, 
Eis_Gbr, 
Eis_Krh, and 
Eis_Tpa.  
Whereas the 
homologues 
from the first 
branch were missing an important AG binding residue, Eis_Mav1, Eis_Mav2, Eis_Min1, 
Eis_Mpa1, and Eis_Mpa2 are all missing one residue for AcCoA binding, R128, which is 
replaced by either glycine or isoleucine.  This lack of charge at this position may not allow 
AcCoA to bind with affinity similar to that with Eis_Mtb.  Most surprising is the AG inactivity 
of Eis_Mka1, which has 74% homology to Eis_Mtb.  The only explanation we can propose from 
the sequence alignment is that Eis_Mka1 is 26 amino acids shorter and is missing amino acid 
sequences from G52 to S55, from L158 to S161, and from H312 to V314.  Upon examination of 
the Eis_Mtb crystal structure (PDB ID 3R1K)2 these residues form three sites for protein–protein 
interaction, possibly responsible for oligomerization (Figure A1-17B) as each missing sequence 
is in an area where protein–protein interactions are likely to be.  This might indicate that 
Eis_Mka does not form hexamers.  It has been shown that the Eis_Mtb hexameric form is 
Table A1-6 Comparison of Number of Modifications for Reactions of Eis Homologues with 
AGs and AcCoA or ProCoA 
AcCoA. 
AG Eis_Avab Eis_Banc Eis_Gbr Eis_Krb Eis_Mab Eis_Msm1b,d Eis_Mtbb,c,d,e Eis_Tpa 
AMK Tri Di Di Di X Tri Tri Tri 
HYG X Di Mono Mono Mono Mono Di Di 
KAN Mono Di Mono Di Di Di Di Di 
NEA Tri Tri Tri Tri Tri Tri Tri Tri 
NEO Tri Tri Tri Tetra Tetra Tri Tri Tetra 
NET Mono Mono Mono Di Di Di Di Di 
PAR Tri Tri Tri Tri Tri Tri Di Tri 
RIB Tri Tri Di Di Di Tri Tri Di 
SIS Di Di Tri Tri Di Tri Tri Di 
 
ProCoA 
AG Eis_Avab Eis_Banc Eis_Gbr Eis_Krb Eis_Mab Eis_Msm1b,d Eis_Mtbb,c,d,e Eis_Tpa 
AMK Mono Di Di MOno X Di Di Di 
HYG X Di Mono Mono Mono Mono Mono Mono 
KAN Mono Mono Mono Mono Di Di Di Di 
NEA Di Tri Di Di Tri Di Di Tri 
NEO Di Tri Tri Di Di Tri Tri Di 
NET Mono Mono Mono Mono Di Mono Mono Di 
PAR Di Di Di Di Tri Di Mono Tri 
RIB Di Tri Di Di Di Di Di Di 
SIS Di Di Di Di Di Mono Mono Di 
X indicates that the AG is not a substrate for the enzyme tested. 
bData from 1 
c Data from 5 
d Data from 9, 10 
e Data from 4 
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required for activity.20  It is known that the Eis_Mtb hexamer is extremely resilient to a variety of 
conditions,20 and based on what we can hypothesize from the Eis_Mka1 data, this area could be 
heavily involved in activity, despite its remote location in relationship to the enzyme active site.  
Crystal structures of all enzymes would allow for a better understanding of inactivity. 
There are structures Available for three Eis_Mtb homologues, Eis_Ava, Eis_Ban, and 
Eis_Msm1, which have been previously published with a comparative structural analysis.1, 2, 5, 9, 
10, 35  Shown in Figure A1-18 are the four currently known crystal structures of Eis_Mtb and its 
three crystallized homologues.  The cartoon overlay of the four crystal structures (Figure A1-
18A) shows only minor changes in the backbone of the structure with only one or two 
misaligned α-helices and a few disordered loops.  The differences are significantly more 
apparent when looking at the space-filled models (Figure A1-18B–E), where the AG-binding site 
(left of the AcCoA-binding site in Figure A1-18B,D,E) varies.  The variance in the AG-binding 
site is likely why each enzyme reacts with the same AGs differently.  Recent work has shown 
Figure A1-18 Comparison of Crystal Structures of Eis Homologues. 
(Only one monomer of these hexameric structures is shown for clarity.)  Panel A depicts the overlay of one monomer from each of 
the four structures and shows that there is little variation in the overall structure of this family of enzymes.  Surface cartoons shown in 
panels B–E demonstrate subtle differences in the active sites of the Eis homologues from (B) Mycobacterium tuberculosis (shown in 
brown with CoA as yellow stick), (C) Bacillus anthracis (shown in gray in the absence of CoA), (D) Anabaena variabilis (shown in 
green with CoA as black stick), and (E) Mycobacterium smegmatis (shown in gold with CoA as red stick).  Eis_Mtb (PDB 3R1K, 
1.95 Å),2 Eis_Msm1 (PDB 3SXN, 2.03 Å),3 Eis_Ava (PDB 2OZG, 2.00 Å),1 and Eis_Ban (PDB 3N7Z, 2.75 Å). 
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that the AG TOB can bind to Eis_Mtb in two distinct orientations, placing two amino groups in 
the appropriate configuration for acetylation at the 6′- and 3″-positions.10  This emphasizes the 
fact that the AG-binding site can dramatically affect not only the identity of AGs that can bind to 
the Eis enzymes but also the various orientations that any given AG can adopt in the AG-binding 
pocket. 
Acetylation of the Polypeptide Antibiotic CAP 
We recently showed that in addition to modifying AGs, Eis_Mtb is also capable of 
acetylating the nonribosomal peptide CAP.33  In addition to the panel of AGs (Figure A1-15A), 
we also tested the seven homologues able to 
acetylate AGs for their ability to modify CAP.  Just 
as we observed for the AGs, there were several 
differences within this family of enzymes.  Eis_Krh, 
Eis_Mab, Eis_Msm, Eis_Mtb, and Eis_Tpa all had 
very similar initial rates in the UV–vis assay, when 
CAP was used as the substrate (Figure A1-20). This 
suggests that these enzymes all catalyze the 
modification of CAP similarly.  Eis_Ava and 
Eis_Gbr both showed significantly reduced 
reactions rates when modifying CAP, suggesting that these two homologues bind CAP less 
effectively than the previous five or have a lower catalytic efficiency.  Interestingly, Eis_Ban did 
not react with CAP at all.  These data supplement the AG data showing that the differences 
observed in the crystal structures of Eis proteins (Figure A1-18) can significantly alter the ability 
of said enzymes to modify different amino groups. 
Kinetic Parameters of AG-Active Eis Homologues for KAN and PAR 
Kinetic parameters were determined for Eis_Gbr, Eis_Krh, Eis_Mab2, and Eis_Tpa and 
compared to those previously published for Eis_Ava,1 Eis_Ban,5 Eis_Msm1,9 and Eis_Mtb.2  
Kinetic values are presented in Table A1-7 along with a comparison of the catalytic turnover 
(kcat) and catalytic efficiency (kcat/Km) to Eis_Mtb.  KAN bound with the highest affinity to 
Eis_Tpa, binding 9-fold better than Eis_Mtb.  Meanwhile, PAR displayed 2.5-fold tighter 
binding to Eis_Ban over Eis_Mtb.  KAN reacted at a rate of around 0.7 reaction per second with 
Eis_Gbr, 1.28 times faster than Eis_Mtb, whereas PAR had the quickest turnover time with 
Figure A1-20 UV–Vis Curves Monitoring the 
Acetylation of CAP by Various Eis Homologues. 
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Eis_Tpa at 5.92 reactions per second, ∼44-fold faster than Eis_Mtb.  The most 
efficient combinations were with AGs 
and Eis_Tpa, showing ∼3- and ∼27-fold 
increases in efficiency for KAN and 
PAR when compared to Eis_Mtb, 
respectively.  Additionally, Eis_Krh 
showed poor kinetic parameters for 
KAN and heightened parameters for 
PAR.  This is somewhat surprising 
considering that Eis_Krh is roughly 10-
kDa larger than Eis_Mtb, with two 
extraneous peptide chains throughout the 
amino acid sequence (Figure A1-18A).  
Although an in-depth kinetic study was 
not performed for each enzyme, there 
are no data that indicate that these 
enzymes do not react similarly to 
Eis_Mtb, having a random sequential 
mechanism.36  Whereas Eis_Mtb may have evolved to modify AGs due to selective pressure, it 
seems that the homologues from Gbr and Tpa have a greater affinity for AGs and these species 
should be watched for development of AG resistance. 
Number of Acetylations 
To investigate the extent to which the AG-active Eis homologues can acetylate AGs, we 
determined the number of sites acetylated by these enzymes on AMK, HYG, KAN, NEA, NEO, 
NET, PAR, RIB, and SIS (Table A1-6).  All Eis homologues were found to acetylate NEA three 
times.  HYG, KAN, and NET all showed mono- or diacetylation by the enzymes, whereas AMK, 
PAR, RIB, and SIS were observed to be either di- or triacetylated.  Interestingly, NEO was 
acetylated between two and four times.  This tetra modification was observed previously only for 
Eis_Mtb and Eis_Msm1 with TOB.  Only Eis_Krh, Eis_Mab, and Eis_Tpa were found to tetra-
acetylate NEO.  This suggests that the binding pockets or at least the AG-binding portion of 
Figure A1-19 Michaelis-Menten Kinetic Plots for All Enzyme-
AG Combinations Not Previously Published.   
KAN and PAR were used as representatives of the two major structural 
classes of AGs. 
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these enzymes are more 
flexible in their substrate 
binding.  Eis_Gbr showed 
the lowest number of 
acetylations, in total 
having monoacetylated 
three of the AGs tested 
(HYG, KAN, and NET), 
suggesting a more limited 
enzyme–AG interaction.  
The only other 
mycobacterial enzyme, 
Eis_Mab, showed similar 
patterns of acetylation to 
those of Eis_Mtb and 
Eis_Msm1, but was more 
limited in its substrate 
profile, not accepting 
AMK and only 
diacetylating RIB. 
Cosubstrate Tolerance of Eis Enzymes 
The AG-active Eis homologues were tested with a variety of acyl-CoAs to establish their 
cosubstrate promiscuity (Table A1-8). As we have previously shown, Eis_Mtb had a very limited 
cosubstrate tolerance, transferring acyl groups from AcCoA, ProCoA, crotonyl-CoA, and 
malonyl-CoA only.4  In addition to the four acyl-CoAs used by Eis_Mtb, n-butyryl-CoA, n-
hexanoyl-CoA, octanoyl-CoA, decanoyl-CoA, lauroyl-CoA, myristoyl-CoA, palmitoyl-CoA, and 
i-valeryl-CoA were tested as potential cosubstrates.  All enzymes could only transfer acyl groups 
from AcCoA and ProCoA, and Eis_Krh could utilize malonyl-CoA to a lesser extent.  These data 
confirm that despite the poor sequence alignment, the CoA-binding pocket of the Eis 
homologues studied is very likely similar to that of Eis_Mtb. 
Table A1-7 Kinetic Parameters Determined for Eis Homologues by Using 
AcCoA with Different AGs. 
Eis 
homologue AG Km (µM) kcat (s–1) 
kcat/Km 
(M–1 s–1) 
kcatXxx/ 
kcatMtb 
kcat/KmXxx/ 
kcat/KmMtb 
Eis_Avaa KAN 1002 ± 43 0.205 ± 0.004 205 ± 9 0.39 0.13 
  PAR 237 ± 36 0.183 ± 0.013 773 ± 132 1.35 0.48 
  
Eis_Banb KAN 57 ± 9 0.135 ± 0.008 2368 ± 399 0.26 1.49 
  PAR 44 ± 11 0.019 ± 0.001 432 ± 110 0.14 0.35 
  
Eis_Gbr KAN 1020 ± 350 0.672 ± 0.036 659 ± 229 1.28 0.41 
  PAR 763 ± 150 2.05 ± 0.18 2687 ± 579 15.07 2.17 
  
Eis_Krh KAN 268 ± 47 0.042 ± 0.002 157 ± 28 0.08 0.1 
  PAR 435 ± 52 1.68 ± 0.07 3862 ± 406 12.35 3.12 
  
Eis_Mab2 KAN 125 ± 27 0.124 ± 0.007 992 ± 377 0.24 0.62 
  PAR 144 ± 14 2.83 ± 0.07 19653 ± 1972 20.8 15.9 
  
Eis_Msm1a,c KAN 665 ± 42 0.360 ± 0.010 541 ± 37 0.68 0.34 
  PAR 738 ± 158 0.235 ± 0.033 318 ± 82 1.73 0.26 
  
Eis_Mtba,c KAN 330 ± 40 0.526 ± 0.027 1594 ± 250 1 1 
  PAR 110 ± 21 0.136 ± 0.012 1236 ± 260 1 1 
  
Eis_Tpa KAN 35 ± 8 0.163 ± 0.007 4657 ± 1083 0.31 2.92 
  PAR 180 ± 10 5.92 ± 0.09 32889 ± 1894 43.53 26.6 
a Data from 1 
b Data from 5 
c Data from 7 
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Degree of n-Propionylation 
The number of n-propionylations each enzyme catalyzes with the different AGs was also 
analyzed to glean more insight into the size of the catalytic pocket.  ProCoA, being slightly 
larger than AcCoA, is not likely to be used as efficiently or result in as many modifications.  As 
expected, all n-propionylations were of equal number or less than the number of acetylations 
observed for the Eis homologue–AG combinations tested.  n-Propionylation was equal to 
acetylation for Eis_Mab2 in all cases, for seven of nine combinations using Eis_Ban (all except 
KAN and PAR) and Eis_Gbr (all except NEA and PAR), six combinations for Eis_Tpa (all 
except AMK, KAN, and NEO), four cases for Eis_Msm1 (HYG, KAN, NEO, and NET), and two 
combinations for Eis_Ava (NET and SIS) and Eis_Krh (HYG and RIB).  These results were 
equal to or greater than the two cases where n-propionylation and acetylation were equal with 
Eis_Mtb (KAN and NEO).4 
For those combinations that displayed a number of n-propionylations lower than that of 
acetylations, additional experiments were performed to establish if Eis homologues could further 
acetylate these n-propionylated AGs.  Sequential acylation reactions in which the enzymes were 
first allowed to catalyze the n-propionylation of the AG for 24 hours prior to addition of AcCoA 
were performed (Table A1-10). From these sequential experiments, one could expect to see that 
(1) no acetyl moiety can be transferred to an n-propionylated AG, indicating that n-
propionylation prevents further acetylation; (2) the total number of modifications (acetylation 
Table A1-8 Comparison of the Cosubstrate Tolerance for Eis Homologues Using NEO as the Substrate. 
acyl-CoA Eis_Avab Eis_Ban Eis_Gbr Eis_Krh Eis_Mab Eis_Msm1 Eis_Mtbc Eis_Tpa 
Ac √ √ √ √ √ √ √ √ 
Pro √ √ √ √ √ √ √ √ 
n-butanoyl × × × × × × × × 
n-hexanoyl × × × × × × × × 
octanoyl × × × × × × × × 
decanoyl × × × × × × × × 
lauroyl × × × × × × × × 
myristoyl × × × × × × × × 
palmitoyl × × × × × × × × 
crotonyl × × × × × × √ × 
malonyl × × × √ × × √ × 
i-valeryl × × × × × × × × 
× indicates that the acyl-CoA is not a cosubstrate of the Eis enzyme tested 
√ indicated that the acyl-CoA is a cosubstrate of the Eis enzyme tested 
b Data from 1 
c Data from 4, 7 
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and n-propionylation) equals that of acetylations when only AcCoA is used, indicating that the 
AG-binding site is likely sufficiently large to accommodate the n-propionylated AGs in the same 
orientation as their corresponding acetylated versions for additional acetylations; or (3) the total 
number of modifications is less than the number of acetylations observed in the presence of 
AcCoA alone, likely pointing to the fact that the AG-binding pocket is not large enough to 
accommodate the extra bulkiness of the n-propionyl group on modified AGs in specific 
orientations in the cavity.  In most cases, additional acetylation of n-propionylated AGs did 
occur.  The one exception was that of Eis_Ban, for which no additional acetylations were 
observed after n-propionylation with the two AGs tested, KAN and PAR.  Other combinations 
where the n-propionylation stopped any further modifications included Eis_Ava with AMK, 
NEA, and PAR; Eis_Krh with SIS; and finally, Eis_Msm1 with NET, RIB, and SIS.  Eis_Mtb 
showed limitation with propionylated NET, RIB, and SIS.  Although additional acetylations are 
possible, these results demonstrate that the inability of AGs to become modified with ProCoA as 
efficiently as AcCoA may lie in the kinetics of the n-propionyl transfer rather than the bulkiness 
of the extra methyl group of the cosubstrate.  The remaining results are spread between scenarios 
2 and 3.  These data indicate that the loss of modification is due primarily to the binding of the 
modified AG to the enzyme (scenario 3) or that n-propionylation has no effect on acetylation 
(scenario 2). All observed combinations are presented in Table A1-10.  
Cosubstrate Competition of Eis Enzymes 
Due to the abundance of both AcCoA and ProCoA in the cellular environment, a 
competition experiment was performed to gain insight into the kinetic mechanism of the 
enzymes (Table A1-10).  AGs were incubated with Eis homologues and a 1:1 mixture of AcCoA 
and ProCoA and the results analyzed.  From these competition experiments, one could expect to 
observe (1) no n-propionylation only acetylation, (2) no acetylation only n-propionylation, (3) 
mixed n-propionylation and acetylation, or (4) lower levels of acetylation than incubation with 
AcCoA alone, due to a competition with the ProCoA for the CoA-binding site.  There were no 
observed cases that follow the second hypothesized observation, meaning that the presence of 
AcCoA limits the amount of n-propionylation that can occur.  The most common observation 
was scenario 3, where there is a majority of acetylation with some n-propionylation (usually 
mono-), followed closely by scenario 4, where less acetylation is observed, likely due to reaction 
inhibition due to an abundance of CoA-containing molecules.  From all these data arise a few 
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interesting cases including NEO with Eis_Ban, by which under pure reaction, either AcCoA or 
ProCoA, only trimodification was observed.  When AcCoA and ProCoA are combined, the 
maximum modification observed is still trimodification (mono-Ac-di-Pro-NEO); however, only 
diacetyl or dipropionyl-NEO is observed for NEO molecules modified by a single CoA species.  
Another interesting outcome was the reaction of Eis_Ban with PAR; in this reaction we saw 
monoacetyl-dipropionylated PAR.  In the sequential reaction only dipropionylated PAR was 
observed.  These data suggest that acetylation occurred either first or second and n-
propionylation then occurred.  Also of interest is the reaction of Eis_Gbr with NEO, after which 
a whole spectrum of modifications was observed.  Everything from triacetyl-NEO to 
tripropionyl-NEO, including the two possible acetyl-propionyl mixed products, was observed as 
seen in Table A1-10. 
Inhibition of Eis Homologues with Eis_Mtb Inhibitors 
Knowing that the active sites of the Eis homologues are 
similar enough to acetylate a variety of AGs and CAP, but 
different enough to display diverse results, we wondered how 
these similarities and differences would be reflected in the 
inhibition of enzymatic activity.  Chlorhexidine (Figure A1-
15C), an inhibitor of Eis_Mtb,6 was tested against all seven 
AG-modifying Eis homologues (Table A1-9).  Although 
chlorhexidine is used as a topical antibiotic, we used the 
compound here simply to test if the inhibitor would broadly 
inhibit all Eis homologues or be specific to Eis_Mtb or Eis 
from mycobacteria.  Chlorhexidine displayed a wide range of 
activities for the Eis homologues, ranging from low nanomolar 
(Eis_Mtb) to micromolar (Eis_Ava and Eis_Ban).  This is an 
approximate 100-fold range in IC50 value, indicating that this inhibitor targets a broad range of 
Eis homologues.  Generally the trend seems to follow that the less homologous the protein is to 
Eis_Mtb, the higher the IC50 value, implying a less potent inhibitor.  Whereas chlorhexidine 
would be a poor candidate as an antitubercular drug, it does tell us that inhibitors of Eis_Mtb 
may inhibit other homologues, but an increase in the IC50 value could be expected.  
 
Table A1-9 IC50 Values of the 
Known Eis_Mtb Inhibitor 
Chlorhexidine with Eis 
Homologues. 
Eis 
species 
Chlorhexidine 
(µM) 
IC50Xxx/ 
IC50Mtb 
Ava 20 ± 7a 111 
Ban 14 ± 4b 77 
Gbr 4.4 ± 0.6 23 
Krh 17 ± 4 91 
Mab 4.4 ± 0.9 23 
Msm1 1.9 ± 0.4a 10 
Mtb 0.188 ± 0.030c 1 
Tpa 7.4 ± 1.6 40 
a Data from 1 
b Data from 5 
c Data from 6 
116 
 
1civ: Conclusion 
In summary, the consolidation of mass spectral analysis, kinetic, inhibitory, and activity 
data tells us that the Eis homologues share activity, cosubstrate tolerance, and modification 
multiplicity.  We have shown that deletion of 13 residues can render an Eis homologue inactive, 
and an additional 10 kDa can have a limited effect on activity.  Although without structural data 
these hypotheses are speculative, we have learned that Eis homologues can be found in a diverse  
community of bacteria and that they behave similarly to Eis_Mtb.  They also have very distinct 
sequences, kinetic profiles, and inhibition.  Whereas the enzymes do not all come from 
pathogenic bacteria, the similarity of the enzymes encoded in the genomes of these 
nonpathogenic species may be a warning that although currently the species do not pose a threat, 
they may become more aggressive in the future.  
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Table A1-10 Sequential Reactions Using ProCoA Followed by AcCoA and Competition Assays with both AcCoA and 
ProCoA. 
ProCoA → AcCoAb 
AG Eis_Ava Eis_Ban Eis_Gbr Eis_Krh Eis_Mab Eis_Msm1 Eis_Mtbc Eis_Tpa 
AMK mono-Ac ND ND mono-Ac-
mono-Pro 
× mono-Ac-
mono-Pro 
mono-Ac-
di-Pro 
di-Pro 
mono-Pro di-Pro mono-Ac-
di-Pro 
mono-Ac-
di-Pro 
 
 
HYG × ND ND ND ND ND mono-Pro mono-Pro 
mono-Ac-
mono-Pro 
 
KAN ND mono-Pro ND di-Ac ND ND di-Pro ND 
mono-Ac-
mono-Pro 
 
NEA di-Pro ND mono-Pro mono-Ac-
mono-Pro 
ND mono-Ac-
Mono-Pro 
mono-Ac-
di-Pro 
ND 
mono-Ac-
mono-Pro 
di-Pro 
di-Pro di-Ac-
mono-Pro 
di-Ac-
mono-Pro 
mono-Ac-
di-Pro 
mono-Ac-
di-Pro 
 
NEO di-Ac ND ND mono-Ac-
di-Pro 
mono-Ac-
di-Pro 
ND tri-Pro di-Ac-Pro 
mono-Ac-
mono-Pro 
mono-Ac-
di-Pro 
mono-Ac-
di-Pro 
tri-Ac-Pro 
di-Ac-di-
Pro 
 
NET ND ND ND mono-Ac ND mono-Pro mono-Pro ND 
mono-Pro 
di-Ac 
mono-Ac-
mono-Pro 
 
PAR mono-Ac-
mono-Pro 
di-Pro mono-Ac-
di-Pro 
mono-Ac-
di-Pro 
ND mono-Ac-
mono-Pro 
mono-Ac-
mono-Pro 
ND 
di-Pro di-Pro 
di-Ac-
mono-Pro 
mono-Ac-
di-Pro 
 
RIB mono-Pro ND ND ND ND di-Pro di-Pro ND 
di-Ac 
mono-Ac-
mono-Pro 
di-Pro 
mono-Ac-
di-Pro 
 
SIS ND ND ND mono-Pro ND mono-Pro mono-Pro ND 
mono-Ac-
mono-Pro 
di-Pro 
 
× indicates that the reaction was not tested as the AG was found to not be a substrate of the enzyme   
ND indicates that the reaction was not tested as the number of n-propionylations was equal to acetylations 
b reactions with ProCoA were followed by incubation with AcCoA c Data from 4 d AcCoA and ProCoA were incubated with Eis and AG in a 1:1 ratio. 
AcCoA + ProCoAd 
AG Eis_Ava Eis_Ban Eis_Gbr Eis_Krh Eis_Mab Eis_Msm1 Eis_Mtbc Eis_Tpa 
AMK 
mono-Ac 
di-Ac 
mono-Ac mono-Ac 
× di-Ac 
di-Ac 
di-Ac di-Ac mono-
Ac-
mono-Pro 
di-Ac 
tri-Ac mono-Ac-
mono-Pro 
mono-
Ac-
mono-Pro 
 
HYG × 
mono-Ac 
mono-Ac mono-Ac mono-Ac mono-Ac 
mono-Ac mono-Ac 
di-Ac mono-Ac-mono-Pro di-Ac 
 
KAN mono-Ac mono-Ac 
mono-Ac 
di-Ac di-Ac di-Ac di-Ac di-Ac 
mono-Pro 
 
NEA 
mono-Ac di-Ac mono-Ac 
di-Ac 
tri-Ac 
di-Ac 
tri-Ac di-Ac 
mono-Pro tri-Ac 
mono-Pro di-Ac-mono-Pro 
di-Ac-mono-
Pro tri-Ac 
di-Ac di-Ac-mono-Pro 
tri-Ac mono-Ac-di-Pro 
 
NEO 
mono-Ac di-Ac di-Ac di-Ac tri-Ac 
tri-Ac 
tri-Ac mono-Ac 
di-Ac mono-Ac-mono-Pro di-Pro 
mono-
Ac-
mono-Pro 
di-Ac-
mono-Pro 
tri-Pro 
mono-
Pro 
mono-Ac-
mono-Pro 
di-Pro tri-Ac tetra-Ac di-Ac 
mono-Ac-
di-Pro 
di-Ac-
mono-Pro 
tri-Ac-
mono-Pro 
mono-
Ac-
mono-
Pro 
mono-
Ac-di-Pro di-Ac-di-
Pro tri-Ac 
tri-Pro 
 
NET 
mono-Ac mono-Ac mono-Ac 
mono-Ac 
mono-Ac 
mono-Ac 
mono-Ac mono-Ac 
mono-Pro 
mono-Pro mono-Pro 
di-Ac 
di-Ac 
di-Ac 
mono-Ac-
mono-Pro 
mono-Ac-
mono-Pro 
mono-
Ac-
mono-
Pro di-Pro 
 
PAR 
di-Ac di-Ac di-Ac 
di-Ac tri-Ac di-Ac di-Ac 
di-Ac 
tri-Ac mono-Ac-di-Pro 
mono-
Ac-
mono-Pro 
tri-Ac 
 
RIB 
di-Ac mono-Ac mono-Ac 
di-Ac di-Ac 
mono-Ac 
di-Ac di-Ac mono-Ac-
mono-Pro 
mono-Pro mono-Pro 
di-Ac 
di-Ac di-Ac 
 
SIS 
mono-Ac mono-Ac mono-Ac mono-Ac 
di-Ac mono-Pro 
mono-Ac 
di-Ac di-Ac di-Ac 
di-Ac 
di-Ac di-Ac 
mono-Ac- mono-Ac-mono-Pro 
mono-
Ac-
mono-Pro 
mono-Ac-
mono-Pro 
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1cv: Experimental 
Phylogenetic Tree Generation 
The amino acid sequences of 22 Eis homologues were obtained from NCBI through the 
Geneious Pro 4.8.5 program to construct a phylogenetic tree (Figure A1-16).  The parameters 
used were as follows: Jukes–Cantor genetic distance and cost matrix Blosum45.  The Eis 
homologue accession numbers from NCBI were YP_325469 (Ava), YP_029001 (Ban), 
YP_003272441 (Gbr), YP_001855041 (Krh), YP_00170485 (Mab1), YP_001705255 (Mab2), 
ZP_05216001 (Mav1), ZP_05217647 (Mav2), ZP_05214704 (Mav3), EKF23162 (Mha), 
ZP_05228133 (Min1), ZP_05227568 (Min2), YP_005335697 (Min3), ZP_04749484 (Mka1), 
ZP_04747464 (Mka2), ZP_06852004 (Mpa1), ZP_06848356 (Mpa2), ZP_06849426 (Mpa3), 
YP_887817 (Msm1), YP_888812 (Msm2), AAF03768.1 (Mtb), and YP_003645809 (Tpa). The 
percent identity of these homolgues to Eis_Mtb is presented in Table A1-5. 
Materials and Instrumentation 
Chemically competent Escherichia coli (TOP10 and BL21 (DE3)) cells were purchased 
from Invitrogen (Carlsbad, CA, USA).  Genomic DNA (Krh and Tpa) and bacterial strains (Gbr, 
Mab, Mav, Min, Mka, and Mpa) were purchased from American Type Culture Collection 
(ATCC; Manassas, VA, USA).  Genomic DNA for Mha37 was a gift from Dr. Nuno Empadinhas 
(University of Coimbra, Portugal).  The pET28a plasmid used in this study was obtained from 
Novagen (Gibbstown, NJ, USA).  All primers used were obtained from Integrated DNA 
Technologies (Coraville, IA, USA).  All cloning enzymes including restriction enzymes, Phusion 
DNA polymerase, and T4 DNA ligase were purchased from New England Biolabs (Ipswich, 
MA, USA).  Sequencing of generated plasmids was performed at the University of Michigan 
DNA sequencing core.  AMK, CAM, CAP, CIP, KAN, NEO, NOR, RIB, SIS, SPT, STR, 
AcCoA, acyl-CoAs (ProCoA, n-butyryl-CoA, n-hexanoyl-CoA, octanoyl-CoA, decanoyl-CoA, 
lauroyl-CoA, myristoyl-CoA, palmitoyl-CoA, crotonyl-CoA, malonyl-CoA, and i-valeryl-CoA), 
and dithionitrobenzoic acid (DTNB) were purchased from Sigma-Aldrich (Milwaukee, WI, 
USA) and used without further purification.  NEA, NET, and PAR were purchased from AK 
Scientific (Mountain View, CA, USA).  All UV–vis assays and kinetic experiments were 
performed using a multimode SpectraMax M5 plate reader in 96-well plates from Fisher 
Scientific (Pittsburgh, PA, USA).  Liquid chromatography–mass spectrometry (LC-MS) 
chromatograms were obtained on a Shimazdu LC-MS-2019EV equipped with an SPD-20AV 
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UV–vis detector and an LC-20AD liquid chromatograph.  The PDB structures 2OZG (Eis_Ava),1 
3N7Z (Eis_Ban),15 3SXN (Eis_Msm1),35 and 3R1K (Eis_Mtb)2 were visualized using PyMOL 
(The PyMOL Molecular Graphics System, version 1.4.1, Schrödinger, LLC). 
DNA Isolation from Bacteria 
DNA was isolated from the following bacteria: M. abscessus ATCC 19977, M. kansasii 
ATCC 12478, M. parascrofulaceum ATCC BAA-614, M. intracellulare ATCC 13950, M. avium 
ATCC 25291, and G. bronchialis ATCC 25592.  Mycobacteria were grown in 7H9 medium with 
albumin–dextrose–catalase (ADC).  One milliliter of turbid culture was pelleted (13000 rpm, 1 
minutes, room temperature) and resuspended in TE buffer (400 µL).  The bacteria were 
inactivated with heat (30 minutes, 80 °C).  After cooling to room temperature, to avoid clumping 
of the cells, four to five glass beads were added and the cells were briefly vortexed.  Lysozyme 
(30 µL, 50 mg/mL) was added, and the suspension was further incubated for 1 hour at 37 °C.  At 
this point SDS (10 µL, 10%) and proteinase K (10 µL, 20 mg/mL) were added, and the 
suspension was gently vortexed, followed by a brief incubation period (15 minutes, 65 °C).  
NaCl (100 µL, 5 M) and CTAB/NaCl (100 µL, 10% CTAB in 0.7 M NaCl) were added 
sequentially, and the suspension was further incubated (10 minutes, 65 °C).  The mixture was 
extracted with phenol/chloroform/isoamyl alcohol 25:24:1 (3 × 750 µL).  The DNA was 
precipitated using isopropanol (0.6×volume) and incubated (20 minutes, −20 °C).  The DNA was 
collected by centrifugation (12000 rpm, 10 minutes, room temperature), the isopropanol was 
removed, and the DNA pellet was washed with ice-cold ethanol (75%, 1 mL) and centrifuged 
(12000 rpm, 5 minutes, room temperature).  The ethanol was removed and allowed to air-dry (10 
minutes, room temperature).  The DNA was redissolved in TE buffer (100 µL, 30 minutes, 37 
°C).  G. bronchialis was grown in BHI, and DNA was isolated as above. 
Cloning, Expression, and Purification of Eis Proteins 
Eis_Mtb,2 Eis_Msm1,9 Eis_Ban,5 and Eis_Ava1 were cloned and purified as previously 
described.  The remaining Eis proteins were cloned using the isolated DNA and Phusion DNA 
polymerase.  The isolated PCR fragments were inserted into a linearized pET28a vector between 
the NdeI (all genes) and XhoI (Eis_Gbr, Eis_Krh, Eis_Mab1, Eis_Mab2, Eis_Mha, and Eis_Tpa) 
or HindIII (Eis_Mav1, Eis_Mav2, Eis_Mav3, Eis_Min1, Eis_Min2–3, Eis_Mka, Eis_Mpa, and 
Eis_Msm2) restriction sites.  The plasmids containing the eis genes were then transformed into E. 
coli TOP10 chemically competent cells.  Sequencing of the isolated plasmid revealed perfect 
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alignment with the reported gene sequences.  Plasmids were transformed into E. coli BL21 
(DE3) chemically competent cells for protein expression. All new Eis enzymes were purified 
exactly as indicated for Eis_Mtb.2  All proteins were dialyzed in Tris-HCl buffer (50 mM, pH 8.0 
adjusted at room temperature) and stored at 4 °C.  After purification, 2.2 mg (Eis_Gbr), 1.8 mg 
(Eis_Krh), 0.1 mg (Eis_Mab1), 0.4 mg (Eis_Mab2), 3.8 mg (Eis_Mav1), 0.8 mg (Eis_Mav2), 0.5 
mg (Eis_Mav3), 7.0 mg (Eis_Mha), 2.6 mg (Eis_Min1), 1.2 mg (Eis_Min2/3), 1.0 mg 
(Eis_Mka1), 0 mg (Eis_Mka2, insoluble), 0.4 mg (Eis_Mpa1), 0.5 mg (Eis_Mpa2), 0.3 mg 
(Eis_Mpa3), 0.5 mg (Eis_Msm2), and 1.9 mg (Eis_Tpa) of protein were obtained per liter of 
culture.   
Spectrophotometric Measurements of Acyltransferase Activity 
The acyltransferase activity of Eis enzymes was tested against a variety of antibiotics 
using AcCoA, by monitoring the 2-nitro-5-thiobenzoate (NTB–) produced by the reaction of free 
CoA with DTNB.  Reactions were monitored at 412 nm (ε412 nm = 14150 M–1 cm–1) for 1 h, 
taking measurements every 30 seconds at 25 °C.  Reaction mixtures (200 µL) containing 
antibiotic (100 µM), AcCoA (500 µM), DTNB (2 mM), and Tris-HCl buffer (50 mM, pH 8.0 
adjusted at room temperature) were initiated by the addition of Eis enzyme (0.5 µM).  The only 
non-AG to be modified by Eis enzymes was CAP (Figure A1-15B); UV–vis curves for this 
antibiotic are presented in Figure A1-12.  All enzymes displaying activity against AGs were also 
tested for cosubstrate promiscuity (Table A1-8).  Here acyl-CoAs (ProCoA, n-butyryl-CoA, n-
hexanoyl-CoA, octanoyl-CoA, decaonyl-CoA, lauroyl-CoA, myristoyl-CoA, palmitoyl-CoA, 
crotonyl-CoA, malonyl-CoA, and i-valeryl-CoA) (500 µM) were tested against NEO (100 µM), 
the most dynamic AG with all AG-active enzymes. 
Determination of Number of Acetylations and n-Propionylations as well as Sequential and 
Competitive Modifications of AGs by Eis Proteins via LC-MS 
The extent of acetylation for each AG that was found to be active by UV–vis assays 
(Figure A1-15A) was determined by using LC-MS.  Reactions (30 µL) containing AG (AMK, 
HYG, KAN, NEA, NEO, NET, PAR, RIB, and SIS, 0.67 mM), AcCoA (3.35 mM), Eis enzyme 
(5 µM), and Tris-HCl buffer (50 mM, pH 8.0 adjusted at room temperature) were incubated 
overnight at room temperature.  Reactions were quenched by the addition of ice-cold methanol 
(30 µL) and were chilled (−20 °C) for at least 20 minutes.  To remove excess enzyme from the 
solution, the reactions were then centrifuged (13000 rpm, 10 minutes, room temperature) and 
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diluted 1:1 with H2O before loading onto the LC-MS.  Samples were run using H2O (0.1% 
formic acid).  A summary of the level of acetylation is presented in Table A1-6.  The n-
propionylation of AGs (AMK, HYG, KAN, NEA, NEO, NET, PAR, RIB, and SIS) was also 
monitored using the above method substituting ProCoA for AcCoA.  A summary of n-
propionylation is also presented in Table A1-6.  Sequential acylations (n-propionylation followed 
by acetylation) were performed and monitored as above.  After the first overnight incubation 
with ProCoA, AcCoA (3.35 mM) and additional Eis enzyme (5 µM) were added, bringing the 
total volume up to 40 µL, and incubated for an additional 24 h.  A summary of the acylated AG 
species obtained during sequential experiments is presented in Table A1-10.  Competition 
experiments were also performed as above in the simultaneous presence of both AcCoA (3.35 
mM) and ProCoA (3.35 mM).  A summary of the acylated AG species obtained during 
competition experiments is also presented in Table A1-10.  Calculated and observed masses for 
all AGs against all Eis homologue proteins are presented at the end of this section, with each 
table summarizing findings for a specific Eis homologue.  Mass spectra for all experiments for 
Eis_Ava, Eis_Ban, Eis_Gbr, Eis_Krh, Eis_Mab2, Eis_Msm1, and Eis_Tpa are presented in the 
following order: (i) acetylation, (ii) n-propionylation, (iii) sequential n-propionylation followed 
by acetylation, and (iv) competition between n-propionylation and acetylation. 
Determination of Steady-State Kinetic Parameters of Eis Proteins for AGs 
The kinetic parameters (kcat and Km) were determined for acetylation with KAN and PAR 
for all enzymes, in reactions (200 µL) with a fixed AcCoA (0.5 µM) concentration.  For Eis_Krh, 
Eis_Mab2, and Eis_Tpa, concentrations of 0, 20, 50, 100, 250, 500, 1000, and 2000 µM were 
used with both AGs.  With Eis_Gbr the ranges varied, KAN concentrations were 0, 20, 50, 250, 
500, and 1000 µM, and PAR concentrations were 0, 20, 50, 100, 250, 500, 1000, and 2000 µM.  
The reaction cocktail containing DTNB (2 mM), Tris-HCl buffer (50 mM, pH 8.0 adjusted at 
room temperature), AcCoA (0.5 µM), and Eis enzyme (0.25 µM) was initiated by the addition of 
the AGs.  The reactions were monitored at 412 nm by taking readings every 20 seconds for 20 
minutes at 25 °C.  The determination of kinetic parameters was done with a nonlinear regression 
using Sigma-Plot 11.0 software (Systat Software Inc., San Jose, CA, USA) (Table A1-7). 
Inhibition of Eis Enzymes 
IC50 values for chlorhexidine (Figure A1-15C) were determined as previously reported.1, 
6, 9  Briefly, reactions (200 µL) were initiated in a stepwise manner.  Chlorhexidine (100 µL) was 
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dissolved in Tris-HCl buffer (50 mM, pH 8.0, 10% DMSO) and subjected to a 5-fold serial 
dilution.  To the chlorhexidine solution was added a mixture (50 µL) of Tris-HCl buffer (50 mM, 
pH 8.0), Eis enzyme (2 µM), and NEO (400 µM) followed by incubation (10 minutes, room 
temperature).  A third reaction mixture consisting of Tris-HCl buffer (50 µM, pH 8.0), AcCoA (2 
mM), and DTNB (8 mM) was used to initiate the reactions.  The reactions were monitored as 
described for the kinetic analysis.  The determination of IC50 values was done with a Hill plot 
analysis using Kaleidagraph 4.1 software, and the data are summarized in Table A1-9. 
 
1cvi: Additional Data 
Mass results are summarized in a table followed by the mass spectra for each enzyme. 
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Appendix 2: Use of Photocrosslinking Amino Acids for Quantitation of Activated Ras 
Isoforms in Live Cells9 
2a: Abstract 
Applying the knowledge gained from previous studies with difficult PPIs in yeast, 
covalent chemical capture was applied to a high-affinity, well-structured PPI.  Photocrosslinking 
was used to improve upon current methods to isolate activated Ras within cells.  Extensive 
optimization went into the production of protein containing Bpa within E. coli as well as the 
construct used.  We have shown that using photocrosslinking, we can directly visualize activated 
Ras crosslinked adducts on a Western blot.  In addition to this, we have worked on developing a 
liquid chromatography mass spectrometry (LC-MS) method to detect Ras isoforms for future 
work that will apply this method to quantify the amount of activated Ras isoforms. 
2b: Introduction 
The recent development of the methods to efficiently 
genetically incorporate a wider variety of unnatural amino 
acids into a wealth of cell types has finally begun to allow the 
expansion of the technique into other research applications.  
Uses have ranged from photocrosslinking moieties for 
covalent capture, fluorescently tagging proteins, or addition 
of a chemical handle for biorthogonal chemistry in cells.  In 
the Mapp lab, this technique has been applied to the covalent 
capture of transient, lower affinity PPIs.  We decided to 
extend this method to a high affinity, well-characterized PPI.  
Leveraging the ability of the Ras Binding Domain (RBD) to capture activated GTPases, we 
wanted to test the potential for improvement to current methods using photocrosslinkers.  The 
specific PPI chosen for this study was the interaction between a kinase in the MAPK pathway, 
                                                
9 The work presented here was done in partnership with Omari Baruti and mass spectrometry work done by Sarah Haynes of the Martin lab. 
Figure A2-1 Schematic of the MAPK 
Pathway. 
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Raf, and Ras which only occurs once Ras is activated and 
GTP-bound (Figure A2-1).2  Using the Ras-binding 
domain (RBD) of Raf has become a well-established 
probe for isolating activated Ras.  The binding interaction 
is at the low nm level and traditionally has been utilized 
with a GST-Raf-RBD fusion protein.2  By adding an 
unnatural amino acid to covalently capture this 
interaction, we can improve pulldown efficiency for mass 
spectrometry purposes as well as directly visualize the 
percentage of activated Ras via Western blot.   
The biological importance of this PPI is its critical 
involvement in many cancers, as the activation of Ras 
leads to cell proliferation.  One element of this interaction 
that has yet to be fully elucidated is the exact 
participation of the 4 major Ras isoforms, H-, N-, K4a-, 
and K4b.  Many of these isoforms have been shown to be a major contributor in different types 
of cancer (Figure A2-2).  K-Ras has been indicated to contain oncogenic mutations in over 90% 
of pancreatic caners, 45% of colorectal cancers, and 35% of lung cancers.1  N-Ras mutations are 
most notable in melanomas while H-Ras mutations are present in 10% of bladder cancers.1  
Although these percentages are known, it has been difficult to study which isoforms of Ras 
become activated under specific conditions and in what ratios compared to other isoforms.  This 
has proven difficult due to the similarity of the isoforms.  H-, N-, and K4a-
, and K4b-Ras, the main Ras isoforms, share 80% homology except for a 
C-terminal hypervariable region which contains almost all of their 
sequence variance.3  In being able to more successfully pulldown activated 
Ras, we hope to be able to extend this method for the study of different 
cancers in the future. 
2c: Genetic Incorporation of Bpa in E. coli 
Before beginning this project, bacterial expression of UAA 
containing proteins needed to be optimized and established within our 
laboratory.  Previously, only yeast genetic incorporation of UAAs had 
Figure A2-3 Expression 
Test of Raf-RBD 
N64Bpa. 
Bpa was added 
immediately or *at 
induction point. 
Figure A2-2 Percentages of Ras Mutation 
Involvement in Various Cancers.1 
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been successfully done.  To start using bacterial expression, we 
purchased the Methanococcus jannaschii tyrosyl-tRNA synthetase 
and tRNA pair on the pEvol backbone (Addgene #31190).  
However, pEvol has a chloramphenicol resistance marker such that 
using the regular pRARE expression 
aiding-vector was not possible.  We tested 
expression without the codon 
supplementing pRARE but saw no 
expression, leading us to contact the 
Protein Core in the Center for Structural 
Biology (Life Science Institute, 
University of Michigan).  They were able to provide us with a better 
expression strain suited for our use, BL21-AI cells expressing a 
Streptomycin resistance pRARE plasmid.  This not only gave us a non-
interfering codon supplementing plasmid but also tighter control over 
expression by placing the T7 RNA polymerase in the araBAD operon (arabinose induction is 
also required for protein expression).   
Once our strain was established, we had to optimize expression conditions since varying 
methods for how to best incorporate UAAs were present in the literature.  The recommended 
minimal media and auto-induction media were both tested, and yielded little expression.  We 
settled upon the regular rich media Terrific Broth for expression and then moved on to testing the 
amounts of arabinose and IPTG to add for induction.  This optimization resulted in the addition 
of 0.5 mM IPTG with 0.02% arabinose for induction.  Literature protocols were also varied in 
the time of addition of UAA.  In testing addition to media upon immediately inoculation 
compared with addition at the time of induction, we saw best expression with addition to the 
media upon inoculation (Figure A2-3). 
2d: Incorporation of Bpa into the RBD of Raf 
Expression of the c-Raf RBD (amino acids 1-202) has traditionally been done using a 
GST solublization tag.  This was not applicable to genetic incorporation studies, as truncated 
protein is produced as a by-product in the event of unsuccessful non-sense suppression of the 
amber TAG stop codon (Figure A2-4).  In the case of multimeric fusion tags such as GST, it can 
Figure A2-4 Crosslinking of 
GST-Raf RBD to Ras. 
Crosslinking of the original GST 
construct was tested to demonstrate 
that crosslinking at this position 
was possible for future studies. 
Figure A2-5 Small Scale 
Expression of Raf RBD 
Tag Testing. 
Coomassie stained 4-12% 
Bis Tris gel showing 5 mL 
expression test from BL21-
AI E. coli. 
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become difficult to obtain accurate measurements of protein 
concentration due to the presence of truncated and full-length 
oligomeric species.  For this reason, a variety of solublization 
tags (MBP, Mocr, and GB1) were tested for replacement of GST 
(Figure A2-5).   
The final construct used, consisted of the GB1 followed 
by Raf RBD TAG mutants and a His6 tag.  This fusion construct 
was seen to have one of the better expressions, solubility, and 
pulldown efficiency (Figure A2-6).  This optimized construct 
allowed us to have a small solubilizing unit with our protein and 
a C-terminal His tag to permit efficient pulldowns using Ni-NTA 
agarose resin.  With the optimized expression conditions, we 
were able to produce approximately 6 mg/L of both wild-type 
Raf RBD fusion protein and TAG Raf RBD with incorporated 
Bpa.   
2e: Establishment of Ras Standards for Mass Spectrometry Analysis 
To establish the proper standards and test our ability to differentiate between Ras 
isoforms on the LC-MS, the 4 major Ras isoforms were purified, digested, and analyzed by LC-
MS.  A variety of proteases were tested including Glu-C (C-terminal cleAvage at aspartic or 
glutamic acids), Asp-N (N-terminal cleAvage at aspartic acid and cysteine), Trypsin (C-terminal 
cleAvage at lysine and arginine), Chymotrypsin (C-terminal cleAvage at tryptophan, 
phenylalanine, and tyrosine), and α-Lytic (C-terminal cleAvage at alanine, threonine, serine, and 
valine).  The best results were yielded with Asp-N and Trypsin, giving coverage of unique 
peptides for each isoform (Figure A2-4). 
2f: Crosslinking of GB1-Raf RBD V69Bpa to Ras 
Once we established that we could successfully express the Raf RBD with the 
incorporated Bpa, we went on to make two TAG mutations, N64Bpa and V69Bpa.  V69Bpa was 
Figure A2-6 Pulldown Test 
Comparing a Ni-His GB1 Isolation 
to Amylose-MBP Isolation. 
The elution off of the Ni resin for the 
GB1 pulldown has a much stronger 
band than the amylose-MBP pulldown 
using HEK293T lysate as a test for 
pulldown efficiency. 
Figure A2-8 Mass Spectrometry Results for Ras Isoforms Digested with Asp-N and Trypsin. 
Sequence coverage is displayed overtop a sequence scale that highlights unique residues for each isoform.  Mass spectrometry 
methods for detecting and selecting peptides can be found in the experimental section. 
 
144 
 
tested against a panel of various 
lysates overexpressing H-Ras, H-Ras 
G12V (constitutively active), and H-
Ras S17N (inactive).  The results 
were compared to a non-TAG 
mutant and demonstrate the ability to 
“quick detect” activated Ras by 
visualizing the crosslinked adduct 
without a pulldown (Figure A2-7).  
This technique could further be used 
to identify active isoforms by using 
the Ras isoform-specific antibodies 
for probing the Western blot.   
2g: Conclusion 
Using a higher affinity PPI that also has a crystal structure, presented a unique 
opportunity to test the ability of photocrosslinking to improve upon already well-established 
methods.  Probing with the RBD of Raf, we aimed to be able to isolate and crosslink Ras which 
only binds this domain while activated.  Through the work on this project we were able to 
expand the genetic incorporation of photocrosslinkers to bacteria within the lab as well as 
develop a construct for optimal Bpa incorporation, protein expression, and purification in 
bacterial cells.  This allowed us to express and purify the Raf RBD with Bpa incorporated at 
several sites along the Ras binding interface.  Preliminary crosslinking studies demonstrate the 
ability not only to crosslink activated Ras but also to detect activated Ras via Western blot 
without any additional pulldown or enrichment. 
To extend this method further, future experiments will focus on a LC-MS analysis of the 
crosslinked Raf RBD samples.  Work done with purified Ras isoform standards has shown the 
ability to detect and search for unique peptides of each Ras isoform, allowing detection and 
eventually quantitation of individual isoforms by LC-MS.  Although the focus here has been the 
Raf RBD, other GTPases including Rak, Rho, and Ral have RBDs that could be used to isolate 
the activated species.  Understanding the amount of activated GTPase as well as individual 
Figure A2-7 Detection of Activated Ras with Raf RBD V69Bpa. 
For a full comparison, each lysate was compared to wild type Raf RBD, 
uncrosslinked Raf RBD V69Bpa, and crosslinked Raf RBD V69Bpa.  
Lysates tested included HEK293T with no overexpression as a control and 
HEK293T overexpression of H-Ras, H-Ras G12V, and H-Ras S17N.  This 
panel displays how much endogenous Ras is present and able to be 
crosslinked in lysate without any overexpression as well as showing 
constitutively active and inactive controls.  We were able to see crosslinking 
in all lanes except for the inactive H-Ras S17N.  Due to the similar molecular 
weights of the Raf RBD and Ras, protein standards of the wild type and 
V69Bpa were run on the last two lanes to ensure we were detecting proteins.  
145 
 
isoform activation will allow for a clearer picture of cellular signaling along these pathways to 
aid in the eventual goal of small molecule modulation.   
2h: Experimental 
Protein expression was carried out in BL21-AI cells expressing an additional pRareCDF 
vector (Protein Core in the Center for Structural Biology, Life Sciences Institute, University of 
Michigan).  Bpa was purchased from Chem-Impex International (Wood Dale, IL).  All plasmids 
used in this study were constructed using standard molecular biology techniques.  All Ras E. coli 
expression plasmids were a kind gift from the Fierke lab (University of Michigan).  Sanger 
sequencing verifying plasmid sequences was performed by the University of Michigan Core 
Facility (Ann Arbor, MI).  
Construction of plasmids  
pGB1+Raf-RBD-His6  
A high copy plasmid expressing Raf-RBD (residues 2-149 of Raf-1) + His6 was created 
via ligation of the fusion gene into a pGB1(Protein Core in the Center for Structural Biology 
(Life Science Institute, University of Michigan) via LIC.  Primers 5’-TACTTCCAATCCAATG 
CAGAGCACATTCAGGGTGC-3’ and 5’-TTATCCACTTCCAATGTTAGTCGCGATGAATT 
CCC-3’ were used to amplify Raf-RBD from a codon optimized gene fragment purchased from 
IDT.  Once the Raf-RBD was ligated into pGB1, site directed mutagenesis was used to remove 
the His tag from the N-terminus with the primers 5’-CTTTAAGAAGGAGATATACATATGTC 
TTCTGGTGTAGATCTGCAGTAC-3’ and 5’-GTACTGCAGATCTACACCAGAAGACATAT 
GTATATCTCCTTCTTAAAG-3’.  A His tag was then added back onto the C-terminus with the 
primers 5’-CTGGGAATTCATCGCGACCACCATCATCATCATCATTAACATTGGAAGTG 
GGATAACGG-3’ and 5’- CCGTTATCCCACTTCCAATGTTAATGATGATGATGATGGTG 
GTCGCGATGAATTCCCAG-3’ to aid in the pulldown of only full-length protein. 
pGB1+Raf-RBD-His6 TAG Mutants  
To create each plasmid, site-directed mutagenesis was used to replace an existing amino 
acid codon with TAG codon within Raf-RBD. In general, PCR primers were designed to have 
~15 bases of homology on either side of the TAG mutation and mutagenesis reactions were 
carried out using manufacturer recommended conditions (Qiagen). 
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Expression and purification of Bpa containing Raf-RBD 
A 30 mL starter culture of LB with Ampicillin and Streptomycin and Chloramphenicol 
was inoculated and grown overnight at 37˚C.  The starter culture was used to inoculate a 1 L 
Terrific Broth culture containing antibiotic and 1 mM Bpa.  This was grown to an OD600 of 0.8 
and chilled at 22˚C.  Induction was carried out with 0.5 mM IPTG and 0.2% arabinose.   After 
growth overnight, cells were collected by centrifugation for 20 minutes at 6,500 x g and 4˚C. 
The cell pellet was dissolved in 50 mM NaPO4 pH 8, 300 mM NaCl, and 10% glycerol and with 
a Roche cOmplete, EDTA-free protease inhibitor tablet.  Lysis was done by sonication for 4 
minutes with 3 second pulses.  To remove insoluble cell debris, lysate was centrifuged at 12,000 
x g and 4˚C for 30 minutes.  The supernatant was incubated with 1 mL of Ni-NTA agarose resin 
(Qiagen) for 2 hours at 4˚C.  A column was used to wash the resin with 10 mL of lysis buffer 
with 5 mM imidazole.  An imidazole gradient was used to elute protein beginning with 10 mL of 
20 mM imidazole, 3 5mL fractions of 40 mM imidazole, and 3 5 mL fractions of 250 mM 
imidazole for elution.  To remove imidazole, protein as dialyzed into NaPO4 pH 8, 150 mM 
NaCl, and 5% glycerol overnight.   Concentration was done using Amicon Ultra PL-10 (10,000 
MWCO).    
Covalent chemical capture and Pulldown of Crosslinked Adducts. 
Mammalian cells overexpressing Ras or Ras mutants were resuspended in 100 µL of lysis 
buffer (25 mM Tris HCl, 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 5% glycerol).   Cells were 
sonicated at 10% amplitude for 20 seconds.  To the lysate, 100 µg of GB1-Raf-RBD (or GB1-
Raf-RBD TAG mutants) was added and incubate for 20 minutes at 4˚C.  +UV samples were then 
irradiated for 20 minutes on ice at 365 nm while -UV samples were maintained on ice on bench 
for this time.  Half of the samples were removed to run on the gel without a pulldown of any 
kind. 
Pulldown samples were incubated with 40 µL of Dynabeads magnetic Ni beads for 2 
hours at 4˚C.  Dynabeads were pre-washed and equilibrated in 3x1mL of lysis buffer.  Samples 
were then washed with 3 x 100µL lysis buffer + 20 mM imidazole and eluted with 3 x 50µL of 
lysis buffer + 250 mM imidazole with a 5 minute incubation for each wash and elution. 
Western Blots 
Samples were denatured by heating at 95˚C for 10 minutes in Laemmli 2x Buffer 
(BioRad) containing 250 mM DTT and run on a 5-15% Bis-Tris gel (BioRad).  The separated 
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proteins were then transferred to PVDF membrane and probed using Western Blot analysis with 
a 1:1000 dilution of rabbit-anti-His antibody (Abcam) and mouse-anti-Ras (Millipore) in 
Odessey Blocking Buffer (Lycore) followed by a 1:10,000 dilution of donkey-anti-mouse IRDye 
680LT and donkey-anti-rabbit IRDye 800CW.  Imaging was done on an Azure C600. 
Preparation of Ras Isoforms 
Using the pETM11-Ras plasmids generously given by the Fierke Lab, recombinant 
protein was grown in BL21-AI cells and Terrific Broth rich media.  Cells were grown at 37˚C 
until an OD600 of 0.8 was reached.  We induced with 1 mM IPTG and 0.1% arabinose with 
growth overnight at 18˚C.  Cells were harvested via centrifugation for 20 minutes at 6,500 x g 
and 4˚C. 
To lyse cells, the pellet was first dissolved in 10 mM Tris/HCl pH 7.6, 0.1 mM GDP, 20 
mM sodium citrate, 50 mM KCl, and 5 mM MgCl2 and 2 mM β-mercaptoethanol with a Roche 
cOmplete, EDTA-free protease inhibitor tablet.  Lysis was done by passing the dissolved pellet 
through an Avestin EmulsiFlex-C3 high-pressure homogenizer at 10,000-15,000 psi.  
Homogenization was used to aid in the isolation of inclusion bodies by giving a more uniform 
lysis.  Lysate was centrifuged at 12,000 x g and 4˚C for 30 minutes and supernatant was 
incubated with 1 mL of Ni-NTA agarose resin (Qiagen) for 3 hours at 4˚C.  The pellet was 
extracted a second time with 10 mM Tris/HCl pH 7.6, 0.1 mM GDP, 20 mM sodium citrate, 50 
mM KCl, and 5 mM MgCl2 and 2 mM β-mercaptoethanol for 1 hour at 4˚C with shaking and 
then re-centrifuged as before.  Using a column, the resin was washed with 10 mL of lysis buffer 
with 5 mM imidazole.  An imidazole gradient was used to elute protein beginning with 10 mL of 
20 mM imidazole, 3 x 5mL fractions of 40 mM imidazole, and 3 x 5 mL fractions of 250 mM 
imidazole for elution.  To remove imidazole, protein as dialyzed into 50 mM tris-citrate pH 6.5, 
50 mM NaCl, 5 mM MgCl2, 0.01 mM GDP and 10 mM β-mercaptoethanol overnight.   
Concentration was done using Amicon Ultra PL-10 (10,000 MWCO).    
Protease Digestion 
All protease digestions were prepared according to Promega manufacturer instructions.  
Briefly, ~8 µg of protein was incubated at 37˚C for 1 hour with 7.5 M urea.  This was followed 
by 20 minutes at 60˚C with 15 mM DTT and finally, 15 minutes in the dark at room temperature 
with 60 mM iodoacetamide.  This final mixture was then diluted with 100 mM tris buffer pH 8 
and 1 mM CaCl2.  Protease (2 µL ~ 2 µg) was added and digested overnight at 37˚C.  Peptides 
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were desalted with an Oasis 96-well plate (Waters) on a vacuum manifold.  70% acetonitrile was 
used to elute peptides.  After transfer to a vial, a Thermo SAvant Vacuum Concentrator was used 
to remove solvent at 45°C. 
 
LC-MS Ras Isoform Identification 
Protein digests were prepared in 3% acetonitrile with 0.1% formic acid and 10 fmol/µL 
alcohol dehydrogenase (ADH, Waters Corp.) in water.  In triplicate, peptides were separated 
using a one-dimensional Waters nanoAcquity UPLC system fitted with a 5 µm C18 (180 µm x 
20 mm) trap column and a 1.8 µm HSS T3 analytical column (75 µm x 250 mm).  Tryptic 
peptides were loaded onto the trap column over 3 minutes, followed by analytical separation 
over a 110 minute gradient (3% acetonitrile to 40% acetonitrile over 92 minutes).  
Peptides were analyzed in positive mode on a Synapt G2-S HDMS traveling wave ion mobility 
time-of-flight mass spectrometer (Waters Corporation).  The nanoESI source was set to 70°C and 
a 3kV potential was applied.  Data-independent acquisition was performed as described 
previously.4 
Raw data were analyzed with ProteinLynx Global SERVER version 3.0.2 (PLGS, Waters 
Corporation), searching against a database of the human proteome (downloaded from UniProt on 
November  9, 2015).  The following criteria were applied to perform the search, in addition to 
the appropriate enzyme specificity: (i) one missed cleAvage allowed, (ii) carbamidomethyl 
cysteine as a fixed modification and methionine oxidation as a variable modification, (iii) a 
minimum of two identified fragment ions per peptide and a minimum of five fragments per 
protein, and (iv) at least two identified peptides per protein.  The false discovery rate (FDR) for 
peptide and protein identification was set at 1% using a reversed database.  Any identified 
peptides with a calculated mass error greater than 10 ppm were not considered.   
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